PosterSessionOnline

INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTA..

ISTH 2015 Congress

20-25 June 2015 Toronto

N. Poster

Poster title

Applicant name

Status


1-TUE-PO	POLYPHOSPHATE AS A NOVEL THERAPEUTIC FOR AGE-RELATED MACULAR DEGENERATION	Linnette Ocariza	Received

1-WED-PO	ACQUIRED HEMOSTATIC DISORDERS BY ORTHOTOPIC LIVER TRANSPLANATION	Dorit Blickstein	Received

2-MON-PO	AN UNBALANCE BETWEEN VON WILLEBRAND FACTOR AND ADAMTS13 FOLLOWING A MAJOR PARTIAL HEPATECTOMY	Dafna Groeneveld	Received

2-TUE-PO	ANTI-OXIDANT TREATMENT IMPROVES CARDIAC DYSFUNCTION IN BMAL1 DEFICIENT MICE	Bianca Hemmeryckx	Received

3-MON-PO	THE NOVEL C.774_775 INS CCGCGCC MUTATION COMBINED WITH C.4085 TA IN THE ADAMTS13 GENE CONTRIBUTES TO THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)	Juvenal Paiva	Received

3-WED-PO	PERSISTENT INTERNATIONAL NORMALIZED RATIO (INR) ELEVATION ASSOCIATED WITH OLMESARTAN-INDUCED ENTEROPATHY IN A PATIENT RECEIVING WARFARIN	Jennifer Lowerison	Received

4-MON-PO	THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN A MEMBER OF A FAMILY WITH ADAMTS13 GENE ABNORMALITIES	Juvenal Paiva	Received

5-MON-PO	CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) CAUSED BY COMPOUND HETEROZYGOSITY OF C.1225CT AND A NOVEL C.2321DELG ADAMTS13 GENE MUTATIONS	Juvenal Paiva	Received

5-WED-PO	HEMOSTATIC EFFECTS OF REGENERATIVE THERAPY IN PATIENTS WITH ALCOHOLIC CIRRHOSIS-A DEVELOPING COUNTRY EXPERIENCE.	Priyanka Saxena	Received

6-MON-PO	QUALITY ASSESSMENT FOR ADAMTS-13 TESTING: A CANADIAN EXPERIENCE	Arnaud Bonnefoy	Received

6-TUE-PO	FAMILIAL FELINE HYPERTROPHIC CARDIOMYOPATHY: A MODEL FOR EVALUATING PLATELET ACTIVATION AND CLOPIDOGREL THERAPY	Ronald Li	Received

7-TUE-PO	PLATELET EFFECTS OF EPISODIC OZONE AND PM EXPOSURE DURING POSTNATAL DEVELOPMENT	Fern Tablin	Received

7-WED-PO	TREATMENT OF AQUIRED FACTOR V INHIBITORS RESULTING IN DISSEMINATED INTRAVASCULAR COAGULATION	Julie Tarrant	Received

7-MON-PO	PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS: THE ROLE OF ADAMTS13	Raimondo De Cristofaro	Received

8-WED-PO	LUPUS ANTICOAGULANT - HYPOPROTHROMBINEMIA SYNDROME IN A 7-YEAR OLD GIRL: A CASE REPORT	PATIROGLU PATIROGLU	Received

8-TUE-PO	EVALUATION OF FACTOR XIA PHARMACOKINETICS IN MICE WITH A THROMBIN GENERATION ASSAY	Mikhail Ovanesov	Received

9-MON-PO	PAR1-STIMULATED PLATELETS ENHANCE ANGIOGENIC ACTIVITIES OF ENDOTHELIAL PROGENITOR CELLS MORE POTENTLY THAN PAR4-STIMULATED PLATELETS	Nailin Li	Received

9-WED-PO	ACHIEVING HAEMOSTATIC CONTROL IN ACQUIRED HAEMOPHILIA A WITH PLASMA DERIVED FVIII INFUSIONS	Pu-Lin Luo	Received

9-TUE-PO	RESISTANCE TO ANTI-PLATELET AGENTS IN PATIENTS WITH ISCHEMIC STROKE	Anil Pathare	Received

10-WED-PO	ACQUIRED VON WILLEBRAND SYNDROME (AVWS) IN PATIENTS WITH CARDIOVASCULAR DISORDERS: A SINGLE CENTRE COHORT STUDY	Maria Joana Costa Pinto Prego de Faria	Received

10-MON-PO	DEVELOPMENT OF AN EX OVO CHICKEN EMBRYO MODEL FOR MEASURING TRACTION FORCES DURING IN VIVO ANGIOGENESIS	Sandra Baker-Groberg	Received

10-TUE-PO	MECHANISM OF ANTIPLATELET ACTION INDUCED BY GUANOSINE VIA INCREASE IN CAMP LEVELS AND ITS ANTITHROMBOTIC ACTIVITY	Eduardo Fuentes	Received

11-TUE-PO	IMPACT OF NON-INHIBITED PLATELET SUPPLEMENTATION ON PLATELET REACTIVITY IN PATIENTS TREATED WITH PRASUGREL OR TICAGRELOR FOR AN ACUTE CORONARY SYNDROME: AN EX-VIVO STUDY	Pierre Fontana	Received

11-MON-PO	MICRORNA-126 REDUCES BLOOD-RETINAL BARRIER BREAKDOWN IN OXYGEN-INDUCED RETINOPATHY MOUSE MODEL	Yanyan Bai	Received

11-WED-PO	ACQUIRED HAEMOPHILIA A IN POLAND A REPORT FROM AHA-POL REGISTRY	Jerzy Windyga	Received

12-TUE-PO	THE EFFECTS OF TWO COMMONLY USED HERBAL PRODUCTS ON HAEMOSTATIC SYSTEM AND THEIR INTERACTIONS WITH ASPIRIN	Wan Hui Wong	Received

12-WED-PO	SUCCESSFUL THERAPY WITH BORTEZOMIB FOR ERRADICATION OF INHIBITOR IN A PATIENT WITH MULTIPLE MYELOMA AND ACQUIRED HEMOPHILIA A	Susana Nobre Fernandes	Received

12-MON-PO	STIMULATION OF PAR-1 OR PAR-4 PROMOTES A SIMILAR PATTERN OF PLATELET-MEDIATED ANGIOGENESIS	Mirta Schattner	Received

13-TUE-PO	EFFICACY OF PLATELET INHIBITION WITH PRASUGREL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION UNDERGOING THERAPEUTIC HYPOTHERMIA AFTER CARDIOPULMONARY RESUSCITATION	Andreas Schaefer	Received

13-MON-PO	PLATELET MEMBRANE GLYCOPROTEIN CD151 PROMOTES ENDOTHELIAL PROGENITOR CELL ANGIOGENESIS	Zhangsen Huang	Received

14-WED-PO	CLINICAL UTILITY OF HEAT INACTIVATED NIJMEGEN MODIFIED BETHESDA ASSAYS IN FVIII DEFICIENCY A 4 YEAR SINGLE CENTRE EXPERIENCE	Tejas Gandhi	Received

14-TUE-PO	ANTIBODY TARGETED, THROMBIN-SENSITIVE POLYMER CAPSULES FOR UROKINASE DELIVERY	Christoph Hagemeyer	Received

14-MON-PO	PROANGIOGENIC PROPERTIES OF FUCOIDAN IS ASSOCIATED WITH RECRUITMENT AND MODULATION OF MACROPHAGE POLARIZATION	Elene Sapharikas	Received

15-WED-PO	COMPARISON OF DIFFERENT COAGULATION ASSAYS FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA	Elizabeth Donnachie	Received

15-MON-PO	UNALTERED ANGIOGENESIS-REGULATORY ACTIVITIES OF PLATELETS FROM MILD TYPE 2 DM PATIENTS DESPITE A MARKED PLATELET HYPERREACTIVITY	Nailin Li	Received

16-TUE-PO	TICAGRELOR REVERSAL: IN VITRO ASSESSMENT OF VARIOUS HEMOSTATIC AGENTS	Anne Godier	Received

16-MON-PO	HUMAN PLATELET LYSATE GEL (HPLG) SUPPORTS AND STIMULATES ENDOTHELIAL PROGENITOR CELL-DRIVEN VASCULOGENESIS	Giordano Pula	Received

17-TUE-PO	TWO DISINTEGRINS, TFV-1 AND TFV-3, PURIFIED FROM TRIMERESURUS FLAVOVIRIDIS SNAKE VENOM, EXHIBIT DISTINCT EFFECTS ON PLATELET ACTIVATION	Tzu Yu Pan	Received

17-WED-PO	ASSESSMENT OF PROTHROMBIN TIME PROLONGATION BY THROMBOELASTOMETRY AND THROMBELASTOGRAPHY DURING LIVER TRANSPLANTATION	Kenichi Tanaka	Received

18-TUE-PO	PLATELET INHIBITION MONITORING WITH THROMBOELASTOGRAPHY (TEG) PLATELET MAPPING IN PEDIATRIC PATIENTS WITH VENTRICULAR ASSIST DEVICE	tiphaine belleville	Received

19-TUE-PO	THE PROGNOSTIC UTILITY OF PLATELET FUNCTION TESTING FOR THE DETECTION OF ASPIRIN RESISTANCE IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE	Marie Lordkipanidze	Received

20-WED-PO	USEFULNESS OF VARIOUS SCORING METHODS WITH CROSS-MIXING TEST FOR DETECTION OF LUPUS ANTICOAGULANT	Sumiyoshi Naito	Received

20-TUE-PO	A TIME COURSE STUDY OF HIGH ON TREATMENT PLATELET REACTIVITY IN ACS PATIENTS ON DUAL ANTIPLATELET THERAPY	Gori Anna Maria	Received

21-MON-PO	PLASMIN, NOT THROMBIN, ACTIVATES COMPLEMENT IN ARTERIAL AND VENOUS THROMBOSIS	Jonathan Foley	Received

21-WED-PO	DEFINING COAGULATION DYSFUNCTION IN PATIENTS WITH LEPTOSPIROSIS	lallindra gooneratne	Received

21-TUE-PO	INHIBITION OF PLATELET AGGREGATION BY GLS-409, AN ANTAGONIST OF BOTH P2Y1 AND P2Y12, IS DISTINCT FROM INHIBITION BY SELECTIVE P2Y1 AND P2Y12 ANTAGONISTS	Thomas Gremmel	Received

22-WED-PO	ACQUIRED VON WILLEBRAND SYNDROME DIAGNOSIS AND MANAGEMENT.	Angelika Batorova	Received

22-MON-PO	ESTABLISHMENT OF A VASCULAR INJURY MODEL DEMONSTRATING DIFFERENT EFFICACIES OF ANTITHROMBOTIC AGENTS ON THROMBUS FORMATION IN MICE	Chaojun TANG	Received

23-WED-PO	ACQUIRED ACTIVATED PROTEIN C RESISTANCE IN ELDERLY PEOPLE WITH AND WITHOUT COGNITIVE IMPAIRMENT	Maria das Graas Carvalho	Received

23-MON-PO	FERRIC CHLORIDE-INDUCED VENOUS THROMBOSIS MODEL IN RATS: FINDING THE OPTIMAL CONCENTRATION OF FERRIC CHLORIDE	Polina Alekseeva	Received

25-TUE-PO	INCREASED MEAN PLATELET VOLUME (MPV) OF ACUTE CORONARY SYNDROMES (ACS) PATIENTS WITH CHEST PAIN AT THE EMERGENCY ROOM (ER)	AL-ZAMZAM ABUBAKAR	Received

26-TUE-PO	RESIDUAL PLATELET FUNCTION IN ACS PATIENTS TREATED WITH PRASUGREL IS LOWER THAN IN PATIENTS TREATED WITH CLOPIDOGREL BUT NOT IN PATIENTS WITH HYPERTENSION	Stanj Heptinstall	Received

27-WED-PO	ACQUIRED INHIBITORS TO FACTOR VIII AND IX, A CASE REPORT	Sasa Anzej Doma	Received

28-TUE-PO	EFFECTS OF MINERALOCORTICOID RECEPTOR ANTAGONISTS ON THE RISK OF MORTALITY, THROMBOSIS AND BLEEDING IN PATIENTS WITH SECONDARY HYPERALDOSTERONISM: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	Laura Elbers	Received

28-MON-PO	RABBIT MODEL OF FERRIC CHLORIDE-INDUCED CAROTID ARTERIAL THROMBOSIS OPTIMIZED FOR TRANSLATIONAL DRUG DISCOVERY	Xinkang Wang	Received

29-MON-PO	DISSECTION OF THE THERAPEUTIC EFFICACY OF FIX-TRIPLE FOR REDUCING HAEMOPHILIC ARTHROPATHY IN HEMOPHILIA B USING A BLOOD-INDUCED JOINT INJURY MURINE MODEL	Guan-Ying Zheng	Received

29-TUE-PO	URINARY 11-DEHYDRO-THROMBOXANE B2 IS ASSOCIATED WITH CARDIOVASCULAR EVENTS AND MORTALITY IN ATRIAL FIBRILLATION PATIENTS.	pasquale pignatelli	Received

29-WED-PO	EFFICACY OF FVIII IN THE TREATMENT OF PATIENTS WITH ACQUIRED HAEMOPHILIA A AND VASCULAR DISEASES	Samantha Pasca	Received

31-TUE-PO	VASCULAR SMOOTH MUSCLE CELLS ARE RESPONSIBLE FOR A PROTHROMBOTIC PHENOTYPE OF SPONTANEOUSLY HYPERTENSIVE RAT ARTERIES	MOHAMADI AMEL	Received

31-WED-PO	NEUTRALIZING AUTOANTIBODY AGAINST FACTOR XIII A SUBUNIT WITH MULTIPLE INHIBITORY EFFECT ON FACTOR XIII ACTIVATION/ACTIVITY RESULTED IN SEVERE BLEEDING WITH FATAL OUTCOME	Krisztina Pénzes-Daku	Received

31-MON-PO	GENERATION OF HEMOPHILIA B MICE IN NSG BACKGROUND USING CRISPR/CAS9 TECHNOLOGY	Meng-Ni Fan	Received

33-WED-PO	PREDICTION OF BLEEDING COMPLICATIONS AFTER RENAL BIOPSY IN POST-RENAL TRANSPLANT PATIENTS WITH UREMIA	Gerhardus Kuiper	Received

33-TUE-PO	ELEVATED ARTERIAL STIFFNESS AND THROMBIN GENERATION IN PATIENTS WITH END-STAGE RENAL DISEASE UNDERGOING HEMODIALYSIS	Veronique REGNAULT	Received

34-MON-PO	GENOME-WIDE KNOCKDOWNS IN ZEBRAFISH TO STUDY THROMBOCYTE FUNCTION	Pudur Jagadeeswaran	Received

34-TUE-PO	THROMBOGENIC STATE AFTER VASCULAR SURGERY AND PERIOPERATIVE CARDIOVASCULAR EVENTS	Daniela CALDERARO	Received

34-WED-PO	ANALYSIS OF THE PROFILE OF IMMUNE CELLS, CYTOKINES AND CHEMOKINES IN PREVIOUSLY UNTREATED PATIENTS WITH HEMOPHILIA	Leticia Jardim	Received

35-WED-PO	PROSPECTIVE VALIDATION OF CLINI-BIOLOGICAL PARAMETERS INCLUDING INITIAL HEMOSTASIS, WHICH IMPROVE THE PREDICTION OF DEATH AT 1 MONTH AMONG PATIENTS WITH SEPTIC SHOCK: SEPSICOAG STUDY	Géraldine LAVIGNE-LISSALDE	Received

35-MON-PO	BRAIN WHITE MATTER MICROSCRUTURE IS ALTERED IN OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: EVIDENCES FROM DIFFUSION-TENSOR MRI IN ASYMPTOMATIC NEUROLOGICAL PATIENTS	Jean-Christophe GRIS	Received

36-WED-PO	Conformational Activation of ADAMTS13 and Control of VWF Dependent Platelet Deposition Under Flow	kieron south	Received

36-TUE-PO	SIMULTANEOUS OBSERVATION OF PERIPHERAL MONONUCLEAR CELL AND PLASMA TFS EXPRESSION FOR PREVENTION AND TREATMENT OF ISCHEMIC CARDIOCEREBROVASCULAR DISEASES	Rui Wang	Received

36-MON-PO	THROMBOTIC RISK OF REDUCED ADAMTS13 ACTIVITY IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES	Hyun Kyung Kim	Received

37-MON-PO	MIXING TEST SPECIFIC CUT-OFF IS MORE SENSITIVE AT DETECTING IN VITRO LUPUS ANTICOAGULANT INHIBITION THAN THE INDEX OF CIRCULATING ANTICOAGULANT	Gary Moore	Received

37-TUE-PO	TOTAL CHEMICAL SYNTHESIS OF COVALENT RANTES-PF4 HETERODIMERS TO STUDY INITIATION AND PROGRESSION OF ATHEROSCLEROSIS	Stijn Agten	Received

38-TUE-PO	ENDOTHELIAL DELETION OF THIOREDOXIN-INTERACTING PROTEIN PRESERVES MOUSE ARTERIES FROM AGING INDUCED BY METABOLIC DISORDERS	Elise Dreano	Received

38-WED-PO	ADAMTS13: VON WILLEBRAND FACTOR CLEAVING PROTEASE. GROWTH FACTOR?	Justin Keener	Received

39-MON-PO	PERSISTENT LUPUS ANTICOAGULANT IN CLINICAL SETTINGS OTHER THAN ANTIPHOSPHOLIPID SYNDROME	Lucia Remotti	Received

39-TUE-PO	HIGH LIPOPROTEIN(A) LEVELS ARE ASSOCIATED WITH CORONARY CALCIUM SCORE IN THE MONTIGNOSO STUDY POPULATION	Anna Maria Gori	Received

40-TUE-PO	ASSOCIATION OF GAMMA-GLUTAMYL TRANSFERASE TO THE PREMATURE CORONARY ARTERY DISEASE IN YOUNG ASIAN INDIANS	Rajani kanth Vangala	Received

40-MON-PO	HOW APPROPRIATE IS THE ANTIPHOSPHOLIPID ANTIBODIES TESTING AT SIRIRAJ HOSPITAL?	Yingyong Chinthammitr	Received

40-WED-PO	CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH UPSHAW-SCHULMAN SYNDROME RECEIVING MAINTENANCE HEMODIALYSIS DUE TO CHRONIC RENAL FAILURE	Masanori Matsumoto	Received

41-TUE-PO	CORONARY ARTERY DISEASE SEVERITY IS A MARKER OF THE ANTI-INFLAMMATORY RESPONSE TO STATIN THERAPY	Udaya Tantry	Received

41-MON-PO	THROMBOMODULIN DOWN-REGULATION IS RELATED TO THE THROMBOSIS RISK IN ANTIPHOSPHOLIPID SYNDROME PATIENTS	Osamu Kumano	Received

42-WED-PO	ANTI-ADAMTS13 ANTIBODY FEATURES (IG ISOTYPE TITERS, FUNCTIONAL ADAMTS13 INHIBITOR AND CIRCULATING IMMUNE COMPLEXES (CIC)) IN PATIENTS WITH ACQUIRED THROMBOSIS THROMBOCITOPENIC PURPURA (ATTP) AT FIRST CONSULTATION IN OUR INSTITUTION.	Juvenal Paiva	Received

42-MON-PO	USE OF D DIMER IN BIOLOGICAL CONTROL OF PREGNANCY	Ana Lena	Received

43-TUE-PO	ATHEROSCLEROTIC CARDIOVASCULAR MORTALITY IN GOUTY ARTHRITIS AND RHEUMATOID ARTHRITIS: IS IT ASSOCIATED WITH MEAN PLATELET VOLUME AND NEUTROPHIL/LYMPHOCYTE RATIO	GULSUM EMEL PAMUK	Received

43-MON-PO	ANTI-ANNEXIN V ANTIBODIES IN PATIENTS WITH OBSTETRIC MORBILITY	Susana Ouviña	Received

45-WED-PO	DETECTION OF PLASMA ADAMTS13 ACTIVITY USING E. COLI DERIVED VWF-A2 SUBSTRATES AND MICROSPHERE-CYTOMETRY ASSAYS	Sriram Neelamegham	Received

45-TUE-PO	EFFECTS OF LOW AND HIGH LEVELS OF NON VKA ORAL ANTICOAGULANTS ON A COMPREHENSIVE PANEL OF ROUTINE AND SPECIALTY COAGULATION TESTS	Franois Depasse	Received

45-MON-PO	PROPOSED TRIAL: HYPATIA - A PROSPECTIVE RANDOMISED CONTROLLED TRIAL OF HYDROXYCHOROQUINE VERSUS PLACEBO DURING PREGNANCY IN WOMEN WITH ANTIPHOSPHOLIPID ANTIBODIES	Karen Schreiber	Received

47-TUE-PO	DIFFERENT CENTRIFUGATION CONDITIONS DO NOT INTERFERE WITH D-DIMER RESULTS	Carlos Aguilar	Received

48-TUE-PO	THROMBIN GENERATION IN THE NORMAL POPULATION FLATTENED THROMBIN GENERATION CURVES ASSOCIATED WITH POOR LIPID PROFILE AND MALE SEX.	Prahlad Ho	Received

48-MON-PO	ANALYTICAL AND CLINICAL PERFORMANCE OF A NEW AUTOMATED CHEMILUMINESCENT ASSAY (CIA)	Teresa Iwaniec	Received

48-WED-PO	ASSESSMENT OF MOD-5014, A LONG ACTING FVIIA, PHARMACOKINETIC, PHARMACODYNAMICS AND CORRECTION OF HEMOPHILIC COAGULOPATHY IN DOGS WITH HEMOPHILIA A AS PART OF THE PREPARATION FOR FIRST IN HUMAN STUDY	Lior Binder	Received

49-TUE-PO	THE RIVAROXABAN-CALIBRATED ANTI-FXA ASSAY CAN RELIABLY IDENTIFY PRESENCE OF RIVAROXABAN IN PLASMA	Jerzy Windyga	Received

50-MON-PO	FREQUENCY OF CLINICALLY SIGNIFICANT ANTIPHOSPHOLIPID ANTIBODIES PROFILE IN PATIENTS WITH VENOUS THROMBOEMBOLISM, STROKE , MYOCARDIAL INFARCTION, PERIPHERAL ARTERIAL DISEASE AND PREGANCY MORBIDITY	Benilde Cosmi	Received

50-WED-PO	AN ANTIBODY PRETREATMENT STRATEGY FOR IMPROVING CELL-BASED THERAPY IN A MOUSE MODEL OF HEMOPHILIA B	Meng-Ni Fan	Received

50-TUE-PO	A FULLY AUTOMATED AID FOR THE IMPROVEMENT OF HIL INTERFERENCE MANAGEMENT IN THE HEMOSTASIS LABORATORY: TEST ASSAY-SPECIFIC FLAGGING OF LABORATORY RESULTS FOR HEMOLYSIS, ICTERUS AND LIPEMIA/TURBIDITY	Janos Polgar	Received

51-TUE-PO	HANDLING OF THE HEMOCLOT THROMBIN INHIBITOR ASSAY REAGENTS ON SYSMEX CS-2100I WHEN MONITORING DABIGATRAN IN ACUTE CLINICAL SITUATIONS	Louise Faaborg	Received

51-MON-PO	CLINICAL ASSESSMENT OF ANTIPHOSPHOLIPID ANTIBODIES AGAINST 2-GLYCOPROTEIN DOMAIN I IN ANTIPHOSPHOLIPID SYNDROME.	PASCUAL MARCO	Received

52-WED-PO	ASSESSMENT OF KNEE JOINT BLEEDING IN HEMOPHILIA B MICE BY FLUORESCENCE MOLECULAR TOMOGRAPHY	Elizabeth Chappell	Received

53-TUE-PO	USEFULNESS OF DILUTE RUSSELLS VIPER VENOM CLOTTING TIME (DRVVT) FOR THE ROUTINE MONITORING OF NEW ORAL ANTICOAGULANTS	Debra Hoppensteadt	Received

53-WED-PO	SERUM ENDOCAN LEVELS AS A POTENTIAL NON-INVASIVE BIOMARKER FOR DIAGNOSING DIFFERENT HEPATIC DISEASES	Rachel Palumbo	Received

54-TUE-PO	PERFORMANCE OF HEMOSIL DIRECT THROMIN INHIBITOR (DTI) ASSAY ON THE ACL TOP FAMILY INSTRUMENTS	Judith Hammelburger	Received

54-WED-PO	EFFECT OF A RECOMBINANT PLANT ELASTASE INHIBITOR WITH ANTI-INFLAMMATORY ACTION - RBBCI (BAUHINIA BAUHINIOIDES CRUZAIN/CRUZIPAIN INHIBITOR) ON A RAT MODEL OF VENOUS THROMBOSIS	Francisco H.A. Maffei	Received

54-MON-PO	IMPACT OF PREANALYTICAL DELAY ON RESULTS OF LIGHT TRANSMITTANCE AGGREGOMETRY IN STEMI PATIENTS	Anna Vybivantseva	Received

55-TUE-PO	IN VITRO CORRECTION OF IMPAIRED BLOOD COAGULATION IN A MODEL OF SEVERE THROMBOCYTOPENIA	Boris Shenkman	Received

55-WED-PO	EVALUATION OF THE IMPORTANCE OF MIXING PATIENT PLASMA WITH A POOL OF NORMAL PLASMAS WHEN DIAGNOSING LUPUS ANTICOAGULANT	Ana Lena	Received

55-MON-PO	ASSOCIATION OF PLATELET RESPONSE TO CILOSTAZOL WITH CLINICAL OUTCOME AND CYP GENOTYPES IN PATIENTS WITH CEREBRAL INFARCTION	JUN YAMANOUCHI	Received

56-MON-PO	Platelet reactivity based risk assessment for frail patients with coronary artery disease on P2Y12 inhibitors	Minka Vries	Received

56-TUE-PO	NEW IMMUNODEPLETED PLASMA FOR DETERMINATION OF FACTOR XI ACTIVITY	Vicente Cortina	Received

57-WED-PO	NEW MIXING TEST INDEX TO DISCRIMINATE BETWEEN LUPUS ANTICOAGULANT AND COAGULATION INHIBITOR	Osamu Kumano	Received

57-MON-PO	PLATELET FUNCTION TESTING IN ACS PATIENTS USING MEASUREMENT OF PLATELET P-SELECTIN: COMPARISON WITH OTHER COMMERCIAL TESTS	Stan Heptinstall	Received

58-MON-PO	EFFICACY OF PRASUGREL ADMINISTRATION IMMEDIATELY AFTER PERCUTANEOUS CORONARY INTERVENTION IN ACUTE MYOCARDIAL INFARCTION	Andreas Schaefer	Received

58-TUE-PO	EVALUATION OF A NEW ASSAY FOR THE MEASUREMENT OF THE DIRECT FXA INHIBITOR RIVAROXABAN (DG-CHROM ANTI-XA) ON THE Q HEMOSTASIS ANALYZER (GRIFOLS)	KIERON HICKEY	Received

59-TUE-PO	HOW THE DIRECT ORAL ANTICOAGULANT APIXABAN AFFECTS THROMBIN GENERATION PARAMETERS	erica scalambrino	Received

59-WED-PO	DETECTION OF ANTIPHOSPHOLIPID ANTIBODIES IN NORMAL PREGNANT WOMEN AND IN PREGNANT WOMEN AT THE TIME OF PREECLAMPSIA ONSET	beatriz grand	Received

60-TUE-PO	THE CORRELATION OF ATYPICAL APTT CURVES WITH TYPE OF COAGULATION DEFECT	Ludek Slavik	Received

60-MON-PO	CORRELATION BETWEEN PLATELET MRP4 EXPRESSION AND PLATELET FUNCTION IN PATIENTS UNDER CHRONIC ASPIRIN TREATMENT	Fabio Pulcinelli	Received

61-WED-PO	PREGNANCY IN WOMEN WITH ANTIPHOSPHOLIPID SYNDROME.	Denisa Jankovicova	Received

61-TUE-PO	EFFICACY OF NOVEL ORAL ANTICOAGULANTS (NOACS) USING DILUTED RUSSELLS VIPER VENOM TEST (DRVVT)	Makoto Kaneko	Received

62-WED-PO	ANTIPHOSPHOLIPID ANTIBODIES IN CEREBRAL VASCULAR EVENTS	Héla Baccouche	Received

62-TUE-PO	EX-VIVO AND IN-VITRO COMPARATIVE ASSESSMENT OF MOD-5014 (FACTOR VIIA-CTP), A NOVEL LONG-ACTING COAGULATION FACTORTO RECOMBINANT FVIIA	Lior Binder	Received

62-MON-PO	PLATELET REACTIVITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION CHRONICALLY TREATED WITH BETA-BLOCKERS BEFORE THE ONSET OF THE ACUTE EVENT.	Antonio Moscardó	Received

63-MON-PO	PROTEOMIC PROFILING OF PLATELET RESPONSE TO ANTIPLATELET AGENTS REVEALS A WIDE INTER-INDIVIDUAL VARIABILITY AND DISTINCT SIGNATURES OF DRUGS ALONE AND IN COMBINATION	simone marcone	Received

63-TUE-PO	IMPACT OF EDOXABAN ON HAEMOSTASIS DIAGNOSIS ASSAYS: PRACTICAL RECOMMENDATIONS	Jonathan Douxfils	Received

64-TUE-PO	INTRODUCTION OF A LIQUID ANTI-XA METHOD FOR QUANTIFICATION OF CURRENT THERAPEUTIC XA INHIBITORS	Jane Needham	Received

65-MON-PO	INHIBITION OF THIOREDOXIN INHIBITS GPVI-MEDIATED PLATELET ACTIVATION	Carmen Coxon	Received

66-MON-PO	PREDICTION OF HIGH ON-TREATMENT PLATELET REACTIVITY IN CLOPIDOGREL-TREATED PATIENTS WITH ACUTE CORONARY SYNDROMES, USING ADVANCED ARTIFICIAL NEURAL NETWORKS	GianMarco Podda	Received

67-MON-PO	ASPIRIN RESISTANCE IN MEDICAL INPATIENTS ON CHRONIC ASPIRIN TREATMENT	Anna Maria Gori	Received

68-MON-PO	TXA2-BINDING PROTEINS, DIPETALODIPIN AND TRIPLATIN, BLOCK PLATELET-MEDIATED NETS FORMATION IN VITRO AND INHIBIT THROMBOSIS IN VIVO WITHOUT IMPAIRING HEMOSTASIS	Daniella Mizurini	Received

68-TUE-PO	DO PT AND APTT SENSITIVITIES TO FACTORSDEFICIENCIES CALCULATED BY THE H47-A2 2008 CLSI GUIDELINE REFLECT THE DEFICIENCIES FOUND IN PLASMA FROM PATIENTS?	Marta E Martinuzzo	Received

69-TUE-PO	MARKERS OF HEMOSTASIS ACTIVATION AFTER EARLY DISCONTINUATION OF FONDAPARINUX IN LOW-RISK PATIENTS HOSPITALIZED WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME	Igor Yavelov	Received

69-WED-PO	EVALUATION OF ?2-GLYCOPROTEIN I LEVELS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME.	Teresa Iwaniec	Received

70-WED-PO	THE ASSOCIATION OF 3 STAT4 SINGLE NUCLEOTIDE POLYMORPHISMS AND ANTIPHOSPHOLIPID SYNDROME	Magdalena Celi&324;ska-Lowenhoff	Received

71-MON-PO	RETINAL VESSEL CALIBRES AND HAEMOSTASIS IN BLACK AND WHITE SOUTH AFRICANS: THE SABPA STUDY	Leandi Lammertyn	Received

72-WED-PO	PRODUCTION AND PURIFICATION OF VERSATILE ENZYMES FOR POTENTIAL ANTIPLATELET APPLICATIONS	Bat-Erdene Jugder	Received

74-TUE-PO	VARIABILITY IN NORMAL RANGES OF THROMBIN GENERATION BETWEEN LABORATORIES IS WIDE AND DEPENDENT ON TEST METHODOLOGY	Hartirathpal Kaur Juspal Singh	Received

74-WED-PO	PLATELET TRANSFUSION REVERSES BLEEDING EVOKED BY TRIPLE ANTI-PLATELET THERAPY INCLUDING VORAPAXAR, A NOVEL PLATELET THROMBIN RECEPTOR ANTAGONIST	Tian-Quan Cai	Received

74-MON-PO	CARDIOLOGICAL AND THROMBOPHILIC RISK PROFILE IN PATIENTS WITH OCULAR ARTERIAL OCCLUSION	Jerzy Dropinski	Received

75-TUE-PO	RESISTANCE TO THROMBOMODULIN BUT NOT TO ACTIVATED PROTEIN C IN CIRRHOTIC PATIENTS	Thomas Sinegre	Received

75-MON-PO	A NOVEL ASSAY DEMONSTRATES PROCOAGULANT PLATELETS ARE INCREASED IN PATIENT UNDERGOING CORONARY ANGIOGRAPHY WITH DIFFERENTIAL EFFECTS BY ANTI-PLATELET AND ANTI-COAGULANT THERAPY	Leonardo Pasalic	Received

76-MON-PO	RELATION BETWEEN INVASIVE CENTRAL PULSE PRESSURE AND THROMBOGENICITY	Udaya Tantry	Received

76-WED-PO	AN IN VITRO TRANSFUSION MODEL FOR THE ASSESSMENT OF PLATELET FUNCTION RECOVERY FOLLOWING EXPOSURE TO TRIPLE ANTI-PLATELET AGENTS	Lisa Jennings	Received

77-TUE-PO	EMERGENCY ASSESSEMENT OF PATIENTS IN DOACS: THE ROLE OF POINT-OF-CARE TESTING.	Paolo Carraro	Received

78-WED-PO	DEVELOPMENT OF A RECEPTOR OCCUPANCY ASSAY FOR ANFIBATIDE, A NOVEL GPIB ANTAGONIST	Alysia Cox	Received

79-WED-PO	PEGYLATED DISINTEGRIN EXHIBITS MORE POTENT ANTITHROMBOTIC ACTIVITY IN VIVO	Chun-Chieh Hsu	Received

79-TUE-PO	EFFECT OF THE RESIDUAL PLATELET COUNT ON DIFFERENT COAGULATION PARAMETERS IN FREEZE-THAW PLASMA SAMPLES AT -20C	YOLANDA PATRICIA ADAMCZUK	Received

80-WED-PO	RESISTANCE TO ASPIRIN IN MYELOPROLIFERATIVE NEOPLASMS. IS IT A REALITY ?	ajzenberg nadine	Received

80-TUE-PO	CORRELATION TO FVIII:C IN TWO THROMBIN GENERATION ASSAYS: TGA CAT AND INNOVANCE ETP	Marcus Ljungkvist	Received

81-WED-PO	PHARMACOKINETICS AND PHARMACODYNAMICS OF APAC, A DUAL NOVEL ANTICOAGULANT AND ANTIPLATELET HEPARIN COMPLEX	Annukka Jouppila	Received

82-TUE-PO	OVERALL HEMOSTATIC POTENTIAL ASSAY IS SENSITIVE TO DIFFERENT PLASMA FREEZING TECHNIQUES	Mojca Bozic-Mijovski	Received

83-TUE-PO	DEFINING THE REFERENCE RANGE FOR BLOOD CLOT GEL POINT AND FRACTAL DIMENSION	Lindsay DSilva	Received

83-MON-PO	CIRCULATING LYMPHOCYTES AND MONOCYTES AS RISK FACTORS FOR CORONARY ARTERY DISEASE IN INDIAN POPULATION	Lakshmi Mundkur	Received

83-WED-PO	HOW SHOULD WE MEASURE THE EFFECT OF PERSANTINE USING THROMBOELASTOGRAPHY? CORRELATION AND AGREEMENT BETWEEN PERCENT ADP INHIBITION AND ADP NET G	patti massicotte	Received

84-WED-PO	NSAIDS IN VIVO TREATMENT AND MRP4 EXPRESSION IN HUMAN PLATELETS	Fabio Pulcinelli	Received

84-MON-PO	TRANSLATIONAL INFORMATICS APPROACH LINKING RISK OF CORNARY ARTERY DISEASE, INFECTION AND INFLAMMATION	Rajani kanth Vangala	Received

85-TUE-PO	TEST SPECIFIC ASSESSMENT OF EFFECTS OF HAEMOLYSIS ON CITRATED BLOOD SAMPLES USING SYSMEX CS SERIES ANALYSERS	Anita Woolley	Received

85-WED-PO	THE EFFECTIVENESS OF P2Y12 RECEPTOR BLOCKADE IS STRONGLY DETERMINED BY THE PRESENCE OF ENDOTHELIAL MEDIATORS PROSTACYCLIN AND NITRIC OXIDE	Rebecca Knowles	Received

86-WED-PO	COMPARISON OF THE BIOCYTEX AND THE VASPFIX ASSAYS OF VASP PHOSPHORYLATION IN CORONARY-ARTERY DISEASE PATIENTS TREATED WITH CLOPIDOGREL PLUS ASPIRIN	Marco Cattaneo	Received

86-TUE-PO	PROVINCE WIDE IMPLEMENTATION OF THE THROMBIN TIME FOR QUALITATIVE ASSESSMENT OF DABIGATRAN CLEARANCE	Artur Szkotak	Received

87-WED-PO	LOCAL PARAMETERS OF HEMOSTASIS ACTIVATION IN THE FIBRILLATING ATRIUM	Noemi Klara Toth	Received

87-TUE-PO	EFFECTS OF RIVAROXABAN ON PT AND APTT AS DETERMINED WITH A FULL RANGE OF REAGENTS: RESULTS OF A UK NEQAS BLOOD COAGULATION EXERCISE	Steve Kitchen	Received

88-MON-PO	ACCURATE RECOVERY OF PEGYLATED AND NON-PEGYLATED THERAPEUTIC FVIII, USING A SPECIFIC APTT REAGENT, AND APPLICATION ON AN AUTOMATED COAGULATION ANALYZER	MARY DOYLE	Received

88-WED-PO	THE ASSESMENT OF ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION UNDER FIBRINOLYTIC THERAPY OR PRIMARY PERCUTANEOUS CORONARY INTERVENTION	Mehmet Sonmez	Received

89-WED-PO	A single rhADAMTS13-treatment improves cardiac long-term functionality and remodeling after ischemia-reperfusion injury in mice	Thilo Witsch	Received

90-MON-PO	HAEMOSTASIS IN CARDIAC ARREST PATIENTS TREATED WITH THERAPEUTIC HYPOTHERMIA	Anne Katrine Wulff Nielsen	Received

91-MON-PO	IS TGA ABLE TO DISCRIMINATE A DIFFERENT COAGULATION PROFILE IN INHIBITOR PATIENTS WITH SEVERE HEMOPHILIA A AS COMPARED TO NON-INHIBITOR PATIENTS?	Maria Elisa Mancuso	Received

91-WED-PO	BLOCKING HETEROMERIZATION OF PLATELET CHEMOKINES CCL5 AND CXCL4 REDUCES INFLAMMATION AND PRESERVES HEART FUNCTION AFTER MYOCARDIAL INFARCTION	Tanja Vajen	Received

92-MON-PO	IMPACT OF EDOXABAN ON A LARGE PANEL OF ROUTINE OF MORE SPECIFIC COAGULATION ASSAYS	Jonathan Douxfils	Received

92-TUE-PO	EVALUATION OF AN AUTOMATED COAGULOMETER IN A NEW HAEMOPHILIA CARE CENTER	Mirta Arias	Received

93-MON-PO	MODIFICATION OF A THROMBIN GENERATION TEST TO IDENTIFY NEW COFACTORS OF THE PROTEIN C PATHWAY IN PLASMA	Silvia Navarro	Received

94-WED-PO	MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING CORONARY ANGIOPLASTY: ROLE OF NADPH OXIDASE P22PHOX GENE POLYMORPHISMS	Betti Giusti	Received

95-MON-PO	PROVISION OF EXTERNAL QUALITY ASSURANCE FOR THROMBOELASTOGRAPHY (TEG) AND THROMBOELASTOMETRY (ROTEM)	Dianne Kitchen	Received

95-TUE-PO	VTE RECURRENCE AND BLEEDING IN PATIENTS WITH CANCER. RESULTS OF THE OPTIMEV STUDY	Sevestre Marie	Received

95-WED-PO	THROMBOGENICITY ACCORDING TO THE VASCULAR SITE OF ATHEROSCLEROSIS DISEASE	DANIELA CALDERARO	Received

96-MON-PO	ANTICOAGULATION ASSESSMENT WITH PROTHROMBIN TIME AND ANTI-XA ASSAYS IN REAL-WORLD PATIENTS ON TREATMENT WITH RIVAROXABAN	Oliver Knigsbrgge	Received

96-WED-PO	THE ROLES OF TRANSGLUTAMINASE 2 AND FXIII-A IN ABDOMINAL AORTIC ANEURYSM DEVELOPMENT	Kingsley Simpson	Received

98-WED-PO	TWO PEPTIDE EPITOPES DERIVED FROM HUMAN AND MYCOBACTERIUM, RESPECTIVELY, REDUCE ATHEROSCLEROTIC LESION IN B6;129S-LDLR(TM1HER)APOB(TM2SGY)/J MICE	Xinjie Lu	Received

98-TUE-PO	CANCER ASSOCIATED THROMBOSIS: DEVELOPING CONSENSUS GUIDANCE TO IMPROVE PATIENT CARE AND OUTCOMES	Roopen Arya	Received

99-MON-PO	MONITORING NEW ORAL ANTICOAGULANTS (NOACS) USING NEW-GENERATION THROMBELASTOGRAPHY TEG6S SYSTEM	Udaya Tantry	Received

100-WED-PO	THE ROLE OF CLOTTING FACTOR IX IN THE DEVELOPMENT OF ATHEROSCLEROSIS	Laís Ívina Silva de Paula Laís Ívina	Received

100-TUE-PO	AGE-ADJUSTED D-DIMER CUT-OFF LEVEL INCREASES THE NUMBER OF CANCER PATIENTS IN WHO PULMONARY EMBOLISM CAN BE SAFELY EXCLUDED WITHOUT CTPA IMAGING: THE ADJUST-PE CANCER SUBSTUDY	Dorienke Wilts	Received

101-MON-PO	FXII618, A NEW FACTOR XII INHIBITOR: VALIDATION FOR THROMBIN GENERATION ASSAY	sara calzavarini	Received

101-WED-PO	PHOSPHORYLATION OF PLATELET ACETYL-COA CARBOXYLASE IS INCREASED IN HUMAN AND MICE ATHEROSCLEROSIS AND COULD BE AN INDICATOR OF PERSISTENT THROMBIN GENERATION.	Sophie Lepropre	Received

102-MON-PO	PF4-R, A NOVEL HEPARIN NEUTRALIZING REAGENT SUITABLE FOR AUTOMATED COAGULOMETERS: COMPARISON WITH HEPARINASE IN ROUTINE COAGULATION TESTS	Elaine Benoit	Received

104-WED-PO	EFFECT OF DABIGATRAN ETEXILATE AND WARFARIN ON ATHEROSCLEROTIC PLAQUE CALCIFICATION IN APOE-/- MICE.	Leon Schurgers	Received

104-MON-PO	TESTING AN IN VITRO MODEL OF LAMINAR FLOW FOR USE IN LARGE-SCALE APTAMER SCREENING	Laura Sommerville	Received

104-TUE-PO	RISK OF CANCER AFTER VENOUS THROMBOEMBOLISM - THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) COHORT	Hilde Jensvoll	Received

105-MON-PO	POLYHEDROCYTES IN WHOLE BLOOD CLOTS OF PATIENTS WITH TYPE 2 DIABETES	Jakub Siudut	Received

105-TUE-PO	MANAGEMENT OF CANCER ASSOCIATED THROMBOSIS IN FRANCE : A NATIONAL SURVEY IN VASCULAR DISEASE AND SUPPORTIVE CARE SPECIALISTS	Isabelle Mahé	Received

106-TUE-PO	VENOUS THROMBOEMBOLISM AFTER SURGICAL TREATMENT OF SKELETAL METASTASES AN UNDERDIAGNOSED COMPLICATION	Riitta Lassila	Received

106-MON-PO	ACTIVATION OF COAGULATION BY ANTINEOPLASTIC DRUGS FOR LYMPHOID TUMORS	Misae Tsunaka	Received

107-TUE-PO	MAJOR AND NON-MAJOR CLINICALLY RELEVANT BLEEDING IN PATIENTS HOSPITALIZED IN PALLIATIVE CARE UNITS: RESULTS OF A FRENCH MULTICENTRE OBSERVATIONAL STUDY.	Tardy Bernard	Received

107-MON-PO	PROCOAGULANT TUMOR MICROENVIRONMENT AS TARGET FOR A TFPI-LIKE MOLECULE	Kátia Luciano Pereira Morais	Received

109-MON-PO	EFFECT OF HYPOXIA ON TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION IN BREAST CANCER CELLS	Xue Yan Cui	Received

110-WED-PO	CAN COMPARING THE VALUE OF THE PROTHROMBIN TIME RATIO AND THE ACTIVATED PARTIAL THROMBOPLASTIN TIME RATIO HELP DIAGNOSE THE CAUSE OF COAGULOPATHY?	Yingyong Chinthammitr	Received

110-MON-PO	THE THROMBOTIC POTENTIAL OF CIRCULATING TUMOR MICROEMBOLI	Annachiara Mitrugno	Received

111-MON-PO	FIBRIN DEGRADATION BY RTPA IMPROVE NANOPARTICLE DRUG DELIVERY FOR TUMORS	Bo Zhang	Received

111-TUE-PO	AGE SHOULD NOT BE CONSIDERED A RISK FACTOR FOR CANCER-RELATED VENOUS THROMBOEMBOLISM: RESULTS FROM THE SCANDINAVIAN THROMBOSIS AND CANCER STUDY	Kristine Blix	Received

112-TUE-PO	CANCER-RELATED VENOUS THROMBOEMBOLISM IN THE GENERAL POPULATION: RESULTS FROM THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY	Kristine Blix	Received

112-WED-PO	EFFECT OF RECOMBINANT LUBRICIN ON COAGULATION PARAMETERS IN HUMAN BLOOD	Jawed Fareed	Received

112-MON-PO	HUMAN ANGIOSARCOMA CELLS EXPRESS TISSUE FACTOR AND GENERATE THROMBIN IN A TISSUE FACTOR-DEPENDENT MANNER	Lauren Witter	Received

113-TUE-PO	INCIDENCE, RISK FACTORS, AND OUTCOME OF EARLY HEMOSTATIC COMPLICATIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY OF 551 PATIENTS	yue han	Received

114-WED-PO	ABILITY OF THROMBOELASTOGRAPHY TO DISTINGUISH THE SEVERITY OF PHENOTYPE IN PATIENTS WITH SEVERE HEMOPHILIA	Maria Elisa Mancuso	Received

114-TUE-PO	DETECTION OF HYPERCOAGULABILITY IN HEPATOCELLULAR CARCINOMA (HCC).	Spiezia Luca	Received

115-WED-PO	ARE WHOLE BLOOD COAGULATION ANALYSES TEMPERATURE DEPENDENT?	Anni Jeppesen	Received

116-TUE-PO	FACTORS INFLUENCING THE USE OF THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS IN THE REAL WORLD CLINICAL PRACTICE	Ramón Lecumberri	Received

117-MON-PO	ACTIVATED PROTEIN C UP- REGULATES THE OVARIAN CANCER CELL MIGRATION AND PROMOTES UNCLOTTABILITY OF CANCER PERITONEAL FLUID	Hamda Althawadi	Received

117-TUE-PO	RESIDUAL VEIN THROMBOSIS TO ASSES THE DURATION OF LOW MOLECULAR WEIGHT HEPARIN (THE EXTENDED CANCER-DACUS)	mariasanta Napolitano	Received

118-MON-PO	ESTROGENS UPREGULATE TFPI-2 EXPRESSION IN MCF-7 CELLS PROBABLY BY PROMOTER DEMETHYLATION	Grethe Skretting	Received

119-MON-PO	ENDOTHELIAL PROTEIN C RECEPTOR IN BREAST CANCER CELLS, CO-EXPRESSED WITH MULTIDRUG RESISTANCE PROTEIN, INHIBITS FIBRIN FORMATION IN TUMOR MICRO ENVIRONMENT	Halema AlFarsi	Received

119-WED-PO	DOES ANTITHROMBOTIC THERAPY INFLUENCE RESULTS OBTAINED BY THROMBOELASTOMETRY?	Mia Hammer Holck	Received

120-WED-PO	SCREENING METHOD USING TWO DIFFERENT ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) REAGENTS FOR SPECIMENS WITH PROLONGED APTT	Emi Takeo	Received

120-TUE-PO	THROMBOEMBOLIC EVENTS IN CHILDREN WITH CANCER IN SRINAGARIND HOSPITAL	Patcharee Komvilaisak	Received

120-MON-PO	CHANGES IN COAGULATION IN ACUTE PROMYELOCYTIC LEUKAEMIA	Richard Dillon	Received

121-MON-PO	FIBRINOLYTIC ACTIVATION IN ACUTE PROMYELOCYTIC LEUKAEMIA	Richard Dillon	Received

121-TUE-PO	THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH LYMPHOMA	Darko Antic	Received

121-WED-PO	TROMBIN GENERATION; ESTABLISHMENT OF REFERENCE INTERVAL AND THE INFLUENCE OF ASPIRIN	Vivi Bo Mogensen	Received

122-MON-PO	CONDITIONAL INACTIVATION OF INTEGRIN ?V SUBUNIT IN VASCULAR SMOOTH MUSCLE CELLS DECREASES THROMBIN GENERATION IN VESSELS AND BLOOD.	MOHAMADI AMEL	Received

122-WED-PO	A NEW ASSAY FOR MEASUREMENT OF THE IN-VIVO THROMBIN ACTIVITY IN COMPARISON TO THE IN-VITRO THROMBIN GENERATION POTENTIAL IN PATIENTS WITH HYPER- AND HYPOCOAGULABLE STATE	Silvia Koder	Received

123-MON-PO	OESTROGENS REGULATE TFPI EXPRESSION THROUGH OESTROGEN RESPONSE ELEMENTS IN TFPI 5 FLANKING REGION	Huda Omar Ali	Received

123-WED-PO	INFLUENCE OF PRE-ANALYTICAL HEPARIN ON T-PA INDUCED FIBRINOLYSIS DETERMINED BY THROMBOELASTOGRAPHY.	Floor Moenen	Received

124-WED-PO	THE EFFECT OF FRESH FROZEN PLASMA IN CRITICALLY ILL PATIENTS	Emil Vibede	Received

125-WED-PO	A DRVVT-BASED ASSAY TO ESTIMATE THE INTENSITY OF ANTICOAGULATION IN PATIENTS TREATED WITH DIRECT ORAL ANTICOAGULANTS	Anne-Laure Sennesael	Received

126-TUE-PO	A NEW GENERIC RISK SCORE FOR PREDICTING VENOUS THROMBOEMBOLIC EVENTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY	Andres Muñoz	Received

126-WED-PO	PRE-ANALYTICAL SAMPLE CHECK IN HAEMOSTASIS: EVALUATION OF THE NEW COAGULOMETER ACL TOP 750 CTS SYSTEM	Chiara Novelli	Received

127-MON-PO	PROCOAGULANT EFFECTS OF LUNG CANCER CHEMOTHERAPY THROUGH RELEASE OF MICROPARTICLES AND CELL-FREE DNA.	Zakhar Lysov	Received

127-TUE-PO	THROMBOPROPHYLAXIS OF AMBULANT PANCREATIC CANCER PATIENTS: SINGLE CENTRE EXPERIENCE UTILIZING THE LESSONS FROM FRAGEM AND CONKO-04.	Iqtedar Ahmed	Received

128-MON-PO	THE REED STERNBERG CELL COAGULOME	Gabriela Cesarman-Maus	Received

128-TUE-PO	TREATMENT OF CANCER ASSOCIATED THROMBOSIS AFTER THE INITIAL 6 MONTH PERIOD.	Petr Kessler	Received

129-MON-PO	FACTOR VII DERIVED PROTEIN EGFP-EGF1 MEDIATE DRUG DELIVERY SYSTEM FOR HUMAN TUMOR	Wei Shi	Received

130-WED-PO	EVALUATION OF WAVEFORM ANALYSIS ON THE DESTINY MAX COAGULATION ANALYSER	Jane Needham	Received

130-TUE-PO	RIVAROXABAN ASSOCIATES WITH FACTOR XA FASTER THAN APIXABAN: A POTENTIAL EXPLANATION FOR THEIR DIFFERENT EFFECTS ON TESTS OF COAGULATION	Calvin Yeh	Received

131-MON-PO	HYPOXIA-INDEPENDENT TUMOR PROGRESSION: ACTIVATION OF TRANSCRIPTION FACTOR HIF 1 VIA PAR1 AND PAR2 RECEPTORS IN BREAST CANCER.	Tainá Gomes	Received

131-WED-PO	FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE SHOWS ANTICOAGULANT EFFECT WHEN USED FOR IN VITRO EXPERIMENTS	Emilie Sandgaard Pedersen	Received

131-TUE-PO	GENERATION OF A RECOMBINANT TRUNCATED ACTIVATED FACTOR X AS ANTI-HEMOPHILIC AGENT	PLANTIER Jean-Luc	Received

133-MON-PO	NEUTROPHIL EXTRACELLULAR TRAPS MEDIATE ARTERIAL AND VENOUS THROMBUS FORMATION IN A MURINE BREAST CANCER MODEL	robson monteiro	Received

134-TUE-PO	NOVEL F10: P. CYS57ARG MUTATION IN A PAKISTANI SEVERE FX-DEFICIENT PROBAND	MUNIRA BORHANY	Received

134-WED-PO	IMPACT OF SILVER NANOPARTICLES ON HEMOLYSIS, PLATELET FUNCTION, COMPLEMENT SYSTEM AND COAGULATION	Julie Laloy	Received

135-MON-PO	PROTEOLYTIC INACTIVATION OF COAGULATION FACTOR V BY OMPT FROM ENTEROHEMORRHAGIC ESCHERICHIA COLI.	John Samis	Received

135-TUE-PO	THE IL-10 POLARIZED CYTOKINE PATTERN IN INNATE AND ADAPTIVE IMMUNITY CELLS CONTRIBUTE TO THE DEVELOPMENT OF FVIII INHIBITORS	Daniel Chaves	Received

136-WED-PO	NEW LIQUID RECOMBINANT THROMBOPLASTIN (DG PT RECOMBILIQ, DIAGNOSTIC GRIFOLS) SUITABLE FOR ROUTINE USE	Anita Woolley	Received

136-MON-PO	COMBINED FV AND FVIII DEFICIENCY (F5F8D) IN A CHINESE FAMILY WITH A NOVEL MISSENSE MUTATION IN MCFD2 GENE	anyou wang	Received

137-TUE-PO	ASSOCIATION OF ARTERIAL AND VENOUS THROMBOSIS WITH CLOTTING FACTOR USED IN PATIENTS WITH HEMOPHILIA	Jiaan-Der Wang	Received

137-MON-PO	SUCCESSFUL ABDOMINAL OPERATION WITHOUT REPLACEMENT THERAPY IN A PATIENT WITH COMBINED FV AND FVIII DEFICIENCY DUE TO NOVEL HOMOZYGOUS MUTATION IN LMAN1	anyou wang	Received

138-WED-PO	SILICA CLOTTING TIME (SCT) VS DILUTE RUSSELL VIPER VENOM TIME (dRVVT) AND ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) IN THE DIAGNOSIS OF ANTIPHOSPHOLIPID ANTIBODIES SYNDROME.	Evelyn Cortina de la Rosa	Received

138-MON-PO	ENGAGEMENT OF THE ACTIVE SITE OF THROMBIN BY DABIGATRAN OR ARGATROBAN MODULATES ITS EXOSITE-MEDIATED INTERACTIONS WITH FIBRIN AND FACTOR VA	Calvin Yeh	Received

139-WED-PO	DISCORDANCE BETWEEN ACTIVATED PARTIAL THROMBOPLASTIN TIME AND HEPARIN LEVEL MEASURED WITH ANTI-XA ASSAY IN ANTITHROMBIN-DEFICIENT PLASMA	Alice Yi	Received

139-MON-PO	FACTOR VA IN SYNERGY WITH PROTEIN S ENHANCES ACTIVATED PROTEIN C BINDING TO PHOSPHOLIPIDS	Magdalena Gierula	Received

141-WED-PO	EVALUATION OF THE NEW QSMART FROM GRIFOLS IN COMPARISON TO THE QHEMOSTASIS ANALYZER	Anita Woolley	Received

141-MON-PO	REFERENCE VALUE AND STABILITY OF FACTOR V	Widhyastuti Reny	Received

142-WED-PO	HEMOCOMPATIBILITY OF ESTETROL AND ESTRADIOL COUPLED TO CYCLODEXTRINES	Julie Laloy	Received

142-TUE-PO	THE TYPE OF REAGENTS DETERMINES THE ACCURACY OF CALIBRATION WITH A PRODUCT SPECIFIC STANDARD FOR THE MEASUREMENT OF THE B-DOMAIN DELETED RFVIII MOROCTOCOG ALFA-AF ACTIVITY.	Jacquemin Marc	Received

143-WED-PO	EVALUATION OF PROLONGED PT / APTT TESTS IN PRESURGICAL PLASMA SAMPLES	ZHRE KAYA	Received

144-WED-PO	VALIDATION OF NEW AUTOMATED LATEX-IMMUNOTURBIDIMETRIC ASSAY FOR MEASURING VWF ACTIVITY	Desiree Coen Herak	Received

145-WED-PO	LABORATORY EVALUATION OF PATIENTS WITH UNDIAGNOSED BLEEDING DISORDERS	Fernanda Bassora	Received

146-WED-PO	COMPARISON OF METHODS OF MEASUREMENT OF FACTOR VIII INHIBITORS IN A NEW HAEMOPHILIA CARE CENTER	Mirta Arias	Received

147-WED-PO	THE NORMAL RANGE OF THE THROMBODYNAMICS VALUES FOR APPARENTLY HEALTHY PREGNANT WOMEN	Tatiana Vuimo	Received

148-MON-PO	EARLY IMMUNOLOGICAL EVENTS IN AAV-F9 MEDIATED ITI FOR HEMOPHILIA B MICE WITH PATHOGENIC FIX INHIBITORS	David Markusic	Received

149-TUE-PO	DIFFERENT STRATEGIES FOR TREATMENT ON HEMOPHILIA PATIENTS WITH INHIBITOR, COSTS VERSUS BENEFITS	Mohammadreza Baghaipour	Received

149-WED-PO	CAN THE OVERALL HAEMOSTATIC POTENTIAL ASSAY PREDICT BLEEDING AND THROMBOSIS RISK IN WARFARINISED PATIENTS?	Caroline Reddel	Received

150-MON-PO	ASSESSMENT OF RECOMBINANT FACTOR IX-FC FUSION PROTEIN (RFIXFC) CLOTTING ACTIVITY IN PLASMA SAMPLES AT CANADIAN HAEMOPHILIA TREATMENT CENTRES	Elaine Benoit	Received

151-MON-PO	A CASE OF SEVERE HEMOPHILIA B ASSOCIATED WITH A LARGE INSERTION OF SVA RETROTRANSPOSON IN THE COAGULATION FACTOR IX GENE	Naoki Mizutani	Received

151-WED-PO	HEPARIN AND PROTAMINE CONFOUND FACTOR ACTIVITY AND INHIBITOR TESTING WHILE ON CARDIOPULMONARY BYPASS	Michelle Sholzberg	Received

152-WED-PO	HEMOSTASIS ALTERATIONS ASSOCIATED TO COMPLICATIONS IN SICKLE CELL SYNDROME	HIGUERA DIEGO	Received

153-MON-PO	THE EFFECTS OF A NOVEL LONG-ACTING FACTOR IX PRODUCT (N9-GP) ON WOUND HEALING	Elizabeth Chappell	Received

154-WED-PO	BLOOD COAGULATION TESTS: REVIEW OF VALIDATION REQUIREMENTS FOR FDA CLEARANCE	Iwona Fijalkowska	Received

154-MON-PO	INHERITED FACTOR VIII AND IX DEFICIENCY IN PATIENTS REPORTED TO A TERTIARY CARE UNIVERSITY HOSPITAL IN INDIA: A RETROSPECTIVE COHORT ANALYSIS	Benson Babu	Received

155-MON-PO	PROTEIN S, A NEW AGENT IN ADJUNCT THERAPY OF HEMOPHILIA B	Rinku Majumder	Received

155-WED-PO	SP-SELECTIN AS A MARKER OF PLATELET ACTIVATION IN AFRICANS WITH PROSTATE CANCER.	HANNAH OMUNAKWE	Received

155-TUE-PO	RATE-LIMITING ROLES OF TENASE COMPLEX OF FACTORS VIII AND IX IN PLATELET PROCOAGULANT ACTIVITY AND FORMATION OF PLATELET-FIBRIN THROMBI UNDER FLOW	Johan Heemskerk	Received

156-MON-PO	IN VIVO EFFICACY OF HUMAN RECOMBINANT FACTOR IX PRODUCED BY THE HUMAN HEPATOMA CELL LINE HUH-7	Nathalie ENJOLRAS	Received

156-WED-PO	FRACTAL DIMENSION (DF) AS A MARKER OF HYPERCOAGULABILITY, CLOT STRUCTURE AND 12 MONTH SURVIVAL IN LUNG CANCER	Nia Davies	Received

156-TUE-PO	TREATMENT OF SEVERE BLEEDING AND PROPHYLAXIS WITH RFVIIA IN A CHILD WITH FVIII INHIBITOR	adalet meral gunes	Received

157-MON-PO	INCORPORATION OF MUTATIONS AT E410 OF FACTOR IX IMPROVES CLOTTING ACTIVITY IN VITRO AND IN VIVO	Nathalie ENJOLRAS	Received

158-MON-PO	THE SLEEPING-BEAUTY TRANSPOSON TECHNOLOGY FOR THE GENERATION OF CELLULAR AND ANIMAL MODELS OF HAEMOPHILIA B AND THE ASSESSMENT OF RNA-BASED THERAPEUTIC APPROACHES	Elena Barbon	Received

159-MON-PO	COMPARISON OF FACTOR IX GLYCOSYLATION IN DIFFERENT AGE GROUPS	Helen Atkinson	Received

159-WED-PO	FACTOR V LEIDEN MUTATION AND HIGH FVIII ARE ASSOCIATED WITH AN INCREASED RISK OF VTE IN WOMEN WITH BREAST CANCER DURING ADJUVANT TAMOXIFEN - RESULTS FROM A PROSPECTIVE, SINGLE CENTER, CASE CONTROL STUDY	Mirjana Kovac	Received

159-TUE-PO	INTRA-LABORATORY VARIATION IN FVIII :C INHIBITOR ASSAY :RESULTS OF A STUDY IN THREE FRENCH CENTERS	Christophe NOUGIER	Received

160-MON-PO	INVESTIGATIONS INTO ANTICOAGULANT RESISTANCE AND ENHANCED ACTIVATION AS PUTATIVE MOLECULAR MECHANISMS OF THE HYPERACTIVITY OF FACTOR IX PADUA	Ben Samelson-Jones	Received

161-WED-PO	INCREASING PLATELETS AND OTHER MEASURES ENHANCING HEMOSTASIS ARE BOTH IMPORTANT TO PREVENT BLEEDING EPISODES WHEN THROMBOCYTOPENIC PATIENTS REQUIRING ANTITHROMBOTIC THERAPY A REVIEW OF THE MEDICAL LITERATURE	Howard Chan	Received

162-TUE-PO	INVESTIGATING POTENTIAL DETERMINANTS OF ITI SUCCESS USING IMMUNE GENE EXPRESSION PROFILING: A PRELIMINARY STUDY	Davide Matino	Received

162-WED-PO	PANCREATIC CANCER PATIENTS EXPRESS ELEVATED FVIII LEVELS AND METASTASIS-ASSOCIATED FIBRIN TURNOVER PRIOR TO THEIR DIAGNOSIS	Nora Varkila	Received

163-TUE-PO	FACTOR VIII DEFICIENCY: INHIBITION OR ABNORMAL CONTACT?	ANA AZEVEDO	Received

164-WED-PO	PROTEIN C LEVELS ARE ASSOCIATED WITH MORTALITY IN PATIENTS WITH ADVANCED CANCER	Dorienke Wilts	Received

165-MON-PO	USING HPSEC TO QUANTIFY THE EFFECT OF GAMMA-CARBOXYLATION ON DIVALENT METAL-INDUCED COMPACTION OF VKD-PROTEINS AND BIOLOGICAL FUNCTION	NIcholas Vanderslice	Received

165-WED-PO	L-ASPARAGINASE LOWERS PLASMA ANTITHROMBIN AND MANNAN-BINDING-LECTIN LEVELS: IMPACT ON THROMBOTIC AND INFECTIOUS EVENTS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA	Arnaud Bonnefoy	Received

166-WED-PO	LONGITUDINAL ANALYSIS OF HEMOSTATIC BIOMARKERS IN CANCER PATIENTS DURING ANTI-TUMOR TREATMENT	Eva-Maria Reitter	Received

167-WED-PO	MICROVESICLES ARE A POTENTIAL BIOMARKER FOR THROMBOSIS AND DIC IN LEUKEMIC PATIENTS: A CROSS-SECTIONAL STUDY	Damien Gheldof	Received

168-MON-PO	EVALUATION OF HOST CELL PROTEIN IMMUNOGENICITY OF A POLISHED RECOMBINANT FACTOR IX INVESTIGATIONAL PRODUCT, IB1001 IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA B	Bojan Drobic	Received

168-TUE-PO	FACTOR XIA, FACTOR IXA AND TISSUE FACTOR ACTIVITY IN BLUNT TRAUMA PATIENTS	Saulius Butenas	Received

169-WED-PO	SIGNIFICANCE OF HAEMOSTATIC PARAMETERS IN PATIENTS WITH URINARY CANCER	Paraskevi Kotsi	Received

169-MON-PO	FACTOR IX IMMUNOGENICITY IN HEMOPHILIA B PATIENTS ON REPLACEMENT THERAPY WITH A RECOMBINANT FACTOR IX INVESTIGATIONAL PRODUCT (IB1001)	Bojan Drobic	Received

170-TUE-PO	HISTIDINE-RICH GLYCOPROTEIN BINDS DNA AND RNA AND ATTENUATES THEIR CAPACITY TO ACTIVATE THE INTRINSIC PATHWAY OF COAGULATION	Trang Vu	Received

171-TUE-PO	LOCALIZATION OF FACTOR XI IN PLATELETS IS NOT RESTRICTED TO ALPHA GRANULES.	Michal Zucker	Received

172-TUE-PO	THE 2,5-DICHLOROPHENYL FRAGMENT AS STARTING POINT IN THE DESIGN OF NEW FXIIA INHIBITORS	Charlotte Bouckaert	Received

174-MON-PO	MOYAMOYA SYNDROME IN A HEMOPHILIA A PATIENT WITH A HIGH-TITRE FVIII INHIBITOR	Wolf Hassenpflug	Received

174-TUE-PO	EVALUATION OF THE EFFECTS OF A NOVEL CONTACT PATHWAY INHIBITOR, IR-CPI, ON IN VITRO PLATELET FUNCTION AND COAGULATION	Jayaprakash Kotha	Received

175-MON-PO	OPTIMIZING PROCOAGULANT ACTIVITY FOR MUTANT RECOMBINANT FACTOR IX WITH RESISTANCE TO HEPARIN- AND ANTITHROMBIN	John Sheehan	Received

175-TUE-PO	BLOOD GROUP, BLEEDING PHENOTYPE AND POST-PARTUM HAEMORRHAGE IN FACTOR XI-DEFICIENT WOMEN	Bethan Myers	Received

175-WED-PO	RIVAROXABAN IN PATIENTS WITH VTE AND CANCER: A SINGLE CENTER EXPERIENCE	Samantha Pasca	Received

176-WED-PO	D-DIMER PLASMA LEVELS AS A MARKER OF PULMONARY EMBOLISM IN PATIENTS UNDERGOING SURGERY FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM	Andrea Artoni	Received

176-MON-PO	TO EVALUATE THE UTILITY OF ISTH SCORING SYSTEM, APTT AND SCHISTOCYTES AS MARKERS OF SEVERITY IN CASES OF DISSEMINATED INTRAVASCULAR COAGULATION.	Anjali Kelkar	Received

176-TUE-PO	IDENTIFICATION OF THREE NOVEL FACTOR XII MUTATIONS ASSOCIATED WITH CONGENITAL FACTOR XII DEFICIENCY	Peipei Jin	Received

177-WED-PO	TISSUE FACTOR PATHWAY INHIBITOR (TFPI) IS A MARKER OF TUMOR PROGRESSION AND PROGNOSIS IN BREAST CANCER	Mari Tinholt	Received

177-MON-PO	ROLE OF PLASMA HIGH MOBILITY GROUP BOX 1 IN DISSEMINATED INTRAVASCULAR COAGULATION WITH LEUKEMIA.	heng mei	Received

178-WED-PO	INCREASED ACTIVATED PROTEIN C RESISTANCE AND D-DIMER IN BREAST CANCER: PHENOTYPIC AND GENOTYPIC DETERMINANTS AND ASSOCIATION WITH TUMOR CHARACTERISTICS	Mari Tinholt	Received

179-WED-PO	THROMBIN GENERATION (TG) IS DOWNREGULATED BY LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM (VTE)	Marina Marchetti	Received

179-MON-PO	EVALUATION OF NEW CHINESE DIAGNOSTIC SCORING SYSTEM FOR DISSEMINATED INTRAVASCULAR COAGULATION.	heng mei	Received

179-TUE-PO	UNEXPECTED HEPATOCYTE GROWTH FACTOR ACTIVATOR (HGFA) ACTIVITY ALLOWS A POSSIBLE CROSSTALK BETWEEN ACTIVATED FACTOR XII AND THE HGF/C-MET PATHWAY IN HUMAN PLASMA	Benedito Prezoto	Received

180-MON-PO	A NOVEL MURINE MODEL OF DISSEMINATED INTRAVASCULAR COAGULATION (DIC) TO AID THE DEVELOPMENT OF NOVEL THERAPEUTICS TO TREAT DIC	Majid Ali	Received

180-WED-PO	HYPERCOAGULABILITY: AN ADDED SIDE EFFECT FOR ANDROGEN DEPRIVATION THERAPY IN PROSTATE CANCER PATIENTS	Harmanpreet Kaur	Received

180-TUE-PO	FXI AND FXII ACTIVITY LEVELS IN YOUNG PATIENTS WITH CRYPTOGENIC ISCHEMIC STROKE	Cristina Duboscq	Received

181-WED-PO	IDENTIFICATION OF TWO NOVEL MISSENSE MUTATIONS CAUSING SEVERE FACTOR XIII DEFICIENCY	MUNIRA BORHANY	Received

182-TUE-PO	SURFACE PLASMON RESONANCE: SENSIQ PIONEER AS A MEANS TO SCREEN DRUG DISCOVERY FRAGMENTS FOR HITS	Clare Wishart	Received

182-MON-PO	BIOMARKER PROFILE OF SEPSIS-ASSOCIATED COAGULOPATHY USING BIOCHIP ASSAYS FOR INFLAMMATORY CYTOKINES	Amanda Walborn	Received

182-WED-PO	FIRST GROUNDING FOR COMPLETE STRUCTURAL CHARACTERIZATION OF FXIII HETEROTETRAMER: SUCCESSFUL DISULFIDES	SNEHA GUPTA	Received

183-WED-PO	REVISITING THE MECHANISM OF COAGULATION FACTOR XIII ACTIVATION; A STRUCTURE FUNCTIONAL PERSPECTIVE	Sneha Gupta	Received

183-MON-PO	HYPOXIA INDUCES DYSREGULATION OF MIR-126 AND AFFECTS VEGF AND MMP-9 EXPRESSION IN ENDOTHELIAL CELLS	Satoshi Fujii	Received

184-WED-PO	MUTATING CORE STRUCTURAL DISULFIDES OF THE FXIII B SUBUNIT AS A MEANS TO UNCOVER THE FUNCTIONAL ROLES OF INDIVIDUAL FXIIIB SUBUNIT SUSHI DOMAINS	mohammad akhter	Received

184-TUE-PO	EFFECT OF A PLANT INHIBITOR OF THE CONTACT SYSTEM ON A MOUSE THROMBOSIS MODEL	Maria Luiza V. Oliva	Received

185-MON-PO	ANTI-THROMBOTIC AND PRO-FIBRINOLYTIC EFFECTS OF LEVOSIMENDAN IN HUMAN ENDOTHELIAL CELLS IN VITRO	Konstantin Krychtiuk	Received

185-TUE-PO	ENDOTHELIAL CELL INCREASES ITS RIGIDITY DURING INFLAMMATION THROUGH MODIFICATION OF THE GAP JUNCTION	Takayuki Okamoto	Received

185-WED-PO	THE ACTIVATION PEPTIDE OF COAGULATION FACTOR XIII IS VITAL FOR ITS EXPRESSION AND STABILITY	Verena Schroeder	Received

186-WED-PO	THE B-SUBUNIT OF COAGULATION FACTOR XIII DOES NOT SPECIFICALLY INTERACT WITH COMPLEMENT FACTORS	Verena Schroeder	Received

187-WED-PO	THE EFFECT OF FACTOR XIII B SUBUNIT POLYMORPHISMS ON FACTOR XIII LEVELS AND ON THE RISK OF CORONARY ARTERY DISEASE; INTERACTION WITH FIBRINOGEN LEVEL AND FACTOR XIII A SUBUNIT P.VAL34LEU POLYMORPHISM	László Muszbek	Received

187-MON-PO	ENDOTHELIAL FIBRINOLYTIC RESPONSE ONTO AN EVOLVING MATRIX OF FIBRIN	Marchi Rita	Received

188-MON-PO	A MICROFLUIDIC VASCULAR INJURY MODEL USING HEAT-ACTIVATED ENDOTHELIAL CELLS	Joanna Sylman	Received

188-WED-PO	FXIII-A V34L AFFECTS THROMBUS CROSS-LINKING, BUT NOT SIZE, IN A MURINE THROMBOSIS MODEL	Cedric Duval	Received

190-WED-PO	RESIDENT TISSUE MACROPHAGES ARE THE PROBABLE SOURCE OF PLASMA CLOTTING FACTOR XIII-A	Kingsley Simpson	Received

190-TUE-PO	ACTIVATION OF THE ENDOTHELIUM MAY BE INVOLVED IN THE HEMOSTATIC ALTERATIONS INDUCED BY MICRURUS TENER TENER VENOM IN C57BL/6 MICE	Emelyn Salazar	Received

190-MON-PO	CIRCULATING ENDOTHELIAL CELLS ARE INCREASED IN POST-THROMBOTIC SYNDROME PATIENTS	Mariane Flores-Nascimento	Received

191-TUE-PO	INCREASED ENDOCAN LEVELS AND ITS ASSOCIATION WITH SEVERITY IN STEVENS JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS.	Daneyal Syed	Received

191-WED-PO	EFFECT OF STABLE GABARAP KNOCKOUT ON THE FVIII SECRETION	Heike Singer	Received

192-MON-PO	EFFECT OF MATERNAL ANTI-HPA-1A ANTIBODIES ON ENDOTHELIAL CELLS	Rima Dardik	Received

192-WED-PO	DIMERIC ORGANIZATION OF MEMBRANE-BOUND FACTOR VIII ON LIPID NANOTUBES	Svetla Stoilova-McPhie	Received

193-MON-PO	ENDOTHELIAL DYSFUNCTIONS IN CIRRHOSIS PATIENTS	CLAUDIA MARIA RADU	Received

195-MON-PO	EVALUATION OF DIFFERENT ASSAYS OF D-DIMER AND SOLUBLE FIBRIN IN EMERGENCY DEPARTMENT PATIENTS WITH SUSPECTED VENOUS THROMBOEMBOLISM	Maria Farm	Received

196-WED-PO	EXPRESSION, PURIFICATION AND CHARACTERIZATION OF CODON OPTIMIZED COAGULATION FACTOR VIII	Andrey Sarafanov	Received

196-MON-PO	PERFORMANCE OF AGE ADJUSTED D-DIMER CUT OFF VALUE: A STEP TOWARDS IMPROVING CLINICAL UTILITY IN DIAGNOSIS OF ASYMPTOMATIC VENOUS THROMBOEMBOLISM	salma shawkat	Received

197-TUE-PO	INTERNATIONAL STUDY TO ASSESS THE PERFORMANCES OF A NEW LIQUID ASSAY FOR DETERMINATION OF FIBRINOGEN	Neil Harris	Received

198-WED-PO	MINIGENE APPROACH TO CHARACTERIZE A NOVEL SPICE SITE MUTATION IN HUMAN F8 GENE CAUSING SEVERE HAEMOPHILIA A	jourdy yohann	Received

200-TUE-PO	A CASE OF THROMBOSIS IN CONGENITAL AFIBRINOGENEMIA PATIENT: A PHYSIOPATHOLOGIC AND MANAGEMENT DILEMMA	Cristina Santoro	Received

201-TUE-PO	CTEPH-ASSOCIATED DYSFIBRINOGENEMIA WITH ENHANCED ACCESSIBILITY ON FIBRIN OF LIGANDS FOR VE-CADHERIN	Benjamin PLANQUETTE	Received

201-MON-PO	AN EVALUATION OF THE TOSOH BIOSCIENCE ST AIA-PACK DDIMER PERFORMED WITH THE AIA-360 AUTOMATE	Julie M Smith	Received

202-MON-PO	EVALUATION OF DIAGNOSTIC ACCURACY OF TWO D-DIMER ASSAYS IN PULMONARY EMBOLISM	Wallace Feese	Received

202-WED-PO	MOLECULAR SIGNATURE OF LSECS: A F8 SECRETING ENDOTHELIAL CELLS	Osman El-Maarri	Received

203-MON-PO	DS-1040: A NOVEL SELECTIVE INHIBITOR OF ACTIVATED FORM OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR	Kengo Noguchi	Received

203-WED-PO	ANCESTRAL RECONSTRUCTION OF COAGULATION FACTOR VIII	Philip Zakas	Received

204-TUE-PO	HAEMOPHILIA PRESENTATIONS.LET ME COUNT THE WAYS.	Vaughan WILLIAMS	Received

205-TUE-PO	INTRACRANIAL HEMORRHAGE IN EARLY NEONATES WITH HEMOPHILIA IN JAPAN	Masashi Taki	Received

205-WED-PO	LONG-TERM PHENOTYPIC CORRECTION OF HEMOPHILIA A MICE BY NON-VIRAL PIGGYBAC TRANSPOSON VECTOR	HIDETO MATSUI	Received

206-WED-PO	DISCORDANT IN VITRO AND IN VIVO ACTIVITY OF FACTOR VIII MUTANTS	Amine Bazaa	Received

207-MON-PO	EXPERIMENTAL VALIDATION OF A STOCHASTIC MULTISCALE MODEL OF FIBRINOLYSIS	Brittany Bannish	Received

207-TUE-PO	NATIONAL INHIBITOR SURVEY IN HAEMOPHILIA PATIENTS (NISH) FROM INDIA	Shrimati Shetty	Received

209-TUE-PO	A STUDY OF DEPRESSION IN FAMILY MEMBERS OF HEMOPHILIAC PATIENTS	Mikyung Kim	Received

209-MON-PO	THE ANTIFIBRINOLYTIC EFFECT OF FACTOR XIII STRONGLY DEPENDS ON CLOT COMPACTION/RETRACTION	Dick Rijken	Received

210-MON-PO	THE ASSOCIATION OF PAI-1 AND CLOT LYSIS TIME WITH BODY COMPOSITION IN AFRICANS IS SEX DEPENDENT	Zelda De Lange	Received

210-WED-PO	RARE ALTERNATE PRESENTATIONS OF THE F8 INTRON 22 INVERSION MUTATION COMPLICATE DETECTION AND MAY LEAD TO MISDIAGNOSIS.	Jacky Cutler	Received

210-TUE-PO	HAEMTRACK: UK PATIENT HOME THERAPY REPORTING SYSTEM	Rob Hollingsworth	Received

212-TUE-PO	ENDOVASCULAR ABDOMINAL AORTIC ANEURYSM REPAIR IN A PATIENT WITH MILD HEMOPHILIA A ON DABIGATRAN FOR ATRIAL FIBRILLATION	Beatriz Delgado	Received

213-TUE-PO	ANALYSIS OF MODERATE PHENOTYPE OF HEMOPHILIA A WITH NOVEL MISSENSE MUTATION, W2229R IN C2 DOMAIN, OF WHICH FVIII HAS NO RESPONSIVENESS WITH DDAVP.	Takashi Suzuki	Received

214-TUE-PO	RUSSIAN NATIONAL REGISTRY OF INHIBITOR HEMOPHILIA PATIENTS: FIRST CUT-OFF ANALYSIS	Nadezhda Zozulya	Received

214-MON-PO	THE INFLUENCE OF RESIDUAL PLATELETS ON PLASMA PAI-1 ASSAYS	Sunelle Barnard	Received

215-MON-PO	CLOT LYSIS PARAMETERS ARE HIGHER IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH A HISTORY OF THROMBOEMBOLISM	Lize Bollen	Received

215-TUE-PO	SEPTIC ARTHRITIS IN HEMOPHILIC TARGET JOINTS A NOT UNCOMMON COMPLICATION AWARENESS IS THE MAIN DIAGNOSTIC FEATURE	Peter Staritz	Received

216-WED-PO	INTERNATIONAL STUDY TO ASSESS THE PERFORMANCE OF IMMUNODEPLETED PLASMAS FOR DETERMINATION OF FACTORS VIII AND IX ACTIVITY	Chris Watson	Received

216-MON-PO	TISSUE PLASMINOGEN ACTIVATOR (T-PA) RELEASED FROM HUMAN CELLS BY SOFT RUSH JUNCUS EFFUSUS L. VAR. DECIPENS	Hiroyuki Sumi	Received

216-TUE-PO	MANAGING MODERN MAJOR ORTHOPAEDIC SURGERY WITH PLASMA DERIVED FVIII CONCENTRATE (FANHDI) IN SEVERE HAEMOPHILIA A PATIENTS WITH ADVANCED ARTHROPATHY	Pu-Lin Luo	Received

217-MON-PO	GLOBAL FIBRINOLYTIC PROFILE IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION	Aurélien Lebreton	Received

217-WED-PO	GENETIC DETERMINANTS FOR FACTOR VIII LEVELS: GENOME-WIDE LINKAGE AND ASSOCIATION ANALYSES FROM THE GAIT PROJECT	Sonia López	Received

217-TUE-PO	Intra-operative monitoring of Hemophilia patients during coronary artery bypass graft surgery using Thromboelastogram	Mudi Misgav	Received

218-TUE-PO	FACTORS INFLUENCING RISK OF BLEEDING AFTER DENTAL EXTRACTION IN HEMOPHILIA PATIENTS	Predrag Miljic	Received

220-MON-PO	CELL-FREE DNA MODULATES CLOT STRUCTURE AND IMPAIRS FIBRINOLYSIS IN SEPSIS.	Travis Gould	Received

220-TUE-PO	INDIVIDUALISED TREATMENT IN HAEMOPHILIA A VARIABILITY IN FACTOR VIII ACTIVITY MEASUREMENT FOR PHARMACOKINETIC DOSING	Jane Needham	Received

221-WED-PO	LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 EXPRESSION IN LIVER IS ASSOCIATED WITH PLASMA FACTOR VIII LEVELS	Luis Fernando Bittar	Received

221-TUE-PO	CYCLOPHOSPHAMIDE EFFICACY AND TOXICITIES IN THE FIRST LINE TREATMENT OF ACQUIRED HEMOPHILIA	John Chapin	Received

222-MON-PO	IN-VITRO IMAGING OF PLATELET/FIBRIN CLOT FORMATION AND LYSIS IN FLOW CONDITION	stéphane LOYAU	Received

222-TUE-PO	TWO YEAR USE OF SHARED GUIDELINES AND A DEDICATED WEB SITE TO IMPROVE MANAGEMENT OF INHERITED BLEEDING DISORDERS IN THE EMERGENCY DEPARTMENT	Annarita Tagliaferri	Received

223-TUE-PO	EVIDENCE OF APCC MODE OF ACTION IN A CLINICAL STUDY TREATING HEMOPHILIA A INHIBITOR PATIENTS WITH PROPHYLAXIS THERAPY	Srilatha Tangada	Received

224-MON-PO	THE EFFECT OF ALPHA-2 PLASMIN INHIBITOR ARG6TRP POLYMORPHISM ON THE RISK OF CORONARY ARTERY DISEASE	Éva Katona	Received

225-TUE-PO	LONG TERM FOLLOW-UP IN THE USE OF DIFFERENT TYPES OF CENTRAL VENOUS CATHETERS IN CHILDREN WITH HEMOPHILIA ON PROPHYLAXIS OR IMMUNE-TOLERANCE REGIMEN	Marta Milan	Received

225-WED-PO	HEMOPHILIA A CAUSED BY RETROTRANSPOSITION OF LONG INTERSPERSED ELEMENT-1 (LINE-1) INTO THE FVIII GENE	Rima Dardik	Received

226-MON-PO	IMPAIRED FIBRINOLYSIS IN BEHET SYNDROME	Domenico Prisco	Received

226-TUE-PO	SUCCESSFUL MULTI-VESSEL PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME IN A SEVERE TAIWANESE HEMOPHILIAC WITH HIV INFECTION UNDER HARRT:THE FIRST REPORTED CASE IN CHINESE POPULATION	Chia-Yau Chang	Received

227-TUE-PO	RELATIONSHIP BETWEEN QUALITY OF LIFE AND COAGULATION FACTOR LEVEL IN HEMOPHILIA CARRIERS: PRELIMINARY RESULTS	Jane Young	Received

227-WED-PO	SURFACE BOUND VON WILLEBRAND FACTOR MODULATES FACTOR VIII PEPTIDE PRESENTATION BY DENDRITIC CELLS	Robin Hartholt	Received

227-MON-PO	VARIABLE RESISTANCE TO PLASMINOGEN ACTIVATOR INITIATED FIBRINOLYSIS FOR INTERMEDIATE-RISK PULMONARY EMBOLISM	William Stubblefield	Received

228-TUE-PO	DOES THE QUALITY OF TREATMENT AND NOT ONLY FACTOR VIII LEVELS INFLUENCE GLOBAL HEMOSTASIS IN PATIENTS WITH HEMOPHILIA A?	Maria Berndtsson	Received

228-MON-PO	CARRIER AND PRENATAL DIAGNOSIS OF CHINESE HAEMOPHILIA A FAMILIES IN ONE CENTER FROM 2007 TO 2014	Yeling Lu	Received

229-WED-PO	FVIII ACTIVITY ASSAY VARIABILITY OF THE PEGLYLATED FORM OF RFVIII ADVATE (BAX 855) IN CLINICAL HEMOSTASIS LABORATORIES: INTERIM RESULTS FROM A WORLD-WIDE FIELD STUDY	Jane Mannion	Received

229-MON-PO	GENETIC ALTERATIONS IN HEMOPHILIAC PATIENTS WITH INHIBITOR IN THE REGION OF MURCIA. SPAIN.	FAUSTINO GARCÍA-CANDEL	Received

230-TUE-PO	DEFINING ADHERENCE TO PROPHYLAXIS IN HAEMOPHILIA: RESULTS OF A DELPHI CONSENSUS PROCEDURE	Liesbeth Schrijvers	Received

231-WED-PO	COMPARISON OF METHODS FOR THE DOSAGE OF FVIII IN A NEW HAEMOPHILIA CENTER CARE	Emanuel Sueldo	Received

231-MON-PO	ANTIBODIES OF HIGH AVIDITY IS THE HALLMARK OF SEVERE HEMOPHILIA A PATIENTS WITH FVIII INHIBITORS	Daniel Chaves	Received

232-MON-PO	THE ROLE OF LARGE POPULATION-BASED DATABASES IN THE EVALUATION OF SAFETY OF BYPASSING AGENTS IN HEMOPHILIA PATIENTS WITH INHIBITORS	Katsiaryna Bykov	Received

233-MON-PO	EFFICACY OF SECONDARY PROPHYLAXIS ON ANNUAL BLEEDING RATIO (ABR) IN ADULT PATIENTS WITH HEMOPHILIA: A SINGLE CENTER OBSERVATION STUDY IN JAPAN.	Teruhisa Fujii	Received

234-TUE-PO	CONTINUOUS INFUSION OF FVIII IN OBESE PATIENTS WITH SEVERE HAEMOPHILIA A: IS WEIGHT-BASED DOSE-ADJUSTMENT REQUIRED?	Boban Ana	Received

234-MON-PO	IMPACT OF THE INTRINSIC PATHWAY IN INDIVIDUAL THROMBIN GENERATION AMONG HEMOPHILIA B PATIENTS	Vuokko Jokela	Received

235-TUE-PO	USE OF APCC IN COMBINATION WITH TRANEXAMIC ACID: A SINGLE CENTRE EXPERIENCE	Jerzy Windyga	Received

236-MON-PO	NEW ANTIVIRAL TREATMENT OF HCV INFECTED YOUNG HAEMOPHILIACS EXPECTATIONS TO CURE HEPATITIS C	Katalin Koehler-Vajta	Received

236-WED-PO	CHANGES OF COAGULATION PARAMETERS DURING HIGH ALTITUDE EXPEDITION.	Susana Der Parsehian	Received

236-TUE-PO	NON-NEUTRALIZING ANTIBODIES MODULATE FACTOR VIII PHARMACOKINETIC IN PATIENTS WITH HEMOPHILIA A WITHOUT FVIII INHIBITORS	Christoph Hofbauer	Received

237-TUE-PO	IPAQ SCORING AND CAROTID INTIMA MEDIA THICKNESS IN PATIENTS WITH HAEMOPHILIA	Fahri Sahin	Received

237-WED-PO	RELATIONSHIP BETWEEN OXIDATIVE STRESS AND BLOOD COAGULATION IN PAEDIATRIC CHRONIC KIDNEY DISEASE (CKD)	Luci Maria SantAna Dusse	Received

238-TUE-PO	LEFT VENTRICLE DIASTOLIC FUNCTIONS AND PHYSICAL ACTIVITY SCORE IN ADULT HEMOPHILIA PATIENTS: AEGEAN HAEMOPHILIA CENTER EXPERIENCE	Fahri Sahin	Received

238-MON-PO	BURDEN OF ILLNESS AMONG PERSONS WITH HEMOPHILIA B: DIRECT AND INDIRECT COSTS	Christina Chen	Received

239-WED-PO	CD44 LOCATED IN THE SURFACE OF SICKLE RED BLOOD CELL (SRBC) CORRELATES WITH REDUCED BLOOD HBF LEVELS AND INCREASED SRBC ADHESION TO FIBRIN	Luciana Wermelinger Serro	Received

239-TUE-PO	REGIONAL DATA SUPPORTS NEED FOR UNIFORM APPROACH TO EXTENDED HALF-LIFE (EHL) PRODUCT TRANSITION	Stacy Croteau	Received

240-MON-PO	ACUTE EFFECTS OF EXERCISE ON SPECIFIC AND GLOBAL COAGULATION PARAMETERS IN SEVERE HEMOPHILIA A	Eva Zetterberg	Received

240-WED-PO	FREE FATTY ACIDS MODULATE THROMBIN ACTIVITY ON FIBRINOGEN AND DESTABILISE FIBRIN CLOTS	Anna Tanka-Salamon	Received

241-TUE-PO	POPULATION PHARMACOKINETIC MODEL OF RECOMBINANT SINGLE-CHAIN FACTOR VIII (RVIII SINGLECHAIN) IN PATIENTS WITH HEMOPHILIA A	Ying Zhang	Received

241-MON-PO	FIRST PROSPECTIVE RESULTS OF JOINT DISTRACTION IN HAEMOPHILIC ANKLE ARTHROPATHY	Lize van Vulpen	Received

243-MON-PO	EVALUATION OF JOINT DAMAGE IN BOYS WITH HEMOPHILIC ARTHROPATHTY BY ULTRASONOGRAPHY AND BIOMARKER OF CARTILAGE TURNOVER URINARY C TERMINAL TELOPEPTIDE OF TYPE II COLLAGEN (U-CTX-II)	Hoda Hassab	Received

244-WED-PO	IMPACT OF MATERNAL D-DIMER LEVELS IN NEWBORN OF PREECLAMPTIC MOTHERS	Melina de Barros Pinheiro	Received

245-WED-PO	FIBRIN CLOT STRUCTURE IS AFFECTED BY LEVELS OF PARTICULATE AIR POLLUTION EXPOSURE IN PATIENTS WITH VENOUS THROMBOSIS	Xiaoxi Pan	Received

245-TUE-PO	A CORE SET OF OUTCOME MEASUREMENT TOOLS IN PATIENTS WITH HEMOPHILIA: A SYSTEMATIC REVIEW OF THE MEASUREMENT PROPERTIES	Samantha Gouw	Received

245-MON-PO	SYMPTOMATIC FEMALE HEMOPHILIA SEEN IN TAIWAN	Ming-Ching Shen	Received

246-MON-PO	NO RELATION BETWEEN PLATELET ACTIVITY AND HEMOPHILIA B PHENOTYPE	Roger Schutgens	Received

246-WED-PO	INCREASED PLASMA CLOT PERMEABILITY AND SUSCEPTIBILITY TO LYSIS ARE ASSOCIATED WITH HEAVY MENSTRUAL BLEEDING OF UNKNOWN CAUSE	Anetta Undas	Received

246-TUE-PO	CLINICAL SIGNIFICANCE OF TYPE 1, TYPE 2 T CELLS, TH17 AND TREG IN THE DEVELOPMENT OF FVIII INHIBITOR IN PEDIATRIC HEMOPHILIA A PATIENTS.	Zhenping Chen	Received

247-MON-PO	OUTCOME OF LONG TERM PLASMA DERIVED FVIII CONCENTRATE FANHDI USE IN THE MATURE HAEMOPHILIA POPULATION.	Pu-Lin Luo	Received

247-WED-PO	SEVERE THROMBOSIS IN PREGNANCY IN A PATIENT WITH CONGENITAL DYSFIBRINOGENEMIA	Vera Geierova	Received

248-TUE-PO	RESULTS OF ANKLE PROSTHESIS IN PATIENTS WITH SEVERE HAEMOPHILIC ARTHROPATHY FOLLOW UP	Daniele Pillitteri	Received

248-WED-PO	ARTERIOVENOUS FISTULAS FOR REPLACEMENT THERAPY IN ADULTS WITH HEMOPHILIA	Jerome Teitel	Received

248-MON-PO	RACE AND THE IMMUNE RESPONSE TO FACTOR VIII REPLACEMENT THERAPY	Saulius Butenas	Received

249-TUE-PO	IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A AND B WITH INHIBITOR. SINGLE CENTRE EXPERIENCE.	Angelika Batorova	Received

249-MON-PO	ANTIBODIES AGAINST POLYETHYLENE GLYCOL (PEG) IN HEALTHY SUBJECTS MYTH OR REALITY?	Christian Lubich	Received

251-TUE-PO	POPULATION PHARMACOKINETICS IN HEMOPHILIA A: TOWARDS INDIVIDUALIZATION OF PERIOPERATIVE REPLACEMENT THERAPY	Hendrika Hazendonk	Received

251-MON-PO	EXPRESSION OF PLATELET PROTEIN DISULFIDE ISOMERASE (PDI) IS INCREASED IN PATIENTS WITH HEMOPHILIA AND VON WILLEBRAND DISEASE	Minna Voigtlaender	Received

252-MON-PO	ALTERNATIONS OF OXIDATIVE STRESS MARKERS IN PATIENTS WITH SEVERE HAEMOPHILIA TREATED BY DIFFERENT PROPHYLAXIS REGIMENS	Irena Djunic	Received

252-WED-PO	VALIDATION OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS BLEEDING ASSESSMENT TOOL (ISTH-BAT) IN HEMOPHILIA CARRIERS	Paula James	Received

253-TUE-PO	BLEEDING AFFECTS HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PEOPLE WITH HAEMOPHILIA PATIENTS (PWH) EVEN A SINGLE BLEED MATTERS	Sylvia von Mackensen	Received

253-MON-PO	HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOFILIA A AND B IN BRAZIL	Daniel Chaves	Received

254-MON-PO	COMPARISON OF PROPHYLAXIS AND EPISODIC TREATMENT IN CHILDREN WITH MODERATE TO SEVERE HEMOPHILIA A	Darintr Sosothikul	Received

254-TUE-PO	INTRACRANIAL HEMORRHAGE AND MANAGEMENT IN HEREDITARY BLEEDING DISORDERS: THE EXPERIENCE OF CUKUROVA UNIVERSITY , ADANA, TURKEY	Ilgen Sasmaz	Received

255-TUE-PO	EXPLORING COST EFFECTIVENESS OF VARIOUS PROPHYLACTIC TREATMENT STRATEGIES FOR SEVERE HAEMOPHILIA USING A COMPUTER SIMULATION MODEL	Kathelijn Fischer	Received

255-MON-PO	USING MINUTE DOSES OF APTT REAGENT AND TISSUE FACTOR AS THE COAGULATION TRIGGER TO QUANTIFY THE COAGULATION PROFILE IN HEMOPHILIA A	Shu He	Received

256-TUE-PO	ULTRASOUND EVALUATION OF HAEMOPHILIC JOINTS BY HAEMOPHILIA PHYSICIANS: A RELIABILITY STUDY	Kathelijn Fischer	Received

257-MON-PO	ONCE WEEKLY NONACOG ALFA IN HEMOPHILIA B (HEMB): A TIME COURSE PROFILE OF SPONTANEOUS BLEEDS IN PATIENTS FROM A PIVOTAL TRIAL	Bartholomew Tortella	Received

259-TUE-PO	INHIBITORS IN HEMOPHILIA (HA): EXPERIENCE OF A SINGLE CENTER IN THE LAST 22 YEARS.	Cristina Santoro	Received

259-WED-PO	A NOVEL MISSENSE MUTATION, P.PHE360CYS, IN F9 GENE RESULTS IN HEMOPHILIA B IN FEMALE PATIENT	Ziqiang Yu	Received

260-WED-PO	INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH SEVERE HEMOPHILIA A: A FOLLOW-UP COHORT STUDY.	Maria Elisa Mancuso	Received

261-MON-PO	BAYESIAN APPROACH TO THE ASSESSMENT OF THE POPULATION SPECIFIC RISK OF INHIBITORS	Alfonso Iorio	Received

261-WED-PO	SATISFACTION PATIENT SURVEY: A KEY TOOL TO IMPROVE PATIENT DELIVERY OF CARE AT A PORTUGUESE COMPREHENSIVE HEMOPHILIA CENTRE	Manuela Carvalho	Received

262-MON-PO	PHARMACOKINETIC CHARACTERISTICS OF FACTOR VIII AND IX CONCENTRATES A SYSTEMATIC REVIEW	Alfonso Iorio	Received

263-TUE-PO	ARGATROBAN IN THE MANAGEMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II: AN OPEN-LABEL, MULTICENTER CLINICAL TRIAL IN FRANCE	Brigitte TARDY	Received

263-WED-PO	THE EFFECT OF NORDIC WALKING ON JOINT STATUS, QUALITY OF LIFE, PHYSICAL ABILITY, EXERCISE CAPACITY AND PAIN IN OLDER MEN WITH HEMOPHILIA	Maryem Salim	Received

264-MON-PO	2003-2014 TWELVE YEAR RESULTS OF INHERITED BLEEDING DISORDERS REGISTRY OF THE EMILIA ROMAGNA REGION IN ITALY	Gianna Franca Rivolta	Received

264-WED-PO	PERIOPERATIVE MANAGEMENT AND OUTCOME OF URGENT APPENDECTOMY IN A PATIENT WITH SEVERE HEMOPHILIA	Murat Sker	Received

264-TUE-PO	CASE REPORT: DABIGATRAN USE IN A POSTOPERATIVE ORTHOPEDIC PATIENT WITH HEPARIN INDUCED THROMBOCYTOPENIA	Luciana Goncalves	Received

265-WED-PO	PREVALENCE, SEVERITY AND CORRELATION FACTORS OF HEMOPHILIC ARTHROPATHY AMONG TAIWANESE HEMOPHILIACS	Chia-Yau Chang	Received

265-MON-PO	CONGENITAL FACTOR DEFICIENCIES: TWENTY-FIVE-YEAR FOLLOW-UP	zafer salcioglu	Received

266-MON-PO	THERE IS A DIRECT RELATIONSHIP BETWEEN THE PHYSICAL ACTIVITY SCORE AND HDL CHOLESTEROL LEVEL IN HEMOPHILIA PATIENTS	Fahri Sahin	Received

266-TUE-PO	THE INCIDENCE OF HEPARIN-INDUCED THROMBOCYTOPENIA IN CRITICALLY ILL MEDICAL PATIENTS	Noppacharn Uaprasert	Received

267-MON-PO	MEASUREMENT OF GAIT VARIABILITY IN PATIENTS WITH AND WITHOUT HEMOPHILIC ARTHROPATHY: MOVE-STUDY (NTR 4561)	Sara Stoof	Received

267-TUE-PO	EVALUATING EFFICACY, SAFETY AND COMPLIANCE OF ARGATROBAN DOSING NOMOGRAM AT CANADIAN TEACHING HOSPITAL	Harsimran Saini	Received

268-MON-PO	THE EFFECTIVENESS OF EXERCISE PROGRAMME AND RADIOISOTOPE SYNOVECTOMYIN HEMOPHILIC PATIENTS	melike sezginevim	Received

268-WED-PO	QUALITY OF LIFE AMONG HAEMOPHILIA IN THAILAND	Yingyong Chinthammitr	Received

268-TUE-PO	RAPID FUNCTIONAL ASSAY FOR HEPARIN-INDUCED THROMBOCYTOPENIA USING A PRACTICAL FLOW CYTOMETRY APPROACH	Michal Cipok	Received

269-WED-PO	IMPACT OF TRANSITION ON CLINICAL OUTCOMES IN HEMOPHILIA: 10 YEARS OF EXPERIENCE AT A MAJOR CANADIAN TREATMENT CENTER	Celina Woo	Received

269-TUE-PO	HEPARIN-INDUCED THROMBOCYTOPENIA AND CALIBRATED THROMBIN GENERATION ASSAY.	Valentine Minet	Received

269-MON-PO	ADHERENCE TO TREATMENT IN PATIENTS WITH HAEMOPHILIA IN GERMANY	Wolfgang Miesbach	Received

270-WED-PO	PRO- AND ANTICOAGULANT FACTORS BALANCE THROMBIN GENERATION INDUCED BY APCC	Peter Turecek	Received

270-TUE-PO	THE ROLE OF CELLULAR IMMUNITY IN CHILDREN WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA	erol erduran	Received

271-TUE-PO	DIAGNOSIS OF VENOUS THROMBOEMBOLISM DURING ELTROMBOPAG THERAPY FOR IMMUNE THROMBOCYTOPENIA AND SUCCESSFUL REPLACEMENT WITH ROMIPLOSTIM.	Odelia Amit	Received

271-WED-PO	MUSCLE STRENGTH IN LOAD-BEARING JOINTS IN HAEMOPHILIC PATIENTS: COMPARATIVE VALUES WITH THE GENERAL POPULATION.	Santiago Bonanad-Boix	Received

272-MON-PO	COMPARING THROMBIN GENERATION IN PATIENTS WITH HAEMOPHILIA A AND PATIENTS ON VITAMIN K ANTAGONISTS	Marie-Sophie de Koning	Received

273-MON-PO	COATED PLATELET LEVELS IN SEVERE HEMOPHILIA DO NOT CORRELATE TO BLEEDING PHENOTYPE	Kelly Lastrapes	Received

274-TUE-PO	EXTENDED PLATELET PARAMETERS AS A MEANS TO DIFFERENTIATE IMMUNE THROMBOCYTOPENIA FROM HYPOPROLIFERATIVE THROMBOCYTOPENIAS	Hrvoje Melinscak	Received

274-MON-PO	SUCCESSFUL IMMUNE TOLERANCE INDUCTION IN AN ADULT WITH HEMOPHILIA A AND CHRONIC INHIBITOR A CASE STUDY	Michelle Sholzberg	Received

275-MON-PO	PROPHYLACTIC APPROACH TO RECCURRENT BLEEDING IN HEMOPHILIA WITH INHIBITORS	Bulent Zulfikar	Received

275-TUE-PO	TREATMENT OF ATRAUMATIC SPLENIC RUPTURE IN AN ADOLESCENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND AUTOIMMUNE CYTOPENIAS: A CASE REPORT	Rungrote Natesirinilkul	Received

276-TUE-PO	CD70 MOLECULE INVOLVED IN THE DENDRITIC CELLS DYSFUNTIONIN PATIENTS WITH IMMUNE THROMBOCYTOPENIA	Xian Zhang	Received

276-MON-PO	UTILIZATION OF ANTI-INHIBITORS PRODUCTS AND INHIBITORS STATUS OF SEVERE HEMOPHILIA PATIENTS: 5 YEARS NATIONAL DATA FROM THE CANADIAN HEMOPHILIA ASSESSMENT AND RESOURCE MANAGEMENT SYSTEM	Aicha N. TRAORE	Received

278-WED-PO	A CASE OF ACUTE CEREBRAL INFARCTION IN A PATIENT WITH HEMOPHILIA B	Sunah Lee	Received

278-TUE-PO	THE INVOLVEMENT OF NEUROPILIN-1 IN PRIMARY IMMUNE THROMBOCYTOPENIA	Hu Zhou	Received

279-MON-PO	RESULTS OF RADIOSYNOVECTOMY IN CHILDREN WITH SEVERE HEMOPHILIAAND FACTOR VIII OR IX INHIBITOR	Pawel Laguna	Received

279-TUE-PO	SUCCESSFUL TREATMENT OF REFRACTORY ITP WITH CYCLOSPORINE A, TWO CASE REPORTS	Antonin Hlusi	Received

279-WED-PO	THE USE OF SECONDARY PROPHYLAXIS IN THE HAEMOPHILIA A PATIENTS	Gonul Aydogan	Received

280-TUE-PO	EFFICACY AND PROGNOSIS OF SHORT TERM AND VERY LOW-DOSE IVIG THERAPY (200 MG/KG/D) FOR NEWLY DIAGNOSED ACUTE IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDREN	Kun Soo Lee	Received

280-MON-PO	F8 MUTATION AND INHIBITOR DEVELOPMENT IN SEVERE FACTOR VIII DEFICIENCY: RESULTS FROM THE IRISH NATIONAL DATABASE	Vince Jenkins	Received

280-WED-PO	COMPARATIVE STUDY OF THE PREVALENCE OF CLOTTING FACTOR DEFICIENCY IN CARRIERS OF HEMOPHILIA A AND B	Boban Ana	Received

281-TUE-PO	A SYNTHETIC PEPTIDE, CORRESPONDING TO THE NONCANONICAL PAR1- TETHERED LIGAND, MIMICS THE APC-INDUCED STIMULATION OF WOUND HEALING IN VITRO.	Ekaterina Kiseleva	Received

281-WED-PO	PREVALENCE AND INCIDENCE OF HEMOPHILIA IN THE NORTH OF TUNISIA	mariem melliti	Received

282-WED-PO	EFFECTS OF MODERATE-INTENSITY PHYSICAL EXERCISE ON PHARMACOKINETICS OF FACTOR VIII AND VON WILLEBRAND FACTOR IN YOUNG ADULTS WITH SEVERE HAEMOPHILIA A.	Nichan zourikian	Received

282-MON-PO	RECURRENT HEMATURIA IN HEMOPHILIA PATIENTS IS NOT INDICATIVE OF THE PRESENCE OF AN UNDERLYING CAUSE	Greta Mulders	Received

282-TUE-PO	DIFFERENTIAL IN VIVO ACTIVATION OF MONOCYTE SUBSETS DURING EXPERIMENTAL ENDOTOXEMIA IN HUMANS	Barbara Thaler	Received

283-MON-PO	SPONTANEOUS INTRACRANIAL BLEEDING IS A MAJOR CAUSE OF DEATH IN NONSEVERE HEMOPHILIA A PATIENTS	Janneke Loomans	Received

283-TUE-PO	REGULATION OF IL-10 AND HIGH MOBILITY GROUP BOX 1 (HMGB1) EXPRESSION IN HUMAN MONOCYTES BY PLATELETS AND NEUTROPHILS	Bjarne sterud	Received

285-TUE-PO	DOES THE COAGULATION CASCADE PLAY A ROLE IN RETINAL PATHOLOGIES?	tami livnat	Received

286-TUE-PO	CLINICAL PRESENTATION OF THROMBOEMBOLIC EVENTS IN INFLAMMATORY BOWEL DISEASE	Lize Bollen	Received

286-MON-PO	ASSESSMENT OF INHIBITOR RISK AFTER SWITCHING FROM PLASMA-DERIVED FACTOR VIII CONCENTRATE TO RECOMBINANT FACTOR VIII (BRASIL-RFVIII: BRAZILIAN STUDY OF INHIBITOR LINKED TO RECOMBINANT FACTOR VIII)	Alessandra Prezotti	Received

287-MON-PO	PHENOTYPIC PROFILE OF A CHILD WITH SEVERE HEMOPHILLIA B AND INHIBITORS WITH NOVEL MUTATION IN THE FIX (F9) GENE	Zorica Trajkova Antevska	Received

287-TUE-PO	LOSS OF PAR-4 RECEPTOR AFFECTS RENAL ISCHEMIA REPERFUSION IN MICE	Marcel Jansen	Received

288-TUE-PO	TIPE2 IS INDUCED BY SIMULATED MICROGRAVITY IN MONOCYTES	Shilong Xiong	Received

288-MON-PO	MILD HEMOPHILIA A COMPLICATED BY INHIBITOR AFTER SURGERY AND FACTOR REPLACEMENT THERAPY	Miguel Escobar	Received

288-WED-PO	IMPROVEMENT OF THE QUALITY OF HEALTH CARE FOR CHILDREN WITH SEVERE HAEMOPHILIA A USING PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES WITH RECOMBINANT FACTOR VIII	Sofijanka Glamocanin	Received

289-TUE-PO	MOUSE MACROPHAGES UPREGULATE PODOPLANIN UNDER INFLAMMATORY AND APOPTOTIC CONDITIONS	Julie Rayes	Received

289-WED-PO	INHIBITOR DEVELOPMENT AS SWITCHING FULL-LENGTH RECOMBINANT FVIII TO B-DOMAIN DELETED RECOMBINANT FVIII IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA A:TAIWANS EXPERIENCE	Chia-Yau Chang	Received

290-WED-PO	ULTRASONOGRAPHY OF JOINTS AND CORRELATION WITH FUNCTION IN HAEMOPHILIC ARTHROPATHY - RESULTS OF A CLINICAL PILOT TRIAL (HAMARTHROSONOPILOT)AND POTENTIAL IMPORTANCE OF JOINT-ULTRASOUND FOR AN INDIVIDUALIZED PROPHYLAXIS	Michael Sigl-Kraetzig	Received

291-TUE-PO	HIGH-FAT DIET IS ASSOCIATED WITH INCREASED VON WILLEBRAND FACTOR-RELATED PROCOAGULANT ACTIVITY IN HUMAN AND MURINE MODELS.	Alison Michels	Received

291-MON-PO	BOVINE AND PORCINE MUCOSAL HEPARINS EXHIBIT SIMILAR BIOLOGIC PROFILES	Jawed Fareed	Received

292-TUE-PO	INFLAMMATORY AND ENDOTHELIAL MARKERS AND THEIR RELATIONS TO THE HAEMOSTATIC POTENTIAL DURING THE MENSTRUAL CYCLE.	Roza Chaireti	Received

293-MON-PO	COMPARATIVE STUDIES ON THE MOLECULAR AND FUNCTIONAL PROFILE OF SHEEP MUCOSAL DERIVED ENOXAPARIN WITH VARYING ANHYDRO-MANNO GROUPS	Schuharazad Abro	Received

294-MON-PO	SEVUPARIN; MINOR EFFECTS ON HEMOSTASIS OF A NOVEL POLYSACCHARIDE DRUG DERIVED FROM HEPARIN	Maria Lindgren	Received

295-WED-PO	EFFECTIVE RADYOACTIVE SYNOVECTOMY IN HEMOPHILIA WITH INHIBITORS	Bulent Zulfikar	Received

295-MON-PO	REVERSAL OF THE HEPARINOID EFFECT WITH PROTHROMBIN COMPLEX CONCENTRATE AN IN VITRO STUDY USING THE THROMBIN GENERATION ASSAY	Emma Fosbury	Received

295-TUE-PO	THE ROLE OF INFLAMMATION IN PREGNANCY-RELATED VENOUS THROMBOSIS	Hilde Skuterud Wik	Received

296-WED-PO	IMPROVING HEMOPHILIA CARE IN BRAZIL: AVAILABILITY OF FACTOR CONCENTRATES AND BEYOND RESULTS OF LEVANTH SURVEY	Samuel Medina	Received

297-TUE-PO	CRITICAL BEHAVIOR OF SUBCELLULAR DENSITY ORGANIZATION DURING NEUTROPHIL ACTIVATION AND MIGRATION	Sandra Baker-Groberg	Received

297-MON-PO	STRATEGIES AND OUTCOMES OF PERIPROCEDURAL BRIDGING THERAPY WITH LOW-MOLECULAR-WEIGHT- HEPARIN IN PATIENTS WITH MECHANICAL HEART VALVES	Jacqueline Schulman	Received

299-TUE-PO	C. CANIMORSUS AFFECTS COAGULATION BY PROTEOLYTIC CLEAVAGE OF FACTOR X	Katrin Hack	Received

299-MON-PO	MEASUREMENT OF HEPARANASE ACTIVITY IN PLASMA REQUIRES THE USE OF SAMPLE ANTITHROMBIN-DEPLETION	Shahsoltan MIRSHAHI	Received

300-WED-PO	IMMUNE TOLERANCE INDUCTION IN PATIENTS WITH SEVERE HEMOPHILIA A WITH INHIBITORS IN KOREA	Young Shil Park	Received

300-MON-PO	NOVEL SYNTHETIC COPOLYMERS ABLE TO BIND UNFRACTIONATED AND LOW MOLECULAR WEIGHT HEPARINS.	Andrzej Mogielnicki	Received

301-WED-PO	THE USAGE OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) DURING MAJOR AND MINOR SURGERIES IN SEVERE HEMOPHILIA PATIENTS WITH INHIBITOR	Bulent Antmen	Received

301-TUE-PO	HUMAN MONOCYTE SUBSETS DIFFERENTLY EXPRESS TISSUE FACTOR	Konstantin Krychtiuk	Received

301-MON-PO	DIFFERENCES BETWEEN NORMAL AND CANCER CELLS IN THE BIO-RESPONSE TO HEPARIN	Yunliang Chen	Received

302-MON-PO	MONITORING UNFRACTIONATED HEPARIN IN CHILDREN APTT, ANTI-XA AND ACT IN A RANDOMIZED CONTROLLED TRIAL OF COMPARING TWO DOSE PROTOCOLS	Katharina Thom	Received

303-WED-PO	A PROSPECTIVE ITALIAN SURVEY ON INTRACRANIAL HEMORRHAGE IN HEMOPHILIA PATIENTS: CHANGES OVER TIME	Ezio Zanon	Received

303-TUE-PO	PROTHROMBIN MUTANTS REVEAL A NEW MECHANISM OF MASP-1 MEDIATED CLOTTING	Lorenz Jenny	Received

304-WED-PO	COMBINATION OF BIOMARKERS FOR ASSESSMENT OF HEMOPHILIC ARTHROPATHY	Yeu-Chin Chen	Received

304-TUE-PO	COMPLEMENT AND TISSUE-FACTOR INDUCED THROMBIN GENERATION IN THE PATHOGENESIS OF VENOUS THROMBOEMBOLISM	Ina Hiland	Received

304-MON-PO	THE EFFICACY AND SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN THROMBOPROPHYLAXIS IN CRITICALLY ILL ADULT PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS	Annukka Ylnen	Received

305-WED-PO	HOW HAEMOPHILIA PATIENTS IN GERMANY PERCEIVE THEIR ACTUAL TREATMENT AND WHAT THEY EXPECT FOR FUTURE TREATMENT WITH NEW LONG-LASTING PRODUCTS	Sylvia von Mackensen	Received

307-WED-PO	FACTOR XI DEFICIENCY AND BLEEDING RISK ON ANTICOAGULATION	John Chapin	Received

307-TUE-PO	TOLL-LIKE RECEPTOR LIGANDS INDUCE THE FORMATION OF PLATELET-NEUTROPHIL AND PLATELET-MONOCYTE COMPLEXES IN HUMAN WHOLE BLOOD	Julia Seyfert	Received

307-MON-PO	ARGATROBAN VS FONDAPARINUX IN HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS: A RESPONSE COMPARATIVE STUDY	Fahad Aleidan	Received

308-TUE-PO	COMPLEMENT ACTIVATION AND THROMBIN GENERATION IN HEALTHY INDIVIDUALS SUBJECTED TO MILD ISOBARIC HYPOXIA AND VENOUS STASIS	Ina Hiland	Received

308-WED-PO	THE EFFECT OF ADVANCING AGE ON THE RESPONSE TO DDAVP IN RE-EXPOSED NONSEVERE HEMOPHILIA A PATIENTS	Janneke Loomans	Received

309-TUE-PO	RETROSPECTIVE EVALUATION OF THE USE OF RECOMBINANT FACTOR VIIA BEFORE AND AFTER THE IMPLEMENTATION OF A PHARMACIST-LED FACTOR STEWARDSHIP PROGRAM	Taylor White	Received

310-TUE-PO	USE OF A 4 FACTOR PROTHROMBIN COMPLEX CONCENTRATE IN A UNITED STATES COMMUNITY HOSPITAL SYSTEM	Linda R Kelly	Received

311-WED-PO	EFFICACY ASSESSMENT OF FONDAPARINUX TREATMENT OF PATIENTS WITH HITHEPARIN INDUCED THROMBOCYTOPENIA (HIT)	Franciszek Grzegorczyk	Received

311-MON-PO	THROMBOPOIETIN RECEPTOR AGONISTS DO NO NOT CAUSE COAGULATION ACTIVATION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA	Lamya Garabet	Received

311-TUE-PO	IN VITRO OPTIMIZATION OF AN INNOVATIVE BIOLOGICAL GLUE COMPOSITION	PLANTIER Jean-Luc	Received

312-WED-PO	SAFETY AND EFFICACY OF STARTING WARFARIN AFTER TWO CONSECUTIVE PLATELET RISES IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA	Lydia Chen	Received

313-TUE-PO	EVALUATION OF THE PERFORMANCE OF EIGHT SCORES FOR PREDICTION OF BLEEDING RISK IN BRAZILIAN HEART DISEASE OUTPATIENTS TREATED WITH WARFARIN	Joao Oliveira	Received

313-WED-PO	RAPID FUNCTIONAL HEPARIN INDUCED THROMBOCYTOPENIA (HIT) ASSAY USING MULTIPLATE: COMPARISON WITH HEPARIN INDUCED PLATELET ACTIVATION (HIPA) ASSAY AND ACL ACUSTAR ANTIGEN ASSAY	Kevin Horner	Received

314-WED-PO	IMMUNOLOGICAL ASSAYS FOR DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS	Michael Nagler	Received

314-MON-PO	SERIAL MEAN PLATELET VOLUMES IN IMMUNE THROMBOCYTOPENIA	Mala Varma	Received

314-TUE-PO	IDARUCIZUMAB SPECIFICALLY REVERSES DABIGATRAN ANTICOAGULATION BUT DOES NOT INDUCE A PROCOAGULANT STATE IN A PORCINE TRAUMA MODEL WITH DABIGATRAN ANTICOAGULATION	Oliver Grottke	Received

315-WED-PO	IMPACT OF OVERDIAGNOSIS OF HIT IN A LARGE COMMUNITY HOSPITAL	John Francis	Received

316-WED-PO	NEW PLATELET FUNCTIONAL METHOD TO IDENTIFY PATHOGENIC ANTIBODIES IN HIT PATIENTS	Fabio Pulcinelli	Received

317-WED-PO	LOW MOLECULAR WEIGHT HEPARIN TREATMENT FOR SUPERFICIAL VEIN THROMBOSIS AND THE RISK OF HEPARIN-INDUCED THROMBOCYTOPENIA	Michelangelo Sartori	Received

317-MON-PO	LEVELS OF CYTOKINES SECRETED BY T LYMPHOCYTE AND THE RELATIONSHIP WITH PROGNOSIS IN CHILDREN IMMUNE THROMBOCYTOPENIA	Jingyao Ma	Received

318-MON-PO	ELEVATED EXPRESSION OF IL-37 IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA	Liu Liu	Received

318-TUE-PO	BLEEDING COMPLICATIONS AFTER INVASIVE DENTAL PROCEDURES IN PATIENTS UNDER VITAMIN K ANTAGONISTS	Ana Spinola	Received

319-MON-PO	ANALYSIS OF HISTOCOMPATIBILITY LOCUS ANTIGEN (HLA)-G AND IMMUNOGLOBULIN-LIKE TRANSCRIPTS (ILTS) ON PATIENTS WITH IMMUNE THROMBOCYTOPENIA	Qi Feng	Received

319-WED-PO	CLINICAL SIGNIFICANCE OF ANTINUCLEAR ANTIBODY TEST AND RISK FACTOR PREDICTORS OF CHILDHOOD CHRONIC IMMUNE THROMBOCYTOPENIA	Bunchoo Pongtanakul	Received

320-MON-PO	AN INCREASED MAJOR LIPID RAFT PROTEIN RAFTLIN ASSOCIATED WITH B CELLS SIGNALING IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA	Xian Zhang	Received

320-WED-PO	CLINICAL SIGNIFICANCE OF IPF OR RP MEASUREMENT IN DISTINGUISHING PRIMARY IMMUNE THROMBOCYTOPENIA FROM APLASTIC THROMBOCYTOPENIC DISORDERS	Yoshiaki Tomiyama	Received

321-TUE-PO	TREATMENT APPROACHES IN SPONTANEOUS RECTUS SHEATH HEMATOMAS IN CLINICAL PRACTICE. A SINGLE-CENTER EXPERIENCE	Veronica Pons	Received

321-MON-PO	NEUTROPHIL ELASTASE IS NOT REQUIRED FOR NEUTROPHIL EXTRACELLULAR TRAP OR DEEP VEIN THROMBUS FORMATION IN MICE	Kimberly Martinod	Received

322-WED-PO	VARIATIONS OF MEAN PLATELET VOLUME OF IMMUNE THROMBOCYTOPENIA	Kenji Yokoyama	Received

322-MON-PO	TISSUE FACTOR-DEPENDENT PLATELET ACTIVATION SUPPORTS NEUTROPHIL RECRUITMENT, ROLLING AND TRANSMIGRATION DURING INFLAMMATION	MEZOUAR Soraya	Received

323-TUE-PO	COMPOSITION-DEPENDENT EFFECTS OF NANOPARTICLES ON COAGULATION	Kamran Bakhtiari	Received

323-WED-PO	THE POLYMORPHISMS OF TUMOR NECROSIS FACTOR-INDUCED PROTEIN 3 GENE MAY CONTRIBUTE TO THE SUSCEPTIBILITY OF CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA IN CHINESE POPULATION	Jingyi Yang	Received

323-MON-PO	EFFECT OF GLUCOSE LEVELS IN INCREASED NEUTROPHIL EXTRACELLULAR TRAP FORMATION (NETS) IN TYPE 2 DIABETES PATIENTS AT DIAGNOSIS AND AFTER 6 AND 12 MONTHS OF METABOLIC CONTROL.	Mirta Schattner	Received

324-WED-PO	ANTI-PLATELET ANTIBODIES PRESENT IN BREAST MILK OF AN IMMUNE THROMBOCYTOPENIC MOTHER CAUSE ELEVATION OF AN APOPTOTIC MARKER IN NORMAL DONORS PLATELETS	Hagit Hauschner	Received

324-MON-PO	IMPACT OF PCSK9 IN A MURINE MOUSE MODEL OF SEPSIS.	Dhruva Dwivedi	Received

325-TUE-PO	CHARACTERISTICS AND ROLE OF EXTRACELLULAR VESICLES IN THE PATHOPHYSIOLOGY OF TRANSFUSION DEPENDENT ?-THALASSEMIA	Carina Levin	Received

325-MON-PO	PLASMA CELL-FREE DNA LEVELS ARE ELEVATED IN PATIENTS WITH ACUTE ISCHEMIC HEART FAILURE PARTIALLY DUE TO NEUTROPHIL EXTRACELLULAR TRAP FORMATION	Alexander Brill	Received

326-WED-PO	ANTI-GPIBALPHA ANTIBODIES INDUCE IMMUNE THROMBOCYTOPENIA IN DISTINCT PATHWAYS: FC-DEPENDENT VS. FC-INDEPENDENT	Miao Xu	Received

326-MON-PO	THE HISTONE-CLEAVING FACTOR SEVEN ACTIVATING PROTEASE DOES NOT PROMOTE DEGRADATION OF NEUTROPHIL EXTRACELLULAR TRAPS	Brenda Luken	Received

327-WED-PO	COMPARISON OF RELAPSE RATES OF IMMUNE THROMBOCYTOPENIA IN PATIENTS WHO RECEIVED INITIAL TREATMENT WITH STEROIDS VERSUS ANTI-RH(D) WITH OR WITHOUT STEROIDS	Mala Varma	Received

327-MON-PO	MECHANISM OF ?- VINIFERIN INHIBITS SUPEROXIDE GENERATION IN HUMAN NEUTROPHIL	CHIN-HSUAN LIN	Received

328-MON-PO	INHIBITORY EFFECT OF NKSE-5A ON SUPEROXIDE ANION GENERATION IN HUMAN NEUTROPHILS	Tzu-chi Tseng	Received

328-TUE-PO	IMPACT OF VARIOUS ANTICOAGULANTS AND STORAGE TIME ONPLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES	Simin Jamaly	Received

329-TUE-PO	PLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES IN HEALTHY INDIVIDUALS SUBJECTED TO MILD ISOBAR HYPOXIA AND VENOUS STASIS	Trond Brvik	Received

329-MON-PO	DIABETES PRIMES NEUTROPHILS TO UNDERGO NETOSIS WHICH SEVERELY IMPAIRS WOUND HEALING	Siu Ling Wong	Received

329-WED-PO	ASSOCIATION BETWEEN A PRO-INFLAMMATORY AXIS COMPRISED BY TSP1-TGFB-CTGF WITH THREE MICRO-RNAS, MIR-19A, 122, AND 133A IN THE PATHOPHYSIOLOGY OF DIABETIC RETINOPATHY: A THERAPEUTIC NOVEL MODALITY	RAUL DELA CADENA	Received

330-MON-PO	DETERMINANTS OF THE REGULATORY ACTION OF PLATELETS TOWARDS NEUTROPHIL ACTIVITIES	Angèle Gros	Received

331-WED-PO	INCREASED BIOMARKERS OF METABOLIC SYNDROME IN TOTAL JOINT ARTHOPLASTY PATIENTS	Andrew Banos	Received

331-MON-PO	THE LEUKOCYTE INTEGRIN B2 PRIMES NEUTROPHILS FOR NETOSIS IN SICKLE CELL DISEASE	Laila Elsherif	Received

331-TUE-PO	MICROPARTICLE LEVEL AND ORIGIN DURING PROGRESSION OF NORMAL PREGNANCY: A LONGITUDINAL STUDY IN HEALTHY WOMEN.	Elena Campello	Received

332-WED-PO	END-STAGE RENAL DISEASE ASSOCIATED WITH METABOLIC SYNDROME: A STUDY OF BIOMARKERS RELEVANT TO CARDIOVASCULAR RISK	Vinod Bansal	Received

332-TUE-PO	CIRCULATING MICROPARTICLES IN CORD BLOOD OF NORMAL PREGNANCY AND OF PREGNANCY WITH PREECLAMPSIA.	Elena Campello	Received

333-WED-PO	BARETTIN: A NATURAL MARINE COMPOUND WITH POTENT ANTICOAGULANT AND ANTI-INFLAMMATORY PROPERTIES	Bjarne sterud	Received

333-TUE-PO	A GAIN-OF-FUNCTION VARIANT OF PROTEIN C MANIFESTS ITSELF AS TYPE II PROTEIN C DEFICIENCY IN A HEALTHY SUBJECT	qiulan ding	Received

333-MON-PO	GENERAL DECREASE OF CIRCULATING MICROPARTICLES IS RELATED TO THE PRESENCE OF FVIII INHIBITORS IN HEMOPHILIA A PATIENTS	Daniel Chaves	Received

334-MON-PO	PRO-COAGULANT ACTIONS OF CIRCULATING MICROPARTICLES IN SICKLE CELL ANEMIA AND SEPSIS ASSOCIATED COAGULOPATHY AND THEIR MODULATION BY A TRIBLOCK POLYMER MST 1-88.	Jawed Fareed	Received

334-TUE-PO	EVALUATION OF PROTEIN C LEVELS IN SICKLE CELL DISEASE SUBJECTS SEEN AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY, NIGERIA.	Obinna Iheanacho	Received

335-WED-PO	PROCOAGULANT ACTIVITY INCREASES WITH DISEASE SEVERITY IN PATIENTS WITH ASTHMA	Marlous Sneeboer	Received

335-MON-PO	THE ROLE OF MICROVESICELES DERIVED FROM MYELOMA CELLS IN THROMBOGENICITY AND ANGIOGENESIS	Anat Aharon	Received

336-MON-PO	ANTITHROMBIN IS INCORPORATED INTO EXOSOMES AND ITS PRESENCE IN THESE VESICLES IS MODULATED BY LOW MOLECULAR WEIGHT HEPARIN	Irene Martínez Martínez	Received

336-WED-PO	ANTI-POLYPHOSPHATE ANTIBODIES AS ANTI-INFLAMMATORY/ANTICOAGULANT THERAPEUTICS	Richard Travers	Received

337-TUE-PO	THROMBOMODULIN INHIBITS TISSUE FACTOR MEDIATED THROMBIN GENERATION IN BLOOD AND PROTHROMBIN COMPLEX CONCENTRATES	Jawed Fareed	Received

338-MON-PO	PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM HAVE HIGHER CONCENTRATION OF LARGE EXTRACELLULAR VESICLES WITH AUGMENTED POTENTIAL TO INITIATE COAGULATION ACTIVATION	Simin Jamaly	Received

338-WED-PO	EARLY MEASUREMENT OF THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) AND ACTIVATED TAFI (TAFIa) PREDICTS OUTCOME IN PATIENTS WITH SEVERE SEPSIS OR SEPTIC SHOCK	FABRIZIO SEMERARO	Received

338-TUE-PO	HEPARANASE ACTIVATES ANTITHROMBIN THROUGH THE BINDING TO ITS HEPARIN BINDING SITE	Irene Martínez Martínez	Received

339-MON-PO	INFLUENCE OF CALR AND JAK2 MUTATIONS ON PROCOAGULANT POTENTIAL OF PLATELET-DERIVED MICROPARTICLES IN ESSENTIAL THROMBOCYTHEMIA (ET)	Sara Gamba	Received

339-TUE-PO	ANTITHROMBIN BINDS TO AND ENHANCES THE BARRIER FUNCTION OF HUVECS INDEPENDENTLY OF CELL-SURFACE HEPARAN SULFATE PROTEOGLYCANS	Franois Saller	Received

339-WED-PO	INFLAMMATORY CYTOKINE UP REGULATION MAY BE AN EARLY MARKER OF THROMBOSIS IN PATIENTS WITH IMPLANTED LVADS	Walter Jeske	Received

340-TUE-PO	TETRAMETHYLPYRAZINE DECREASES RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) VIA SUPPRESSION OF FOXA2 AND INDUCTION OF NOS IN HEPG2 CELLS	Junling Li	Received

340-WED-PO	ANNEXIN A1 CONCENTRATION IS INCREASED IN PATIENTS WITH PREECLAMPSIA	Luiza Perucci	Received

341-MON-PO	MODULATING THROMBOTIC DIATHESIS IN HEREDITARY THROMBOPHILIA: A ROLE FOR CIRCULATING MICROPARTICLES?	Elena Campello	Received

342-TUE-PO	SIMILAR RESPONSES OF PHOSPHATIDYLSERINE AND PHOSPHATIDYLETHANOLAMINE TOWARDS COFACTOR ACTIVITY OF HUMAN PROTEIN Z, A NATURAL ANTICOAGULANT	Tanusree Sengupta	Received

342-MON-PO	CIRCULATING EXTRACELLULAR VESICLE (EV) AFTER ACUTE HINDLIMB ISCHEMIA	Carmen Roncal	Received

343-TUE-PO	THE EFFECT OF AGE ON GLYCAN MICROHETEROGENEITY OF HUMAN ALPHA-2-MACROGLOBULIN	Laura Calvert	Received

343-WED-PO	DETERMINATION OF HEPARIN LEVEL IN BLOOD PLASMA SENSITIVITY AND SPECIFICITY AS A MARKER FOR IDENTIFICATION OF SYSTEMIC MAST CELL ACTIVATION DISEASE	Hans-Joerg Hertfelder	Received

344-WED-PO	CYTOKINE-MEDIATED TRIGGERING OF THROMBIN GENERATION AND INFLAMMATION IN PATIENTS WITH STEVENS- JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS.	Omer Iqbal	Received

344-TUE-PO	QUANTITATIVE IMMUNOASSAY FOR THE MEASUREMENT OF ACTIVATED PROTEIN C COMPLEXES WITH ALPHA-2-MACROGLOBULIN (APC:a2M)	Francisco España	Received

345-TUE-PO	IDENTIFICATION OF A NOVEL MUTATION P.K234EFS24 IN THE PROC GENE AND A PHENOTYPE-GENOTYPE CHARACTERISTICS OF THAI PATIENTS DIAGNOSED WITH HEREDITARY PROTEIN C DEFICIENCY AND SYMPTOMATIC THROMBOEMBOLISM	Bundarika Suwanawiboon	Received

345-WED-PO	NONCLINICAL EVALUATION OF CATIONICALLY MODIFIED POLYSACCHARIDE ANTIDOTES FOR UNFRACTIONATED HEPARIN	Bartlomiej Kalaska	Received

346-WED-PO	SCREENING TOOL FOR BLEEDING DISORDERS IN WOMEN WITH HEAVY MENSTRUAL BLEEDING	Sophie Wiewel-Verschueren	Received

346-MON-PO	VALIDATION STUDIES ON COAGULATION LABORATORY ASSAYS USEFUL FOR ASSESSING THE PLASMA LEVELS OF APIXABAN	Debra Hoppensteadt	Received

347-TUE-PO	INVESTIGATION OF PROTEIN S DEFICIENCY INDUCED PURPURA FULMINANS	Raja Prince	Received

347-MON-PO	HOW DO REAL-WORLD APIXABAN CONCENTRATIONS COMPARE TO EXPECTED CONCENTRATIONS?	Jignesh Patel	Received

348-WED-PO	REVERSAL OF DABIGATRAN COULD BE ACHIEVED BY HEMODIALYSIS WITH OR WITHOUT OTHER HEMOSTATIC AGENTS	Rachelle Li	Received

348-MON-PO	THE DAILY PRACTICE OF NOACS; AN OBSERVATIONAL COHORT STUDY	arina ten cate-hoek	Received

349-WED-PO	INCREASED COAGULATION AND FIBRINOLYTIC POTENTIAL OF SOLVENT-DETERGENT PLASMA: AN OBSERVATIONAL STUDY BETWEEN SD-TREATED POOLED PLASMA AND FRESH FROZEN QUARANTINE PLASMA	Yvonne Henskens	Received

349-MON-PO	POTENT ANTITHROMBOTIC EFFECT OF A NOVEL, SMALL-MOLECULE AND DIRECT INHIBITOR OF FACTOR XIA IN PREVENTION AND TREATMENT OF THROMBOSIS IN RABBIT MODEL OF ARTERIAL THROMBOSIS AT DOSES THAT PRESERVE HAEMOSTASIS	Pancras Wong	Received

350-WED-PO	PROSPECTIVE HEMOSTASIS REGISTRY OF PATIENTS IN CARDIAC SURGERY (HEROES-CS): EVALUATION OF THE INTRODUCTION OF A THROMBOELASTOGRAPHY BASED TRANSFUSION PROTOCOL IN CARDIAC SURGERY.	Yvonne Henskens	Received

350-MON-PO	COMPARING FEIBA WITH RECOMBINANT FVIIA FOR REVERSAL OF RIVAROXABAN WITH A MODIFIED ANTI-XA ASSAY IN UNDILUTED PLASMA	Jorell Gantioqui	Received

350-TUE-PO	ASSOCIATION RATE CONSTANTS RATIONALISE THE PHARMACODYNAMICS OF APIXABAN AND RIVAROXABAN	GEORGES EL JERDI	Received

351-MON-PO	DISCOVERY OF ONO-7750512, AN ORALLY BIOAVAILABLE SMALL MOLECULE FACTOR XIA INHIBITOR: THE PHARMACOKINETIC AND PHARMACOLOGICAL PROFILES	Sho Koyama	Received

353-WED-PO	PROTHROMBIN COMPLEX CONCENTRATE CAN INCREASE THROMBIN GENERATION IN THE PRESENCE OF LOW PLATELET NUMBER	Colleen Hamid	Received

353-MON-PO	ENHANCEMENT OF FIBRINOLYSIS BY A FACTOR XA INHIBITOR EDOXABAN AND COMBINATION WITH AN INHIBITOR OF ACTIVATED THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IN VITRO	Yoshiyuki Morishima	Received

354-WED-PO	EVALUATION OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE USE AND ITS ROLE IN THE REVERSAL OF NOVEL ORAL ANTICOAGULANTS	Sarah Sienko	Received

354-MON-PO	NOVEL ORAL ANTICOAGULANTS: INCIDENCE AND MANAGEMENT OF MAJOR BLEEDING. RETROSPECTIVE REVIEW AT A SINGLE CENTER.	Juan Peris	Received

355-MON-PO	INITIATING THROMBOPROPHYLAXIS WITH RIVAROXABAN UP TO 26 HOURS AFTER ELECTIVE KNEE ARTHROPLASTY DOES NOT INCREASE THE INCIDENCE OF VENOUS THROMBOEMBOLISM	Owais Mian	Received

357-MON-PO	EVALUATION OF ANTICOAGULANT THERAPY WITH DABIGATRAN BASED ON ECARIN CLOTTING TIME	Takeshi Suzuki	Received

357-TUE-PO	PARADOXICAL ENHANCEMENT OF THE INTRINSIC PATHWAY-INDUCED THROMBIN GENERATION IN HUMAN PLASMA BY MELAGATRAN, A DIRECT THROMBIN INHIBITOR, BUT NOT EDOXABAN, A DIRECT FACTOR XA INHIBITOR	Taketoshi Furugohri	Received

358-TUE-PO	EVALUATION OF ANTICOAGULATION WITH RIVAROXABAN BY ANTI-XA ACTIVITY, THROMBIN GENERATION AND COMPLEX THROMBIN ANTI-THROMBIN LEVELS IN PATIENTS WITH NEW ONSET NON VALVULAR ATRIAL FIBRILLATION.	Victor Neira	Received

358-MON-PO	SWITCH FROM VITAMIN K ANTAGONISTS (VKAS) TO DIRECT ORAL ANTICOAGULANTS (DOACS): A PRATICAL APPROACH	Samantha Pasca	Received

359-TUE-PO	LOW DOSE RIVAROXABAN FOR SECONDARY PROPHYLAXIS AFTER FULL ANTICOAGULATION IN PATIENTS WITH VENOUS THROMBOEMBOLISM	Howard Chan	Received

359-MON-PO	WARFARIN AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE REAL WORLD OF PATIENTS WITH ATRIAL FIBRILLATION	pasquale pignatelli	Received

360-MON-PO	GLOBAL ANTICOAGULANT SCREENING USING A DILUTE RVV REAGENT	Zhenghua Cao	Received

360-TUE-PO	INTRA-INDIVIDUAL VARIABILITY IN TROUGH AND PEAK DABIGATRAN LEVELS IN REAL-LIFE ATRIAL FIBRILLATION PATIENTS	Petra Sinigoj	Received

361-TUE-PO	DIRECT-ACTING ORAL ANTICOAGULANTS IN THE REAL WORLD: INSIGHTS INTO HEALTH CARE PROVIDERS UNDERSTANDING OF MEDICATION DOSING AND USE	Menaka Pai	Received

361-MON-PO	A CHROMOGENIC FACTOR XA INHIBITOR ASSAY FOR QUANTIFYING RIVAROXABAN LEVELS: OPTIMIZATION AND VALIDATION ON THE ACL TOP 700	Paula Jacobi	Received

361-WED-PO	IMPROVING EDUCATION AND ADVOCACY FOR YOUNG WOMEN WITH MENORRHAGIA THROUGH USE OF INNOVATIVE TECHNOLOGY	Jennifer Dietrich	Received

362-TUE-PO	DIRECT ORAL ANTICOAGULANTS IN CLINICAL PRACTICE - REAL WORLD AUDIT DATA	Sarah Bond	Received

363-WED-PO	A FIXED DOSE OF PROTHROMBIN COMPLEX CONCENTRATE DOES NOT REDUCE THE INR QUICKER & RELIABLE IN VITAMIN K ANTAGONISTRELATED INTRACRANIAL HAEMORRHAGE	Rahat Abdoellakhan	Received

363-MON-PO	FROM LABORATORY TO CLINICAL PRACTICE: DABIGATRAN EFFECTS ON THROMBIN GENERATION AND COAGULATION IN PATIENT SAMPLES	Tuukka Helin	Received

364-WED-PO	RISKS AND PREDICTORS OF ISCHEMIC/BLEEDING COMPLICATIONS IN CARDIAC PATIENTS UNDERGOING ELECTIVE NON-CARDIAC SURGERY AN ANALYSIS OF THE PRAGUE-14 STUDY	Zuzana Motovska	Received

364-MON-PO	THE ADDITION OF IDARUCIZUMAB TO PLASMA SAMPLES CONTAINING DABIGATRAN ALLOWS THE USE OF ROUTINE COAGULATION ASSAYS FOR THE DIAGNOSIS OF HEMOSTASIS DISORDERS	Marc Jacquemin	Received

365-WED-PO	THE PHARMACOKINETICS AND IMMUNE RESPONSE OF NEW CATIONIC DEXTRAN ANTIDOTES OF HEPARIN	Batlomiej Kalaska	Received

365-TUE-PO	RENAL FUNCTION COURSE IN PATIENTS TREATED WITH NEW ORAL ANTICOAGULANTS.	Anna Maria Gori	Received

366-WED-PO	GENDER AND BLEEDING IN ATRIAL FIBRILLATION: A REAL-WORLD PROSPECTIVE COHORT STUDY	Jeroen Jaspers Focks	Received

366-TUE-PO	THE EFFECTS OF DIRECT ORAL ANTICOAGULANTS APIXABAN AND RIVAROXABAN ON HAEMOSTASIS TESTS: RESULTS FROM A COMPREHENSIVE CROSS-LABORATORY EXERCISE.	Roslyn Bonar	Received

367-WED-PO	LOW-DOSE 4-FACTOR PCC FOR URGENT WARFARIN REVERSAL	Wesley Zemrak	Received

367-MON-PO	A NOVEL PROTHROMBIN TIME (PT) METHOD TO MEASURE ALL NON-VITAMIN K DEPENDENT ORAL ANTICOAGULANTS (NOACS)	Tomas Lindahl	Received

369-TUE-PO	CIRCULATING CONCENTRATION OF RIVAROXABAN OR DABIGATRAN ANTICOAGULANTS IN CLINICALLY SELECTED PATIENTS	Jane Needham	Received

370-MON-PO	REAL-LIFE USE OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN COMPARISON WITH VITAMIN K ANTAGONISTS FOR NON-VALVULAR ATRIAL FIBRILLATION: DATA FROM A PROSPECTIVE COHORT	Michela Giustozzi	Received

370-WED-PO	INTRAVENTRICULAR FIBRINOLYSIS RESTORES GLYMPHATIC CIRCULATION AFTER SUBARACHNOID HEMORRHAGE.	Maxime GAUBERTI	Received

371-MON-PO	THE MODULATION OF PROTHROMBINASE LIFETIME BY RIVAROXABAN	Maria Cristina Bravo	Received

371-TUE-PO	MANAGEMENT OF BLEEDING AND EMERGENCY SITUATIONS FOR PATIENTS TREATED WITH DABIGATRAN- SINGLE CENTRE EXPERIENCE.	Tatiana Prigancova	Received

371-WED-PO	EVALUATING THE INTER-OBSERVER RELIABILITY OF POTENTIAL PREDICTOR VARIABLES TO DEVELOP A MORE ACCURATE PREDICTION TOOL FOR BLEEDING FOR PATIENTS ON ORAL ANTICOAGULANT	Parvaneh Fallah	Received

372-TUE-PO	BLEEDING AND TREATMENT FAILURE IN PATIENTS TAKING DIRECT ORAL ANTICOAGULANTS REFERRED TO EMERGENCY DEPARTMENT: A COHORT MANAGEMENT STUDY	Seena Padayattil Jose	Received

372-WED-PO	EFFECTS OF HEMOSTATIC GAUZE WITH SELF-PROPELLING THROMBIN PARTICLES ON SURVIVAL AND BLOOD LOSS IN A SWINE MODEL OF LETHAL ARTERIAL HEMORRHAGE	Alex St. John	Received

373-MON-PO	IS IT POSSIBLE TO ASSES RIVAROXABAN ACTIVITY WITHOUT SPECIFIC CALIBRATORS?	María de Lourdes Herrera	Received

373-TUE-PO	PERFORMANCES OF A NEW COMMERCIAL CHROMOGENIC ASSAY FOR THE MEASUREMENT OF APIXABAN CONCENTRATION IN PLASMA	Jean-Marc Minon	Received

373-WED-PO	CLINICAL MANAGEMENT AND OUTCOME OF MAJOR BLEEDING IN PATIENTS ON TREATMENT WITH VITAMIN K ANTAGONISTS: RESULTS FROM THE CLIMBING STUDY.	LAURA FRANCO	Received

374-MON-PO	A NEW ASSAY FOR THE MEASUREMENT OF RIVAROXABAN CONCENTRATIONS IN HUMAN PLASMA	Valeri Krougliak	Received

374-WED-PO	COMPARATIVE STUDIES ON A BRANDED RECOMBINANT FACTOR VIIA AND ITS GENERIC VERSION TO DEMONSTRATE EQUIVALENCE.	Paul OMalley	Received

375-MON-PO	MONITORING VITAMIN K ANTAGONIST TREATMENT : INTERESTS OF GOOD THERAPEUTIC EDUCATION	Dalila Atchafa Tadlaoui	Received

375-TUE-PO	PROTHROMBINASE INDUCED CLOTTING TIME (PICT) FOR MEASURING THE ACTIVITY OF DIRECT FACTOR XA INHIBITORS IN CLINICAL SETTING.	Pável Eduardo Olivera Sumire	Received

376-WED-PO	A MICROFLUIDIC CHAMBER FOR ELONGATING MEGAKARYOCYTES AND PRODUCING FUNCTIONAL PLATELETS	Dominique Baruch	Received

376-MON-PO	HOW PARTICIPATING IN A CLINICAL TRIAL HAS HAD A FAR REACHING EFFECT A CASE STUDY.	Claire McGregor	Received

377-MON-PO	BARRIERS TO INFORM HEMOPHILIC CARRIERS OF THAT POSSIBILITY IN JAPAN	Tomie FUJII	Received

377-WED-PO	NOVEL ROLES OF THE DUAL-SPECIFICITY PHOSPHATASES 1 AND 6 IN MEGAKARYOPOIESIS AND PROPLATELET FORMATION	Alexandra Mazharian	Received

377-TUE-PO	QUALITATIVE FOLLLOW UP OF EMERGENCY DEPARTMENT (ED) PATIENTS DISCHARGED ON RIVAROXABAN FOR LOW RISK VENOUS THROMBOEMBOLISM	Kristen Nordenholz	Received

378-TUE-PO	NET CLINICAL BENEFIT OF DABIGATRAN VERSUS WARFARIN IN PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM: A POOLED ANALYSIS OF RE-COVER AND RE-COVER II	Sam Schulman	Received

378-WED-PO	FUNCTIONALLY ACTIVE TISSUE FACTOR IS EXPRESSED DURING MEGAKARYOCYTE MATURATION AND IS TRANSFERRED TO A SUBSET OF PLATELETS	Marina Camera	Received

378-MON-PO	MECHANICAL THROMBOPROPHYLAXIS SOLVING DILEMMAS	Cara Doyle	Received

379-TUE-PO	IDENTIFICATION OF POSSIBLE DRUG RELATED PROBLEMS IN PATIENTS ON ORAL ANTICOAGULANTS. A SYSTEMATIC REVIEW OF MEDICATION CHARTS BY PHARMACIST.	Eva-Marie Jacobsen	Received

379-WED-PO	FUNCTIONAL ANALYSIS OF NBEAL2 IN HUMAN MEGAKARYOCYTES VIA COLOCALIZATION WITH SUBCELLULAR COMPARTMENTS	Richard Lo	Received

380-MON-PO	THE IMPACT OF FOOTWEAR ON ANKLE ARTHROPATHY IN PATIENTS WITH HEMOPHILIA.	Karen Strike	Received

380-WED-PO	CCL5 RELEASED FROM PLATELETS DRIVES INCREASED MEGAKARYOCYTE MATURATION AND PROPLATELET FORMATION	Kellie Machlus	Received

382-MON-PO	FIRST EXPERIENCE WITH THE HAEMOASSIST, AN ELECTRONIC SUBSTITUTION DIARY THAT WORKS ON THE BASIS OF A PERSONAL DIGITAL ASSISTANT (PDA)	Manuela Siebert	Received

383-TUE-PO	MEAL-INDUCED PLATELET ACTIVATION DIFFERS BETWEEN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES AND IS RELATED TO INSULIN SECRETION	Galia Spectre	Received

383-WED-PO	MEGAKARYOCYTES AND PLATELETS EXPRESS NICOTINIC ACETYLCHOLINE RECEPTORS BUT NICOTINE DOES NOT AFFECT MEGAKARYPOIESIS OR PLATELET FUNCTION	Peter Bugert	Received

384-TUE-PO	INFLUENCE OF PLATELET COUNT IN PLATELET RICH PLASMA FOR ADENOSINE TRIPHOSPHATE RELEASE ASSAY	Katrien Devreese	Received

385-TUE-PO	ACTIVATION OF HUMAN PLATELETS BY STAPHYLOCOCCUS AUREUS SECRETED PROTEASE STAPHOPAIN A	Amie Waller	Received

385-WED-PO	GENE EXPRESSION PROFILE IN MEGAKARYOCYTES FROM TYPE 2 DIABETIC MICE EMPHASIZES INCREASE IN STEFINA EXPRESSION LEVELS	Canault Matthias	Received

386-WED-PO	IDENTIFICATION OF MEGAKARYOCYTIC PROGENITOR CELLS AMONG SUBCUTANEOUS PRE-ADIPOCYTES	Keiichi Tozawa	Received

386-MON-PO	RESPONSE OF LEUCOCYTE COUNT, LEUCOCYTE DIFFERENTIAL COUNT AND THROMBOCYTE COUNT ON FREQUENT BLOOD DONATIONS AMONG MALE SUBJECTS IN UNIVERSITY OF CALABAR TEACHING HOSPITAL DONOR CLINIC, CALABAR, NIGERIA	Dorathy Chioma Okpokam	Received

387-WED-PO	PLATELET FACTOR XIII: THE RESCUE IN THE FACTOR FXIII DEFICIENCY.	CLAUDIA MARIA RADU	Received

387-TUE-PO	EVALUATION OF MULTIPLATE WHOLE BLOOD IMPEDANCE AGGREGOMETRY IN ROUTINE INVESTIGATION OF BLEEDING DISORDERS	Joanne Joseph	Received

388-MON-PO	MILD HAEMOPHILIA A: A MANAGEABLE CONDITION?	Daryl Pollock	Received

388-WED-PO	RAC1 REGULATES PLATELET MICROPARTICLES FORMATION AND RHEUMATOID ARTHRITIS DETERIORATION	Xue Chen	Received

389-WED-PO	ALTERATIONS IN THE EXTRACELLULAR VESICLES PROPERTIES INDICATE HYPERCOAGULABLE STATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Inna Tzoran-Rosenthal	Received

389-MON-PO	SOURCE DATA VERIFICATION PILOT: USING CENTRAL MONITORING IN AN OBSERVATIONAL CRITICAL CARE BIOMARKER STUDY	Ellen McDonald	Received

390-TUE-PO	DETERMINATION OF THRESHOLD AGONIST CONCENTRATIONS FOR WHOLE BLOOD AGGREGATION USING THE MULTIPLATE ANALYZER	Sara Israels	Received

390-WED-PO	EFFECT OF ACETYLSALICYLIC ACID ON THE CONCENTRATION OF MONOCYTE MICROPARTICLES COEXPRESSING TISSUE FACTOR IN PATIENTS WITH DIABETES MELLITUS TYPE 2	Marcelo Luide Goncalves	Received

390-MON-PO	RAISING AWARENESS OF VENOUS THROMBOEMBOLISM PREVENTION: HOW THE JEWISH GENERAL HOSPITAL IS MEETING THE REQUIREMENTS FOR HOSPITAL ACCREDITATION	Jessica Emed	Received

391-WED-PO	LOW MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN PATIENTS WITH PERSISTENT LUPUS ANTICOAGULANT AND A HISTORY OF THROMBOSIS	Lena Hell	Received

391-TUE-PO	ASSESSMENT OF TIME-RELATED PREANALYTICAL INFLUENCES ON PLATELET FUNCTION: COMPARISON OF THE MULTIPLATE, THE PFA-100 AND THE VERIFY NOW	Jilma Petra	Received

392-WED-PO	MEAL INTAKE INCREASES CIRCULATING PROCOAGULANT MICROPARTICLES IN PATIENTS WITH DIABETES MELLITUS	Galia Spectre	Received

392-MON-PO	A SURVEY OF CLINICAL RESEARCH COORDINATORS TO MANAGE THE CLINICAL RESEARCH PAPERWORK MOUNTAIN	Terri Schnurr	Received

393-TUE-PO	GPVI AND THE CLEC-2/PODOPLANIN AXIS AS POTENTIAL BIOMARKERS OF PLATELET ACTIVATION IN INFLAMMATORY CONDITIONS	Samantha Montague	Received

393-MON-PO	THE JEWISH GENERAL EXPERIENCE IN DEVELOPING PATIENT TEACHING MATERIALS ON WARFARIN AND VENOUS THROMBOEMBOLISM	Carla Strulovitch	Received

394-MON-PO	THE IMPACT OF ?3 CYTOPLASMIC TAIL MIMETIC PEPTIDES ON PLATELET AGGREGATION AND ?IIB?3 ACTIVATION	Huong Nguyen	Received

394-WED-PO	CLINICAL SIGNIFICANCE OF CIRCULATING MICROPARTICLES IN PH- MYELOPROLIFERATIVE NEOPLASMS (MPN)	yue han	Received

395-WED-PO	PLATELET MICROVESICLES IN VASCULAR INFLAMMATION	Tanja Vajen	Received

395-TUE-PO	LOCAL ANAESTHETICS INHIBIT ACTIVATION OF PROTEIN DISULFIDE ISOMERASE (PDI).	Anne Bertling	Received

395-MON-PO	BILE SALT CHENODEOXYCHOLATE SUPPRESSES NORMAL PLATELET FUNCTIONS THROUGH CYCLIC AMP ACTIVATION PATHWAY	Pat Metharom	Received

396-TUE-PO	PROSPECTIVE ANALYSIS OF PLATELET ACTIVATION MARKERS TO PREDICT SEVERE INFECTION AND MORTALITY IN INTENSIVE CARE UNITS.	Céline Delierneux	Received

396-WED-PO	IMPACT OF A FAT-TOLERANCE TEST ON PLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES ASSESSED BY NANOPARTICLE TRACKING ANALYSIS	Cathrine Ramberg	Received

396-MON-PO	THE ROLE OF HETEROTRIMERIC G PROTEINS IN REGULATION OF GPIIB-IIIA ACTIVATION AND PLATELET CONTRACTILITY	Naphtali Savion	Received

397-MON-PO	THE GUT MICROBIOTA REGULATES VON WILLEBRAND FACTOR EXPRESSION AND PLATELET PROTHROMBOTIC FUNCTION VIA TOLL-LIKE RECEPTOR-2	Sven Jckel	Received

398-WED-PO	PERFORMANCE OF THREE FUNCTIONAL ASSAYS FOR THE MEASUREMENT OF DABIGATRAN PLASMA CONCENTRATIONS	Geneviève Freyburger	Received

398-TUE-PO	COMPARATIVE IMPACTS OF ANTIRETROVIRAL HIV THERAPIES ON PLATELET FUNCTION	Erica Smyth	Received

401-TUE-PO	OPIATES MAY ATTENUATE PLATELET ACTIVATION	Ankit Macwan	Received

401-WED-PO	DILUTE RUSSELL VIPER VENOM TIME, A PARTIAL SOLUTION FOR SCREENING AND CONCENTRATION DETERMINATION OF DIRECT ORAL ANTICOAGULANTS	An Stroobants	Received

401-MON-PO	PLATELET-SPECIFIC GARP DEFICIENCY DOES NOT AFFECT THROMBOSIS AND HEMOSTASIS IN MICE	Elien Vermeersch	Received

402-WED-PO	DRUG INTERACTIONS OF NEWER ORAL ANTICOAGULANTS DABIGATRAN, RIVAROXABAN, AND APIXABAN WITH ROUTINELY USED NONANTICOAGULANT/ANTIPLATELET DRUGS	Shermin Sayani	Received

402-MON-PO	CONSTRUCTION OF EXPRESSION SYSTEM FOR BIOLOGICALLY FUNCTIONAL RECOMBINANT RHODOCYTIN	TOMOYUKI SASAKI	Received

402-TUE-PO	IN VIVO AND PROTEASE-ACTIVATED RECEPTOR 1-MEDIATED PLATELET ACTIVATION IN PATIENTS PRESENTING FOR CARDIAC CATHETERIZATION	Thomas Gremmel	Received

403-MON-PO	Localization of Zn2 and Ca2 in Dense-Granules of Human Platelets and the Extent of their Release upon Platelet Activation	Sara Henderson	Received

403-TUE-PO	PLATELET FACTOR-3 (PF-3) AVAILABILITY AND PLATELET COUNT OF PREGNANT WOMEN IN IRRUA, EDO STATE.	ROSE ANYANWU	Received

404-TUE-PO	FLOW CYTOMETRY BASED EVALUATION OF PLATELET-NEUTROPHIL COMPLEX FORMATION IN HUMAN AND MURINE WHOLE BLOOD: A DETAILED ANALYSIS OF EX VIVO SAMPLE PREPARATION, CYTOMETER SETTINGS AND MOLECULAR BASICS	Maximilian Mauler	Received

404-MON-PO	NEUTROPHILS CONTRIBUTE TO THE GENERATION OF PROCOAGULANT PLATELETS BY A MYELOPEROXIDASE INDEPENDENT MECHANISM	Leonardo Pasalic	Received

404-WED-PO	SUCCESSFUL USE OF HEMODIALYSIS IN A DABIGATRAN OVERDOSE	Fernando Araújo	Received

405-WED-PO	CLINICAL IMPACT OF BLEEDING COMPLICATIONS WITH DIRECT ORAL ANTICOAGULANTS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ORTHOPAEDIC SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	Eleonora Tamborini Permunian	Received

406-WED-PO	ROLE OF ANTICOAGULANT CLINICS IN THE MANAGEMENT OF PATIENTS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS (NOACS) AT CORK UNIVERSITY HOSPITAL (CUH)	Catriona OLeary	Received

406-MON-PO	IMPROVING THE QUANTIFICATION OF IN VITRO THROMBUS FORMATION	Kjersti Claesson	Received

407-WED-PO	ARE NON-VKA ORAL ANTICOAGULANTS (NOACS) PLASMA CONCENTRATIONS ASSOCIATED WITH THE RISK OF POSTOPERATIVE BLEEDING? PRELIMINARY RESULTS FROM THE REAL LIFE COHORT.	Pável Eduardo Olivera Sumire	Received

407-MON-PO	RS6929846-DEPENDENT REGULATION OF BTN2A1 EXPRESSION IN INNATE AND ADAPTIVE IMMUNE CELLS AFFECTS PLATELET REACTIVITY TO THROMBIN	Cécile Oury	Received

408-MON-PO	MOUSE CLEC-2 CAN SUPPORT PLATELET ADHESION TO MOUSE PODOPLANIN UNDER ARTERIAL FLOW	Stephanie Lombard	Received

408-TUE-PO	PLATELET AGGREGATION AND BIOLOGICAL RESPONSE MODIFIERS RELEASE BY COMBINATIONS OF STREPTOCOCCUS SANGUINIS AND PORPHYROMONAS GINGIVALIS	Archie McNicol	Received

409-TUE-PO	INCREASE IN IONIC STRENGTH INHIBITS PLATELET AGGREGATION IRRESPECTIVE OF SOLUTE TYPE IN VITRO	GORDON OGWENO	Received

409-MON-PO	AKT TRANSLOCATION AND PHOSPHORYLATION REGULATES PLATELET AGGREGATION DOWNSTREAM OF G12/13 AND GI PATHWAYS	Zhongren Ding	Received

410-WED-PO	INTERFERENCE STUDY OF DIRECT THROMBIN INHIBITORS AND ANTI-XA INHIBITORS ON HEMOSTASIS ASSAYS ON A COBAS T 411 SYSTEM	An Stroobants	Received

410-TUE-PO	A NEW APPROACH TO MEASURING PLATELET AGGREGATION AND PLATELET-LEUCOCYTE CONJUGATE FORMATION IN A SMALL VOLUME OF FIXED WHOLE BLOOD	MOHAMMAD ALGAHTANI	Received

410-MON-PO	EFFECTS OF CYCLIC NUCLEOTIDES ON PLATELET AGGREGATION AND BIOLOGICAL RESPONSE MODIFIER RELEASE INDUCED BY STREPTOCOCCUS SANGUINIS STRAIN 2017-78	Archie McNicol	Received

411-WED-PO	NEUTRALIZATION OF BLEEDING INDUCED BY NON-VITAMIN K ORAL ANTICOAGULANTS BY PROTHROMBIN COMPLEX CONCENTRATES ALONE AND IN COMBINATION WITH ANTIFIBRINOLYTIC AGENTS	Walter Jeske	Received

411-MON-PO	TRANSGLUTAMINASE ACTIVE COATED PLATELETS FUNCTION IN PLATELET-DEPENDENT FIBRIN FORMATION VIA FXIII AND INTEGRIN ALPHAIIBBETA3	Judith Cosemans	Received

412-TUE-PO	EFFECTS OF PH AND CONCENTRATION OF SODIUM CITRATE ANTICOAGULANT ON PLATELET AGGREGATION MEASURED BY LIGHT TRANSMISSION AGGREGOMETRY INDUCED BY ADENOSINE DIPHOSPHATE	Marco Cattaneo	Received

412-MON-PO	PIVOTAL ROLE OF SGK1 IN THE REGULATION OF PLATELET SECRETORY PROTEOME, DENSE GRANULE BIOGENESIS AND SECRETION	Britta Walker	Received

413-TUE-PO	Platelet activation in the presence of Neutral Protamine Hagedorn insulin: a new feature of antibodies against protamine/heparin complexes	Tamam Bakchoul	Received

413-WED-PO	EVALUATION OF APPROPRIATENESS OF RIVAROXABAN PRESCRIPTION IN A TERTIARY CARE HOSPITAL IN SINGAPORE	Su Ching Tan	Received

413-MON-PO	IMPACT OF ELEVATED SHEAR STRESS ON INTEGRIN ?LPHAIIB ?ETA3 LIGAND INTERACTION	Marianna Gyenes	Received

414-MON-PO	PLATELET FUNCTION IS REGULATED BY ACETYLATION AND DEACETYLATION MECHANISMS CONTROLLED BY SIRTUINS.	Antonio Moscardó	Received

414-TUE-PO	CHARACTERISING CELL-TYPE INTERACTIONS FOLLOWING PLATELET ACTIVATION IN A NOVEL LOW VOLUME WHOLE BLOOD ASSAY	Paul Armstrong	Received

414-WED-PO	IDARUCIZUMAB ANTAGONIZES DABIGATRAN-INDUCED ALTERATIONS ON PLATELET AND FIBRIN DEPOSITION IN AN IN VITRO THROMBOSIS MODEL WITH CIRCULATING HUMAN BLOOD	Eduardo Arellano-Rodrigo	Received

415-MON-PO	FIBRIN STIMULATES SPREADING AND ACTIVATION OF PLATELETS THROUGH GPVI	OSAMA ALSHEHRI	Received

415-TUE-PO	CHARACTERISATION OF PROCOAGULANT PLATELETS IN WHOLE BLOOD USING A NOVEL CELL DEATH MARKER	Leonardo Pasalic	Received

416-TUE-PO	NATURAL HISTORY OF ACQUIRED GLANZMANN THROMBASTHENIA : A CASE REPORT	Mathieu Fiore	Received

416-MON-PO	KINDLIN-2 IN MEGAKARYOCYTE AND PLATELET FUNCTIONS	Canault Matthias	Received

416-WED-PO	DETECTING RELEVANT RIVAROXABAN OR DABIGATRAN LEVELS IN CLINICAL CARE BY ROUTINE COAGULATION TESTS OR THROMBOELASTOGRAPHY IN PATIENTS WITH ATRIAL FIBRILLATION.	Yvonne Henskens	Received

417-TUE-PO	HOT-WATER EXTRACTS OF THE MUSHROOM, AGARICUS BRASILIENSIS, INHIBITS PLATELET ACTIVATION VIA P2Y1 RECEPTOR.	KANEO SATOH	Received

417-WED-PO	CORRELATION OF CHROMOGENIC RIVAROXABAN ANTI-XA AND DABIGATRAN ANTI-IIA ACTIVITY WITH ROUTINE PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME	Jane Needham	Received

418-TUE-PO	A REDUCED RESPONSE TO TRAP-6 IN PLATELET AGGREGATION STUDIES IS NOT USUALLY DUE TO A PAR-1 RECEPTOR DEFECT.	Michael Mitchell	Received

418-WED-PO	FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE (4F-PCC) REVERSES BLEEDING ASSOCIATED WITH NEW ORAL ANTICOAGULANTS (NOAC) DABIGATRAN, RIVAROXABAN, EDOXABAN AND APIXABAN IN A RABBIT MODEL OF ACUTE BLEEDING	Eva Herzog	Received

419-MON-PO	VASCULAR SMOOTH MUSCLE CELLS STIMULATE PLATELETS VIA CLEC-2: INVOLVEMENT OF INTRACELLULAR AND EXTRACELLULAR LIGANGS OF CLEC-2	Katsue Suzuki-Inoue	Received

420-WED-PO	BLEEDING ON NOVEL ORAL ANTICOAGULATION - OUR EXPERIENCE IN THE NORTHERN REGION, UNITED KINGDOM:PRESENTING FEATURES AND MANAGEMENT OF BLEEDING IN INDIVIDUALS TREATED WITH A NOVEL ORAL ANTICOAGULANT (NOAC):RESULTS OF AN OBSERVATIONAL COHORT STUDY	Shikha Chattree	Received

420-TUE-PO	GRANULES SECRETION IN PATIENTS WITH GLANZMANNS THROMBASTHENIA	Daniele Pillitteri	Received

420-MON-PO	PLATELET-FIBRIN THROMBI CAN KILL STENOTROPHOMONAS MALTOPHILI	Volker R. Stoldt	Received

421-TUE-PO	THE GFI1B C.503GT MUTATION IN THE FIRST ZINC FINGER DOMAIN PREDICTS A MILDER BLEEDING PHENOTYPE THAN THE GFI1B C.880-881INSC MUTATION	david rabbolini	Received

422-MON-PO	INHIBITION OF SORBITOL DEHYDROGENASE INCREASES PLATELETS ADHESION IN MICE TREATED WITH FIDARESTAT	Mariane Flores-Nascimento	Received

422-TUE-PO	ABNORMAL PROPLATELET FORMATION AND EMPERIPOLESIS IN CULTURED MEGAKARYOCYTES FROM GRAY PLATELET SYNDROME PATIENTS	Erica De Candia	Received

423-TUE-PO	MULTIPLEX PHOSPHOSPECIFIC FLOW CYTOMETRY FOR THE SCREENING OF PLATELET SIGNALLING DISORDERS	Marie Levade	Received

423-WED-PO	USE OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR NON-VALVULAR ATRIAL FIBRILLATION IN REAL-LIFE: COMPARISON WITH PHASE III TRIALS	Maria Cristina Vedovati	Received

424-TUE-PO	THIOREDOXIN REDUCTASE PROTECTS PLATELETS FROM CELL DEATH	Matthew Harper	Received

425-MON-PO	REVERSAL OF THE ANTITHROMBOTIC PROPERTIES OF QUERCETIN-3-RUTINOSIDE WITH THE B DOMAIN OF PDI IN A MOUSE THROMBOSIS MODEL	LIN LIN	Received

425-WED-PO	ANTICOAGULATION PHARMACOKINETICS DURING DABIGATRAN THERAPY	Thomas Orfeo	Received

426-TUE-PO	VALIDATION OF THE SELF-PBQ (SELF-ADMINISTERED PEDIATRIC BLEEDING QUESTIONNAIRE) AS A SCREENING TOOL FOR A NEW DIAGNOSIS OF VON WILLEBRAND DISEASE	Angie Tuttle	Received

426-WED-PO	EFFICACY OF PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME AS A GAUGE FOR SPECIFIC FACTOR INHIBITION	Catherine Keller	Received

428-MON-PO	Deletion of PI3K p110&945; results in enhanced platelet priming	Thomas Blair	Received

429-MON-PO	PROFILING OXYLIPINS RELEASED BY GPVI-ACTIVATED PLATELETS AND THE EFFECT OF INHIBITORS OF CYCLOOXYGENASE-1 AND 12-LIPOXYGENASE	Robert Turnbull	Received

429-TUE-PO	SKIN NECROSIS AND PURPURA FULMINANS IN CHILDREN WITH AND WITHOUT THROMBOPHILIA - A TERTIARY CENTERS EXPERIENCE	Yariv Fruchtman	Received

430-MON-PO	Platelet deformation controls cell tethering frequency and translocation velocity under hydrodynamic shear	Changjie Zhang	Received

430-WED-PO	Thrombin-stimulated phosphorylation of Disabled-2 is involved in the regulationof its interaction with CIN85 during human platelet activation	Hui Ju Tsai	Received

430-TUE-PO	INCIDENCE RATE AND RISK FACTORS OF VENOUS THROMBOEMBOLISM IN ASIAN PEDIATRIC ONCOLOGY PATIENTS.	Wai Ming Mendy Ong	Received

431-TUE-PO	CLINICAL FEATURES, RISK FACTORS AND OUTCOME OF PULMONARY EMBOLISM IN CHILDREN ADMITTED TO A SINGLE ACADEMIC CENTER IN SO PAULO BRAZIL: LOTS TO LEARN OR READY TO TEACH?	Jorge D. A. Carneiro	Received

431-WED-PO	INTEGRIN ALPHA IIB BETA 3-MEDIATED C-SRC ACTIVATION: DIFFERENTIAL BINDING TO INACTIVE AND ACTIVE C-SRC	Joel Bennett	Received

432-TUE-PO	AN INTERNATIONAL SURVEY REGARDING MANAGEMENT OF COAGULOPATHY IN CHILDREN UNDERGOING LIVER BIOPSY.	Maria Magnusson	Received

432-MON-PO	MEMBRANE ESTROGEN RECEPTOR (MER) PROTEASE ACTIVATED RECEPTOR (PAR) CROSS TALK MODULATES PLATELET FUNCTION	Joseph Aslan	Received

433-TUE-PO	EVALUATION OF THROMBOPHILIA IN CHILDREN BEFORE RENAL TRANSPLANT AND OUTCOME OF PROPHYLACTIC ANTICOAGULATION POST-TRANSPLANT	Jorge D. A. Carneiro	Received

433-WED-PO	DROSPIRENONE ENHANCES GPIB-IX-V MEDIATED PLATELET ACTIVATION	Xiaolin Wu	Received

433-MON-PO	PLATELET CD34 EXPRESSION IS INCREASED IN FAMILIES WITH DISTINCT GFI1B MUTATIONS: UTILITY AS A SCREENING TEST	Marie-Christine Morel-Kopp	Received

434-MON-PO	A CASE OF MYH9 DISORDERS CAUSED BY A NOVEL MUTATION (P.K74E).	Takeshi Kanematsu	Received

434-WED-PO	A PARADOXICAL HAEMORRHAGIC STATE CAUSED BY DELETION OF THE SRC KINASE INHIBITOR CSK IS PARTIALLY RESCUED BY DELETION OF CD148	Jun Mori	Received

434-TUE-PO	DETERMINING THE USABILITY OF THE PEDIATRIC THROMBOSIS EDUCATIONAL TOOL (P-TET) IN CHILDREN RECEIVING ANTICOAGULATION THERAPY	Madeline Montoya	Received

435-TUE-PO	RARE LABORATORY PRESENTATION OF TYPE 2B VON WILLEBRANDS DISEASE IN A 6 YEAR OLD BOY.	IRENE REGAN	Received

435-WED-PO	EFFECT OF HOMOCYSTEINE AND FOLIC ACID IN CA2 HOMEOSTASIS AND ROS PRODUCTION IN PLATELETS FROM BILE-DUCT LIGATION RATS.	Paola Romecin	Received

435-MON-PO	CALR MUTATIONS ARE ASSOCIATED WITH LOWER PLATELET AND ENDOTHELIAL ACTIVATION THAN THE JAK2 MUTATION IN ESSENTIAL THROMBOCYTHEMIA	Eduardo Arellano-Rodrigo	Received

436-MON-PO	DIFFERENT MICROTUBULE ABNORMALITIES IN TWO CASES OF MACROTHROMBOCYTOPENIA ASSOCIATED WITH TUBB1 VARIANTS	Simon Stritt	Received

436-TUE-PO	SYNERGISTIC EFFECT OF ELEVATED LIPOPROTEIN (A) LEVELS WITH INHERITED THROMBOPHILIA RISK FACTORS IN CHILDREN WITH ARTERIAL ISCHEMIC STROKE	Desiree Coen Herak	Received

437-WED-PO	SPHINGOSINE KINASE DEFICIENCY MODULATES PLATELET ACTIVATION	Benoit DECOUTURE	Received

437-MON-PO	SOLUBLE GLYCOPROTEIN VI: A POTENTIAL BIOMARKER FOR DISEASE ACTIVITY AND PLATELET REACTIVITY IN ACUTE GOUT.	Geraldine McCarthy	Received

437-TUE-PO	THE ROLE OF FVR2 POLYMORPHISM IN CHILDREN CARRIERS OF FVLEIDEN	Zoey Kapsimali	Received

438-TUE-PO	WHOLE BLOOD THROMBOELASTOMETRY (ROTEM) PROFILES IN CHILDREN WITH CYANOTIC CONGENITAL HEART DISEASES UNDERGOING CARDIAC SURGERY	Spiezia Luca	Received

438-MON-PO	PERSONALIZED REFERENCE INTERVALS FOR PLATELET COUNT REDUCE THE PREVALENCE OF UNEXPLAINED THROMBOCYTOPENIA AND INCREASE THAT OF REACTIVE THROMBOCYTOSIS IN ELDERLY PEOPLE	Patrizia Noris	Received

439-MON-PO	MYH9 DISEASE: IDENTIFICATION OF TWO MUTATIONS ASSOCIATED WITH UNCOMMON CLINICAL PHENOTYPE	JOSE RIVERA	Received

439-TUE-PO	THE INCIDENCE OF DEEP VEIN THROMBOSIS IN CHILDREN WITH PERIPHERALLY INSERTED CENTRAL CATHETERS VERSUS TUNNELED CENTRALLY INSERTED CATHETERS	Julie Jaffray	Received

440-WED-PO	LYSINE ACETYLTRANSFER SUPPORTS PLATELET FUNCTION	Joseph Aslan	Received

440-MON-PO	ACTN1-RELATED THROMBOCYTOPENIAS (ACTN1-RT): PHENOTYPE/GENOTYPE OF A SERIES OF 13 NEW CASES	Anne Vincenot	Received

441-TUE-PO	THROMBOEMBOLIC COMPLICATION IN CHILDHOOD WITH NEPHROTIC SYNDROME: EXPERIENCE IN THREE PEDIATRIC HOSPITAL IN ARGENTINA.	Monica Martinez	Received

441-MON-PO	ROCK1 OR FLI1 MUTATIONS IN PATIENTS WITH MILD THROMBOCYTOPENIA.	Canault Matthias	Received

442-MON-PO	CONGENITAL THROMBOCYTOPENIAS AND IMMUNE THROMBOCYTOPENIC PURPURA : A MISLEADING DIAGNOSIS	Maria Coutinho	Received

442-TUE-PO	ACQUIRED VON WILLEBRAND SYNDROME (AVWS) - AN UNDERDIAGNOSED COMPLICATION IN SEVERELY ILL PEDIATRIC PATIENTS WITH BLEEDING COMPLICATIONS	Ivonne Wieland	Received

442-WED-PO	RELEASE OF EXTRA CELLULAR DNA CONTRIBUTES TO RENAL ISCHEMIA REPERFUSION INJURY THROUGH PLATELET ACTIVATION AND FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS	Marcel Jansen	Received

443-MON-PO	FIVE NEW HETEROZYGOUS MUTATIONS IN THE GPIB AND GPIX ARE ASSOCIATED WITH THE BOLZANO PHENOTYPE	BACCINI Véronique	Received

443-TUE-PO	THE IMPACT OF SERUM BILE ACID LEVELS ON THE MRNA EXPRESSION OF PRO-AND ANTICOAGULANT PROTEINS IN LIVER TISSUE.	Maria Magnusson	Received

444-WED-PO	SPECIFIC REGULATION OF MOUSE PLATELET ADP SECRETION BY SARCO-ENDOPLASMIC RETICULUM CALCIUM ATPASE TYPE 3	ziane elaib	Received

444-MON-PO	INCREASE THE NUMBER OF GP IIB-IIIA AND P2Y12 RECEPTORS IN ACTIVATED PLATELETS POSSIBLE EVIDENCE FOR PROTEINS SYNTHESIS DE NOVO	Olga Sirotkina	Received

444-TUE-PO	THROMBOMODULIN GEN ANALYSIS IN A CASE OF ATYPICAL HEMOLYTIC-UREMIC SYNDROME	Noelia Vilalta	Received

445-MON-PO	RISK FACTORS AND CO-MORBIDITIES IN ADOLESCENT THROMBOEMBOLISM ARE DIFFERENT THAN THOSE IN YOUNGER CHILDREN	Titilope Ishola	Received

445-TUE-PO	CLINICAL CHARACTERIZATION OF VENOUS THROMBOEMBOLISM IN CHILDHOOD AT A TERTIARY LEVEL HOSPITAL	Laura Andreoni	Received

446-MON-PO	DO PRETERM INFANTS WITH PATENT DUCTUS ARTERIOSUS (PDA) WHO FAIL PRIMARY PHARMACOTHERAPY HAVE LOWER PLATELET COUNTS? : A SYSTEMATIC REVIEW AND META-ANALYSIS	Souvik Mitra	Received

446-TUE-PO	LETS CUT TO THE BONE: RISK FACTORS OF VENOUS THROMBOEMBOLISM IN CHILDREN WITH MUSCULOSKELETAL INFECTIONS	Rungrote Natesirinilkul	Received

447-TUE-PO	FEASIBILITY AND SAFETY OF ENOXAPARIN WHOLE MILLIGRAM DOSING IN PREMATURE AND TERM NEONATES	Rebecca Goldsmith	Received

447-MON-PO	CATHETER DIRECTED THROMBOLYSIS AS SAFE AND EFFECTIVE THERAPY FOR PROXIMAL LOWER LIMB DEEP VEIN THROMBOSIS IN ADOLESCENTS	Kathryn Musgrave	Received

448-WED-PO	MODULATION OF ACTIN CYTOSKELETON ON SHEAR-DEPENDENT FIBRILLOGENESIS OF FIBRONECTIN	Huong Nguyen	Received

449-WED-PO	JANUS KINASE 3 (JAK3) DEPENDENT SIGNALING IS CRITICAL TO CA2-DEPENDENT PLATELET ACTIVATION AND THROMBUS FORMATION	Patrick Mnzer	Received

450-TUE-PO	CANCER CELLS INDUCE THE RELEASE OF MICROPARTICLES FROM HUMAN PLATELETS	Gianni Guidetti	Received

450-MON-PO	EFFECTS OF MATERNAL HYPERTENSION ON NEONATAL HEMOGRAM IN SOUTH-SOUTH NIGERIA	Helen Okoye	Received

451-MON-PO	TREATMENT WITH ROMIPLOSTIM IN CHILDREN. INCIDENCE AND QUALITY OF THE RESPONSE.	María del Carmen Gómez del Castillo	Received

451-TUE-PO	THE EFFECTS OF INTERFERON&945;-2B ON THE DEFECTIVE BONE MARROW MESENCHYMAL STEM CELLS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA	Tiantian Sun	Received

452-TUE-PO	SUNITINIB IS TAKEN UP BY PLATELETS AND INHIBITS PLATELET ACTIVATION AND THROMBUS FORMATION IN CANCER PATIENTS	Marijke Kuijpers	Received

452-WED-PO	EFFECT OF PAR-4 TETHERED-LIGAND PEPTIDE ANALOGS ON HUMAN PLATELET ACTIVATION	Iraklis Moschonas	Received

453-WED-PO	PLATELET HSP70 PROMOTES INTEGRIN ALPHAIIBBETA3 ACTIVATION AND PLATELET AGGREGATION	Rachel A. Rigg	Received

453-TUE-PO	ALLELIC VARIANTS WITHIN ANXA5 DIFFERENTIALLY IMPACT ON THE CONTROL OF GENE EXPRESSION	Giovanni Tiscia	Received

453-MON-PO	INVESTIGATING THE ROLE OF POLYPHOSPHATES IN NEONATAL HEMOSTASIS	Axel Schlagenhauf	Received

454-WED-PO	INFLUENCE OF PRO-MMP-9 ON PLATELET AGGREGATION AND ADHESION TO FIBRINOGEN	Aneta Wrzyszcz	Received

455-WED-PO	THE DEFECTIVE CD36 GENE MUTATIONS CAUSE A MOLECULAR EXPRESSION DIVERSITY ON PLATELETS AND MONOCYTES EVEN IN NON-DEFICIENT PHENOTYPE POPULATION	Shogo Tamura	Received

455-MON-PO	USE OF PROTHROMBIN COMPLEX CONCENTRATES (PCC) IN PAEDIATRIC EXTRACORPOREAL LIFE SUPPORT PATIENTS	aisha bruce	Received

456-MON-PO	ANTITHROMBIN PLASMA LEVELS AND FIBTEM DETERMINATION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ASPARAGINASE TREATMENT	Spiezia Luca	Received

456-TUE-PO	THE EFFECT OF ULTRA HIGH LEVELS OF C-REACTIVE PROTEIN (CRP) ON THE COAGULATION SYSTEM	Ramin Artang	Received

457-MON-PO	WARFARIN THERAPY IN CHILDREN: CAN FAMILIES SAFELY AND EFFICIENTLY MONITOR INRS AT HOME?	Kathy Harney	Received

457-TUE-PO	ASSESSMENT OF THE EFFECT OF INTER-ALPHA TRYPSIN INHIBITOR BY THROMBIN GENERATION ASSAY	Plantier Jean-Luc	Received

457-WED-PO	ELASTIN-DERIVED PEPTIDES REGULATE LEUKOCYTE-PLATELET AGGREGATES	Pascal MAURICE	Received

458-MON-PO	PROPHYLACTIC ENOXAPARIN IN YOUNG INFANTS ARE THE CURRENTLY RECOMMENDED DOSES TOO LOW?	Kathy Harney	Received

458-WED-PO	PLATELET DENSE GRANULE SECRETION DEFECTS MAY OBSCURE OUR UNDERSTANDING OF ?-GRANULE SECRETION MECHANISMS: EVIDENCE FROM MUNC13-4-DEFICIENT PLATELETS	Matthew Harper	Received

458-TUE-PO	PROLONGATION OF CLOT LYSIS TIME BY A DIRECT THROMBIN INHIBITOR: INVOLVEMENT OF THROMBIN GENERATION ENHANCEMENT AND THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR	Yoshiyuki Morishima	Received

459-MON-PO	THROMBOEMBOLIC EVENTS IN CHILDREN	zafer salcioglu	Received

460-MON-PO	BIVALIRUDIN USE IN CHILDREN ON ECMO FOLLOWING HEPARIN FAILURE	aisha bruce	Received

461-WED-PO	The Ras/RapGAP Rasa3 negatively regulates Rap1b and integrin &945;IIb&946;3-mediated spreading	Anthony Battram	Received

461-MON-PO	THROMBOEMBOLIC EVENTS IN PEDIATRIC PATIENTS WITH CYANOTIC CONGENITAL HEART DISEASES IN SRINAGARIND HOSPITAL	Patcharee Komvilaisak	Received

461-TUE-PO	A NOVEL APPROACH FOR HEMOPHILIA THERAPY THROUGH ANTIBODY TARGETED TFPI	Sumin Lee	Received

462-TUE-PO	FUNCTIONAL COMPONENTS OF JAPANESE TRADITIONAL SOYBEAN FOOD NATTO?NATTOKINASE, VITAMIN K2 AND POLYAMINE?	Hiroyuki Sumi	Received

462-WED-PO	DEXTRAN SULFATE TRIGGERS PLATELET AGGREGATION VIA PEAR1, INDEPENDENT FROM SYK	Christophe Vandenbriele	Received

463-TUE-PO	FIBRINOLYTIC ACTIVITY PRODUCED BY FERMENTED SWEET CORN WITH BACILLUS SUBTILIS NATTO	Hiroyuki Sumi	Received

464-WED-PO	IDENTIFICATION OF LOW MOLECULAR WEIGHT FACTORS RELEASED FROM PLATELETS THAT INDUCE PROCR IN MONOCYTES	Robert Turnbull	Received

464-MON-PO	EXAMINING THE FEASIBILITY OF RECOMBINANT FACTOR VIIA TO COMPENSATE FOR PHYSIOLOGICAL OR DRUG-INDUCED IMPAIRMENT OF PLATELET FUNCTION: AN IN-VITRO STUDY.	Harald Haidl	Received

464-TUE-PO	INHIBITION OF FIBRINOLYSIS BY HEPARIN, LOW MOLECULAR WEIGHT HEPARIN AND A NOVEL ANTICOAGULANT, ANTITHROMBIN-HEPARIN COVALENT COMPLEX (ATH)	Gabriela Chang	Received

465-TUE-PO	COMPLEMENT C3 AND HYPOFIBRINOLYSIS: A POTENTIAL ROLE FOR PROTEIN GLYCATION	Katharina Schuett	Received

465-WED-PO	CELL SURFACE EXPRESSION OF CHEMERIN RECEPTORS ON HUMAN PLATELETS UPON CELL ACTIVATION	Zhifei Shao	Received

466-WED-PO	GPIB? ACTIVATION MEDIATES PLATELET TISSUE FACTOR (TF) PHOSPHORYLATION, TRANSFER TO LIPID RAFTS (LR) AND ACTIVITY. TFPI AND PROTEIN S, RELEASED BY OTHER AGONISTS, WOULD ASSEMBLE THE INHIBITORY COMPLEX (TF/FVIIA/TFPI/PS) IN LR, DAMPENING FXA ACTIVITY	Olga Panes	Received

466-MON-PO	DENSER CLOTS PREDISPOSE TO POST THROMBOTIC SYNDROME	Annemieke Bouman	Received

467-MON-PO	PRACTICE VARIATION IN THE TREATMENT OF DVT AND PREVENTION OF POST THROMBOTIC SYNDROME BETWEEN INTERNISTS AND VASCULAR SURGEONS: A CANADIAN SURVEY OF PHYSICIAN PRACTICES.	Rick Ikesaka	Received

467-TUE-PO	EFFECTS OF AN ACIDIC ENVIRONMENT ON COAGULATION DYNAMICS	Matthew Gissel	Received

468-TUE-PO	EXERCISE-INDUCED CORE BODY TEMPERATURE ELEVATIONS SHIFT HEMOSTASIS TO A PROTHROMBOTIC STATE	Waander L. van Heerde	Received

468-WED-PO	EVALUATION OF ISTH-BLEEDING ASSESSMENT TOOL IN INDIVIDUALS WITH SUSPECTED INHERITED PLATELET FUNCTION DISORDER REFERRED TO TERTIARY HEALTH CARE FACILITY IN PAKISTAN.	ANILA RASHID	Received

469-TUE-PO	IN VITRO INTERACTIONS OF SUGAMMADEX WITH VARIOUS ANTICOAGULANTS	Annelieke Kruithof	Received

469-WED-PO	EFFECT OF CARDIOPULMONARY BYPASS PUMP ON THE PLATELET FUNCTION USING PLATELET FUNCTION ANALYZER (PFA-100) PRE AND POSTOPERATIVE CARDIAC SURGERY OPERATION.	AL Bakr Rashed Bakr R	Received

470-WED-PO	DECREASED PLATELET REACTIVITY IN WOMEN WITH HEAVY MENSTRUAL BLEEDING: A NOVEL APPROACH IN THE GYNAECOLOGY CLINIC TO DIAGNOSE THROMBOPATHY USING A NOVEL PLATELET FUNCTION TEST.	Heleen Eising	Received

470-MON-PO	TOLL-LIKE 9 GENE EXPRESSION IN THE POST THROMBOTIC SYNDROME, RESIDUAL THROMBOSIS AND RECURRENT DEEP VENOUS THROMBOSIS: A CASE-CONTROL STUDY	Whitney Cheung	Received

471-MON-PO	PATIENTS PREFERENCES REGARDING ELASTIC COMPRESSION STOCKING THERAPY FOR THE PREVENTION OF POST THROMBOTIC SYNDROME	Annemieke Bouman	Received

471-WED-PO	DIAGNOSTIC ACCURACY OF FLOW CYTOMETRY ANALYSIS OF PLATELET LEUKOCYTE AGGREGATES IN ACUTE CORONARY SYNDROME PATIENTS VERSUS NORMAL VOLUNTEERS	najib dally	Received

472-MON-PO	COMPARISON OF SELF-RATED AND PROFESSIONAL-RATED SCORES OF THE VILLALTA SCALE FOR EVALUATION OF THE POST-THROMBOTIC SYNDROME IN PATIENTS WITH PROXIMAL DEEP VEIN THROMBOSIS	Trond Isaksen	Received

472-TUE-PO	EARLY ANTICOAGULATION AND PREGNANCY OUTCOMES IN PATIENTS REFERRED TO A SERVICE OF THROMBOSIS AND THROMBOPHILIA IN PREGNANCY	VENINA BARROS	Received

472-WED-PO	A STEP FORWARD IN THE EVALUATION OF PLATELET FUNCTION TESTING: ROUTINE, SIMULTANEOUS MEASUREMENT OF PLATELET AGGREGATION, SEROTONIN (5-HT) CONTENT AND SECRETION BY HPLC-ELECTROCHEMICAL DETECTION IN HEMOSTASIS LABORATORIES.	Diego Mezzano	Received

473-MON-PO	IS POST THROMBOTIC SYNDROME PERCEIVED TO BE A CLINICALLY RELEVANT OUTCOME?: A SURVEY OF PHYSICIAN PRIORITIES	Rick Ikesaka	Received

473-WED-PO	OUTCOMES OF 65 PREGNANCIES IN 34 WOMEN WITH 5 DIFFERENT FORMS OF INHERITED PLATELET FUNCTION DISORDERS ENROLLED IN A RETROSPECTIVE AND MULTICENTRIC STUDY, ON BEHALF OF EHA-SWG ON THROMBOCYTOPENIAS AND PLATELET FUNCTION DISORDERS	Patrizia Noris	Received

474-TUE-PO	NEW THROMBOPHILIC RISK FACTORS IN PATIENTS WITH VASCULAR PLACENTAL COMPLICATIONS (VPC) AND PREGNANCY OR HORMONAL THERAPY - RELATED THROMBOSIS AND MANAGEMENT IN THE CLINICAL PRACTICE . RESULTS FROM THE INTERNATIONAL TEAM PROJECT.	Amparo santamaria	Received

474-WED-PO	THE VALUE OF IMPEDANCE AGGREGOMETRY IN ACUTE LEUKEMIA PATIENTS	Andra Costache	Received

475-WED-PO	A NATIONAL REGISTRY OF PATIENTS WITH INHERITED PLATELET DISORDERS: BLEEDING SCORE IS ASSOCIATED WITH TIME OF FOLLOW-UP	Shoshana Revel-Vilk	Received

476-TUE-PO	MATERNAL DEATH AND VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS ADMITTED IN A MATERNITY OF HIGH RISK: RESULTS PRE AND POST APPLICATION OF A RISK SCORE.	Roberta Santos	Received

476-MON-PO	FIBRINOGEN CHARACTERISTICS HELP PREDICT CHRONIC THROMBOTIC VENOUS DISEASE AFTER ACUTE DEEP VEIN THROMBOSIS	Timothy Morris	Received

476-WED-PO	PLASMA MARKERS OF FIBRINOLYSIS, THROMBIN GENERATION AND PLATELET ACTIVITY IN MYELOPROLIFERATIVE NEOPLASMS	Hung Chang	Received

477-TUE-PO	A COMMON GENETIC BACKGROUND SHARED BY WOMEN WITH HISTORY OF ADVERSE PREGNANCY OUTCOMES AND CARDIOVASCULAR DISEASE: A WINDOW TO FUTURE CARDIOVASCULAR RISK.	Ilaria Romagnuolo	Received

477-WED-PO	COMPARISON OF A NOVEL AUTOMATED MICROCHIP FLOW-CHAMBER SYSTEM AND CONVENTIONAL PLATELET FUNCTION TESTS IN PATIENTS WITH ISCHEMIC CEREBROVASCULAR DISEASES	Masako Yamazaki	Received

478-MON-PO	THE ROLE OF INFLAMMATION IN POST-THROMBOTIC SYNDROME AFTER PREGNANCY-RELATED VENOUS THROMBOSIS	Hilde Skuterud Wik	Received

478-WED-PO	GENETIC AND NON-GENETIC DETERMINANTS OF MPV DIFFER IN MALES AND FEMALES RESULTS FROM THE GUTENBERG HEALTH STUDY	Marina Panova-Noeva	Received

479-WED-PO	EVALUATION OF PLATELETS COUNT AND ACTIVATION DURING MENSTRUAL CYCLE IN YOUNG WOMEN IN ORAL CONTRACEPTIVE USE	Luci Maria SantAna Dusse	Received

479-TUE-PO	THE IMPACT OF MODE OF DELIVERY AND POSTPARTUM THROMBOPROPHYLAXIS ON ROTATIONAL THROMBOELASTOMETRY (ROTEM) IN PREGNANT WOMEN WITH A HIGH RISK OF POSTPARTUM VENOUS THROMBOEMBOLISM.	Boriana Guimicheva	Received

479-MON-PO	MOM, WHY SHOULD I WEAR THESE SOCKS? TAKING THE FIRST STEP IN THE JOURNEY TO UNDERSTANDING THE ROLE OF COMPRESSION GARMENTS IN THE TREATMENT OF PEDIATRIC POST-THROMBOTIC SYNDROME	Madeline Montoya	Received

480-WED-PO	REVISITING THE HEMOSTATIC DISORDER OF UREMIA : PATIENTS ON PERITONEAL DIALYSIS (CRF-PD) HAVE NORMAL PLATELET AGGREGATION AND SECRETION BUT INCREASED PLATELET TISSUE FACTOR ACTIVITY (TF-PCA), PROBABLY THE CAUSE OF INTRAVASCULAR CLOTTING ACTIVATION.	Olga Panes	Received

480-TUE-PO	RETROSPECTIVE STUDY OF PATIENTS WHO WERE TREATED WITH FONDAPARINUX PRE-, PERI- AND/OR POSTPARTUM FOR PROPHYLAXIS OR TREATMENT OF VENOUS THROMBOEMBOLISM (FONDAPPP)	Carl-Erik Dempfle	Received

480-MON-PO	INADEQUATE ANTICOAGULATION IS THE ONLY RISK FACTOR FOR DEVELOPMENT OF POST THROMBOTIC SYNDROME IN UNPROVOKED DEEP VEIN THROMBOSIS	PRAVAS MISHRA	Received

481-MON-PO	PATIENT COMPRESSION HOSIERY CONCORDANCE	GARY BENSON	Received

481-TUE-PO	ROTATIONAL THROMBOELASTOMETRY IN PREGNANCY AND ITS ROLE IN ASSESSMENT OF HAEMOSTASIS IN WOMEN WITH FACTOR XI DEFICIENCY	Joanna Davies	Received

482-TUE-PO	THROMBIN GENERATION IN WOMEN UNDERGOING IVF TREATMENT IS PROLONGED, BUT NOT ENHANCED COMPARED TO CONTROLS.	Roza Chaireti	Received

482-MON-PO	THE UTILITY OF THROMBELASTOGRAPHY AND MULTIPLATE AS SCREENING TOOLS FOR RARE INHERITED BLEEDING DISORDERS NOT ASSOCIATED WITH A COAGULATION FACTOR DEFICIENCY	Eva Leinoe	Received

483-MON-PO	BLEEDING SCORE AND CLOTTING SCREENING TESTS PERFORMED BEFORE ELECTIVE SURGERY TO DIAGNOSE UNKNOWN HEMORRHAGIC DISEASES.	Gabriella Gamba	Received

484-TUE-PO	EFFECTS OF SILDENAFIL CITRATE ON COAGULATION PROCESS DURING PREGNANCY: A PROMISING THERAPEUTIC APPROACH IN COMBINATION WITH LOW MOLECULAR WEIGHT HEPARIN FOR RECURRENT PREGNANCY LOSS	Rayana Luna	Received

485-WED-PO	SUCCESSFUL USE OF LOCAL PLATELET PELLET FOR CHILDREN WITH SEVERE EPISTAXIS	davut albayrak	Received

485-TUE-PO	A RISK SCORE FOR PREDICTION OF RECURRENCE IN PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM (DAMOVES)	Ana Isabel Franco	Received

485-MON-PO	A NEW SWISS FAMILY WITH CONSTITUTIONAL HYPOFIBRINOGENEMIA AND LIVER DISEASE	Alessandro Casini	Received

486-TUE-PO	ANALYSIS OF PROTHROMBIN MUTANTS IN NA BINDING DOMAIN AS A POTENTIAL CANDIDATE CONVEYING ANTITHROMBIN RESISTANCE	Moe Murata	Received

486-WED-PO	ELEVATED SOLUBLE PLATELET GLYCOPROTEIN VI LEVELS IN PATIENTS AFTER LIVING DONOR LIVER TRANSPLANTATION	Takeshi Matsumoto	Received

486-MON-PO	SAFE USE OF FXI CONCENTRATE IN A SINGLE CENTRE EXPERIENCE OVER 19 YEARS	Gavin Ling	Received

487-WED-PO	NICOTINIC ACETYLCHOLINE RECEPTOR FUNCTION IN PLATELETS FROM ALZHEIMER DISEASE PATIENTS	Peter Bugert	Received

487-TUE-PO	ORAL ANTICOAGULANT THERAPY FOR THE PREVENTION OF RECURRENT THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA	Eduardo Arellano-Rodrigo	Received

488-TUE-PO	ACSF2 EXPRESSION AND RISK OF RECURRENCE AFTER A FIRST UNPROVOKED DEEP VENOUS THROMBOSIS EVENT. RESULTS FROM THE RETRO STUDY	Ramón Lecumberri	Received

489-MON-PO	ALTERNATIVE STRATEGY TO TREAT HEMOPHILIA TROUGH PROTEIN S INACTIVATION: INSIGHT FROM A MOUSE MODEL	Luca Bologna	Received

490-WED-PO	INCREASED MITOCHONDRIAL ELECTRON TRANSPORT ASSOCIATED WITH APOPTOSIS IN HYPER-REACTIVE PLATELETS OF PATIENTS WITH ACUTE PULMONARY EMBOLISM	Samin Rezania	Received

490-MON-PO	GENOTYPE AND PHENOTYPE REPORT ON PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY IN SOUTH OF IRAN	Mehran Karimi	Received

490-TUE-PO	INHERITED PROTHROMBOTIC RISK FACTORS IN CHILDREN WITH INTRACRANIAL VENOUS THROMBOSIS: SINGLE CENTER EXPERIENCE IN TURKEY	TURKAN PATIROGLU	Received

491-WED-PO	ANTENATAL GENETIC ANALYSIS OF A JAPANESE TYPE I CD36-DEFICIENT WOMAN IN THE PREGNANCY	Naomi Sanda	Received

491-TUE-PO	THROMBOPROPHYLAXIS SKIPPED DOSES IN HOSPITALIZED PATIENTS.CAN WE RECOGNIZE WHICH ARE THE CAUSES OR FACTORS?	alicia beatriz vilaseca	Received

492-WED-PO	A RELIABLE AND SIMPLE DIAGNOSTIC APPROACH TO DETECT PLATELET SECRETION DEFECTS IN SUBJECTS WITH MUCOCUTANEOUS BLEEDING	Stan Heptinstall	Received

493-MON-PO	CHARACTERIZING MECHANISMS OF FACTOR VIII BINDING TO THE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1	Patricia Young	Received

493-WED-PO	PLATELET CD40L CONTROLS BLEEDING DURING P2Y12 BLOCKERS TREATMENT.	Canault Matthias	Received

493-TUE-PO	IMPACT OF INHERITED RISK FACTORS OF VENOUS THROMBOEMBOLISM (VTE) ON THE ASSOCIATIONS BETWEEN RED CELL DISTRIBUTION WIDTH AND RISK OF VTE.	Trygve Ellingsen	Received

494-TUE-PO	IMPACT OF INHERITED RISK FACTORS OF VENOUS THROMBOSIS ON RISK OF STROKE AND VTE IN ATRIAL FIBRILLATION	Ina Rye-Holmboe	Received

494-WED-PO	CLINICAL AND GENETIC PREDICTORS OF POOR PLATELET RESPONSE TO CLOPIDOGREL IN PATIENTS WHO UNDERWENT PERCUTANEOUS CORONARY INTERVENTION	A. Anil Timur	Received

495-WED-PO	NO INCREASE IN PLATELET AGGREGATION IN HEALTHY WOMEN STARTING COMBINED ORAL CONTRACEPTIVES	Julie Brogaard Larsen	Received

495-TUE-PO	IMPACT OF THE FIBRINOGEN GAMMA GENE RS2066865 VARIANT ON THE RISK OF VENOUS THROMBOSIS IN CANCER PATIENTS	Olga Dziewiecka	Received

496-TUE-PO	CHARACTERISTICS OF HOSPITAL-ASSOCIATED THROMBOSIS ATTRIBUTED TO THROMBOPROPHYLAXIS FAILURE	Emma Gee	Received

497-TUE-PO	ANTI-VIMENTIN ANTIBODIES INCREASE THROMBUS FORMATION AT VENOUS SHEAR RATES IN VITRO AND IN VIVO: IMPLICATION FOR VENOUS THROMBOEMBOLISM IN AUTOIMMUNE DISEASES	Miguel Cruz	Received

497-MON-PO	ACQUIRED GPVI DEFICIENCY IN TWO UNRELATED PATIENTS WITH MILD THROMBOCYTOPENIA	JOSE RIVERA	Received

497-WED-PO	STUDY OF PLATELET FUNCTION IN HEMOPHILIA A IN THE REGION OF MURCIA	Antonia Melero Amor	Received

498-MON-PO	IDENTIFICATION OF THE PATHOPHYSIOLOGICAL MECHANISM OF THE VKCFD2 CAUSING MUTATION P.ARG98TRP IN HUMAN VKORC1 GENE	Katrin Czogalla	Received

499-TUE-PO	FORGOTTEN NO MOREA CASE OF A 54 YEAR OLD FEMALE WITH LEMIERRES SYNDROME	Edward Gacrama	Received

499-MON-PO	SCOTT SYNDROME PLATELETS SHOW ALTERATIONS IN PROTEIN EXPRESSION LEVELS, CALCIUM-DEPENDENT PHOSPHORYLATION AND CLEAVAGE AS REVEALED BY PROTEOMICS	Johan Heemskerk	Received

499-WED-PO	CEREBRAL VENOUS THROMBOSIS OCCURRING DURING OXYMETHOLONE THERAPY IN A PATIENT WITH FANCONI APLASTIC ANEMIA	erol erduran	Received

500-MON-PO	A FAILURE TO DIAGNOSE DYSFIBRINOGENAEMIA: DATA FROM MULTICENTRE STUDIES AMONGST UK NEQAS AND PRO-RBDD PROJECT LABORATORIES.	Ian Jennings	Received

500-TUE-PO	PREAVELANCE OF RISK FACTORS PREDISPOSING TO THROMBOSIS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION	Jerzy Dropinski	Received

501-TUE-PO	NO DIFFERENCES IN THROMBIN GENERATION BETWEEN PATIENTS WITH AND WITHOUT PORTAL VEIN THROMBOSIS IN END-STAGE LIVER DISEASE	Dana Tomescu	Received

501-WED-PO	THROMBOSIS IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: ENDOGENOUS AND EXOGENOUS RISK FACTORS	O.V. Shpitonkova	Received

502-WED-PO	EVALUATION OF AGE-DEPENDENT DOSING RECOMMENDATIONS FOR THE ADMINISTRATION OF TINZAPARIN IN THE TREATMENT OF PAEDIATRIC THROMBOSIS	Tina Biss	Received

503-MON-PO	DECREASED FIBRINOLYTIC RESISTANCE IN FXI-DEFICIENCY IS INDEPENDENT OF CLOTTING IMPAIRMENT	Francesca Incampo	Received

503-WED-PO	USING A FUNCTIONAL PLATELET ACTIVITY ANALYSIS IN CHILDREN WITH UNEXPLAINED BLEEDING. FIRST RESULTS FROM RUSSIA	Pavel Zharkov	Received

503-TUE-PO	A-FIBRINOGEN THR312ALA POLYMORPHISM IS AN INDEPENDENT GENETIC RISK FACTOR FOR VENOUS THROMBOEMBOLISM IN THE POPULATION OF NORTH-WESTERN RUSSIA	Sergey Kapustin	Received

504-WED-PO	FOUR YOUNG CHILDREN WITH THROMBOTIC COMPLICATIONS AS A RESULT OF ANTITHROMBIN HEPARIN-BINDING DEFECTS.	Michael Mitchell	Received

504-TUE-PO	VENOUS THROMBOEMBOLISM (VTE) IN HOSPITALISED NON-SURGICAL CANCER PATIENTS AND ITS BURDEN ON HEALTHCARE IN AN ASIAN TERTIARY HOSPITAL	Lai Heng Lee	Received

505-WED-PO	RISK OF THROMBOSIS IN A COHORT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS	Sule Unal	Received

506-WED-PO	COMPARISON OF THE IMPACT OF SERPINC1, PROC AND PROS1 MUTATIONS ON THROMBOTIC PHENOTYPES IN CHILDREN AND ADULTS: AN OBSERVATIONAL MULTICENTER COHORT STUDY	Verena Limperger	Received

506-TUE-PO	ANTICOAGULANTS FOR PREVENTION OF THROMBOTIC COMPLICATIONS IN PATIENTS ON PARENTERAL NUTRITION: A SYSTEMATIC REVIEW.	Stefano Barco	Received

507-TUE-PO	LONG-TERM PARENTERAL NUTRITION-ASSOCIATED THROMBOEMBOLIC AND HEMORRHAGIC COMPLICATIONS IN 236 SINGLE-CENTER OUTPATIENTS.	Stefano Barco	Received

507-WED-PO	ACQUIRED VON WILLEBRAND DISEASE IN A PATIENT WITH UNDERLYING BECKWITH-WIEDEMANN SYNDROME	Fatma Gumruk	Received

508-MON-PO	PLACENTAL INSUFFICIENCY RESOLUTION WITH FULL ANTICOAGULATION IN PATIENTS WITH PRIOR BAD OBSTETRIC OUTCOME AND DYSLIPIDAEMIA DURING PREGNANCY.	roberta santos	Received

508-WED-PO	NOVEL HOMOZYGOUS MUTATION IN MCFD2 AND HETEROZYGOUS SMALL DELETION IN LMAN1 GENES CAUSING COMBINED FACTOR V AND VIII DEFICIENCY	Mualla Cetin	Received

509-TUE-PO	UROKINASE PLASMINOGEN ACTIVATOR PROTECTS CARDIAC MYOCYTES FROM OXIDATIVE DAMAGE AND APOPTOSIS VIA OGG1	Philipp Hohensinner	Received

509-MON-PO	D-DIMER MEASUREMENT HAS NO DIAGNOSTIC VALUE DURING PREGNANCY A LONGITUDINAL STUDY OF 4314 SAMPLES FROM 791 HEALTHY WOMEN	Katrine Hedengran	Received

510-TUE-PO	FACTOR VII ACTIVATING PROTEASE (FSAP) EXPRESSION IS NEGATIVELY REGULATED BY TRANSFORMING GROWTH FACTOR-BETA (TGF-?) IN THE LIVER.	Sebastian Seidl	Received

510-MON-PO	MEN WITH FACTOR V LEIDEN HAVE INCREASED SPERM COUNTS	Thijs van Mens	Received

511-MON-PO	INCIDENCE OF VENOUS THROMBOSIS IN PREGNANCIES AFTER SPONTANEOUS AND ART CONCEPTION - AN ITALIAN COHORT STUDY -	MICHELA VILLANI	Received

511-TUE-PO	PHOSPHATIDYLINOSITOL-3,4,5-TRISPHOSPHATE STIMULATES CA2 ELEVATION AND AKT PHOSPHORYLATION TO CONSTITUTE A MAJOR MECHANISM OF THROMBOXANE A2 FORMATION IN HUMAN PLATELETS.	KALWANT AUTHI	Received

511-WED-PO	THE INFLUENCE OF CHILDHOOD IMMUNIZATIONS ON WARFARIN EFFECT	siddons suzanne	Received

512-TUE-PO	A SYSTEMS BIOLOGY MODEL FOR THE COAGULATION NETWORK DESCRIBES BIOMARKER CHANGES OBSERVED IN A CLINICAL STUDY WITH FVIIA VARIANT	Fei Hua	Received

512-MON-PO	POST-PARTUM PROPHYLAXIS IN PRACTICE.	Emmanuelle Le Moigne	Received

513-MON-PO	THE M2 HAPLOTYPE WITHIN THE ANNEXIN A5 GENE AND ANTIPHOSPHOLIPID ANTIBODIES IN UNSELECTED PREGNANT WOMEN- A PROSPECTIVE HOSPITAL- BASED STUDY-	MICHELA VILLANI	Received

513-WED-PO	HEMOSTASIS PROFILE IN CALVES RECEIVING THE CARMAT BIOPROSTHETIC ARTIFICIAL HEART	David SMADJA	Received

515-MON-PO	EFFECT OF PROPHYLAXIS WITH LMWH ON IMPLANTATION IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE PROCEDURES (IVF OR ICSI): A PROSPECTIVE RANDOMIZED STUDY	daniela tormene	Received

515-TUE-PO	EVALUATION OF THE THERAPEUTIC EFFECT OF NOVEL STROKE DRUG SMTP-7 ON EMBOLIC STROKE IN MONKEYS	Eriko Suzuki	Received

516-TUE-PO	THE ASSOCIATION OF FACTOR VIII AND VON WILLEBRAND FACTOR LEVELS AND THE OUTCOME OF THROMBOLYSIS IN ISCHEMIC STROKE PATIENTS	Noemi Klara Toth	Received

516-MON-PO	PREDICTION OF VENOUS THROMBOEMBOLIC RELATED FETAL LOSSES BY A NEW GENETIC RISK SCORE	Jose A. Paramo	Received

517-TUE-PO	ADAMTS13 DESTABILIZES THROMBI IN A MOUSE MODEL OF THROMBOTIC FOCAL CEREBRAL ISCHEMIA	Frederik Denorme	Received

518-TUE-PO	REMOTE PLATELET FUNCTION TESTING USING MEASUREMENTS OF P-SELECTIN IN PATIENTS WITH ACUTE STROKE OR TIA ALREADY RECEIVING TREATMENT WITH ANTIPLATELET AGENTS	Stan Heptinstall	Received

518-WED-PO	TWO FAMILIES FROM ARGENTINA WITH FX DEFICIENCY DUE TO TWO DIFFERENT MUTATIONS (P.CYS241GLY AND P.GLN138ARG ).	Hugo A. Guglielmone	Received

519-TUE-PO	INHIBITION OF TAFI AND PAI-1 IS PROTECTIVE IN A MOUSE MODEL OF CEREBRAL ISCHEMIA/REPERFUSION INJURY	Frederik Denorme	Received

521-MON-PO	ALL CAUSE MORTALITY AND USE OF ANTITHROMBOTICS WITHIN 90 DAYS OF DISCHARGE IN ACUTELY ILL MEDICAL PATIENTS	Charles Mahan	Received

521-TUE-PO	GENETIC ABLATION OF EXTRA DOMAIN A OF CELLULAR FIBRONECTIN PROTECTS HYPERCHOLESTEROLEMIC MICE FROM ACUTE STROKE BY REDUCING THROMBO-INFLAMMATION	Nirav Dhanesha	Received

522-MON-PO	RISK OF VENOUS THROMBOSIS AND COAGULATION PROFILE IN DUTCH NATIVES AND IMMIGRANTS IN THE NETHERLANDS: RESULTS FROM THE MEGA STUDY	Suely Rezende	Received

522-WED-PO	EFFECTS OF FACTOR XIII DEFICIENCY ON THROMBOELASTOGRAPHY. BASAL THROMBELASTOGRAPH AND LYSIS BY ADDITION OF STREPTOKINASE ARE MORE AFFECTED THAN SOLUBILITY TESTS	Marta E Martinuzzo	Received

522-TUE-PO	EFFECTS OF THE MAIN ACTIVE COMPONENT COMBINATION BETWEEN ASTRAGALUS AND PANAX NOTOGINSENG ON INFLAMMATION AND APOPTOSIS OF NERVE CELL AFTER CEREBRAL ISCHEMIA-REPERFUSION	Chang-Qing Deng	Received

523-WED-PO	HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY: A REPORT OF ELEVEN VENEZUELAN CASES	MARION ECHENAGUCIA	Received

523-MON-PO	IMPACT OF TORNADOES ON HOSPITAL ADMISSIONS FOR VENOUS THROMBOEMBOLISM AND CARDIOVASCULAR EVENTS	Ana Casanegra	Received

524-MON-PO	JOINT EFFECTS OF F5 GENE VARIANTS AND TALL STATURE ON VTE RISK	Tine Lnneberg	Received

524-WED-PO	DIAGNOSIS OF FXIII DEFICIENCY: DATA FROM MULTICENTRE STUDIES AMONGST UK NEQAS AND PRO-RBDD PROJECT LABORATORIES.	Ian Jennings	Received

524-TUE-PO	THROMBOELASTOMETRY (ROTEM) PROFILES IN PATIENTS UNDERGOING THROMBOLYTIC THERAPY FOR ACUTE ISCHEMIC STROKE.	Elena Campello	Received

525-MON-PO	JOINT EFFECT OF OBESITY AND RISK ALLELES IN THE KNG1 GENE ON RISK OF VENOUS THROMBOEMBOLISM.	Tine Lnneberg	Received

525-TUE-PO	SEVERE OBESITY IS A RISK FACTOR FOR CEREBRAL VENOUS THROMBOSIS: A CASE-CONTROL STUDY	Jonathan Coutinho	Received

525-WED-PO	THE CLINICAL FINDINGS OF CHILDREN WITH FACTOR X DEFICIENCY AT A SINGLE CENTER IN THE MIDDLE EAST OF TURKEY	Funda Tayfun	Received

526-MON-PO	JOINT EFFECT OF CANCER AND THE GP6 RS1613662 SINGLE NUCLEOTIDE POLYMORPHISM ON VTE RISK	Olga Dziewiecka	Received

527-WED-PO	INHERITED FXI DEFICIENCY IS NOT A RARE DISEASE IN THE NORTHERN REGION OF TURKEY	albayrak davut	Received

527-TUE-PO	THE ALTERATION OF IRON TRANSMEMBRANE PROTEINS EXPRESSION IN THE RAT HIPPOCAMPUS FOLLOWING FOCAL CEREBRAL ISCHEMIA	Jun Liao	Received

527-MON-PO	SEX HORMONE-BINDING GLOBULIN AND HEMOSTATIC VARIABLES IN WOMEN USING COMBINED OR PROGESTIN-ONLY PILLS.	Justine Hugon-Rodin	Received

528-MON-PO	INVOLVEMENT OF HEREDITARY THROMBOPHILIA IN CEREBRAL VENOUS THROMBOSIS OCCURRING IN YOUNG PATIENTS	Héla Baccouche	Received

528-TUE-PO	NONCLINICAL AND CLINICAL DEVELOPMENT OF TMS-007, A MEMBER OF THE ANTI-INFLAMMATORY SMALL-MOLECULE THROMBOLYTIC SMTPS	Keiji Hasumi	Received

529-TUE-PO	ANTITHROMBIN LEVELS IN ADULT STROKE PATIENTS AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL	Omolade Awodu	Received

529-MON-PO	CHRONIC LIVER DISEASE IS A SIGNIFICANT RISK FACTOR FOR VENOUS THROMBOEMBOLISM AMONG MEDICAL PATIENTS IN SINGAPORE GENERAL HOSPITAL	Lai Heng Lee	Received

530-WED-PO	CLINICAL PRESENTATION AND MANAGEMENT OF RARE FACTOR DEFICIENCIES:CASE STUDY	Bulent Antmen	Received

530-MON-PO	THE EFFECT OF HEMODIAFILTRATION AND HEMODIALYSIS ON COAGULATION PARAMETERS IN PATIENTS WITH END-STAGE RENAL DISEASE	Krisztina Pénzes-Daku	Received

531-MON-PO	MIR-15A, MIR-96, MIR-144, MIR-150, MIR-155, MI210, MIR-212, MIR-223, MIR-424 AND MIR-451 ARE DIFFERENTLY EXPRESSED IN PLATELETS FROM DVT PATIENTS	Mariane Flores-Nascimento	Received

532-TUE-PO	THROMBOLYSIS USING N-ACETYLCYSTEINE IN ACUTE ISCHEMIC STROKE	Maxime Gauberti	Received

533-TUE-PO	MULTIPLE MENINGIOMAS DOES NOT INCREASE THE RISK OF INTRACRANIAL HEMORRHAGE AFTER INTRAVENOUS THROMBOLYSIS FOR ACUTE ISCHEMIC STROKE	Navdeep Lail	Received

534-MON-PO	INCREASED CIRCULATING DNA, CALPROTECTIN AND MYELOPEROXIDASE, AS NEUTROPHIL EXTRACELLULAR TRAP MARKERS, ARE RISK FACTORS FOR DEEP VEIN THROMBOSIS	Pilar Medina	Received

534-WED-PO	CONGENITAL FXI DEFICIENCY: PRELIMINARY RESULTS OF PHENOTYPIC (CLINICAL AND LABORATORY) AND GENOTYPIC CHARACTERIZATION OF A CASE SERIES FROM A SINGLE CENTER.	Cristina Santoro	Received

535-WED-PO	FACTOR VII DEFICIENCY AND PROPHYLAXIS DUE TO INTERVENTIONS	Violeta Dejanova-Ilijevska	Received

536-TUE-PO	ALTERED FIBRIN CLOT STRUCTURE/FUNCTION IN PATIENTS WITH CEREBRAL SINUS VENOUS THROMBOSIS AND THE RISK OF RECURRENCE.	Jakub Siudut	Received

536-MON-PO	IDENTIFICATION AND VALIDATION OF PLASMA microRNAS INVOLVED IN VENOUS AND ARTERIAL THROMBOSIS.	Silvia Navarro	Received

536-WED-PO	COURSE OF PREGNANCY, LABOUR AND PERIOPERATIVE MANAGEMENT OF TWO PATIENTS WITH BERNARD-SOULIER SYNDROME CASE REPORTS AND LITERATURE REVIEW	Anna Sikorska	Received

537-WED-PO	INHERITED FXIII DEFICIENCY IN THE NORTHERN REGION OF TURKEY	albayrak davut	Received

537-MON-PO	THE INCIDENCE OF CATHETER-RELATED THROMBOSIS IN PATIENTS ON LONG-TERM PARENTERAL NUTRITION: A SYSTEMATIC REVIEW AND META-ANALYSIS.	Stefano Barco	Received

538-MON-PO	VENA CAVA THROMBOSIS IN ADULTHOOD VS PEDIATRICS PATIENTS: DIFFERENT PHENOTYPES AND RISK FACTORS FOR THE SAME ENTITY.	Georgina Stefanía Daher Reyes	Received

538-WED-PO	VON WILLEBRAND DISEASE: BE OR NOT TO BE, THAT IS THE QUESTION	ANA AZEVEDO	Received

539-TUE-PO	INDIVIDUAL ABSOLUTE AND RELATIVE RISK (RR) OF PULMONARY EMBOLISM (PE) IN PREGNANCY AND PUERPERIUM IN PRESENCE OF HEREDITARY THROMBOPHILIC RISK FACTORS	Rainer B. Zotz	Received

539-MON-PO	A CLINICAL AUDIT OF HERITABLE THROMBOPHILIA TEST PROFILE IN A TERTIARY HEALTH CARE FACILITY, PAKISTAN.	ANILA RASHID	Received

540-MON-PO	THROMBOPHILIC PROFILE IN EXTRAHEPATIC PORTAL VEIN OBSTRUCTION- EXPERIENCE FROM A TERTIARY CENTRE IN INDIA	Pratibha Dhiman	Received

541-MON-PO	ISTHS CLARION CALL: TO RAISE THE AWARENESS OF THROMBOSIS WORLDWIDE - A GLOBAL DISEASE BURDEN	Thiruchelvam Ayadurai	Received

542-TUE-PO	THROMBIN GENERATION TEST AT R2 POLYMORPHISM OF FACTOR V	Jana Prochazkova	Received

542-MON-PO	RISK FACTORS OF THROMBOSIS AND SICKLE CELL ANEMIA	Awa oumar Toure	Received

542-WED-PO	ORM1: A NOVEL REGULATOR OF THROMBIN GENERATION AND POTENTIAL CARDIOVASCULAR RISK FACTOR	Mohammed Alsahli	Received

543-WED-PO	Role of coagulation factor XI in promoting distal platelet activation and consumption in whole blood under shear flow	Jevgenia Zilberman-Rudenko	Received

543-TUE-PO	FACTOR V LEIDEN IN THE ABSENCE OF APC RESISTANCE IN A PATIENT AFTER LIVER TRANSPLANTATION	Jerzy Windyga	Received

543-MON-PO	GENETIC VARIABILITY OF KNG1 AND F11 GENES USING NEXT GENERATION SEQUENCING.	Laura Martin	Received

544-TUE-PO	VENOUS THROMBOEMBOLISM ASSOCIATED WITH FIRST PREGNANCY IN 80 WOMEN WITH HEREDITARY ANTITHROMBIN DEFICIENCY.	Horellou Marie Helene	Received

545-MON-PO	EVALUATION OF PROTEIN S SPECIFIC ACTIVITY PERMITS ACCURATE DIAGNOSIS OF PROTEIN S TOKUSHIMA, A MISSENSE MUTATION WITH TYPE II PROTEIN S DEFICIENCY	Hiroko Tsuda	Received

545-WED-PO	SELECTIVE NEUTRALIZATION OF THE SERPIN PROTEASE NEXIN-1 BY A SPECIFIC MONOCLONAL ANTIBODY	Marie-Christine BOUTON	Received

546-TUE-PO	ANTIPHOSPHOLIPID ANTIBODIES AS EMBOLIC RISK MARKER OF INFECTIVE ENDOCARDITIS.	Jean Devignes	Received

547-MON-PO	THE POSSIBLE ROLE OF C.1824CT PROTHROMBIN GENE VARIANT IN PATHOGENESIS OF THROMBOPHILIA	Valentina Djordjevic	Received

547-TUE-PO	HEREDITARY AND ACQUIRED THROMBOPHILIAS IN WOMEN	Ivo Elezovic	Received

548-WED-PO	THE IMMEDIATE AND LATE EFFECTS OF THYROID HORMONE (TRIIODOTHYRONINE) ON MURINE COAGULATION GENE TRANSCRIPTION	Salloum-Asfar Salam	Received

548-TUE-PO	CHARACTERIZATION OF A NEW HEREDITARY PROTHROMBIN VARIANT ASSOCIATED WITH INCREASED RISK OF VENOUS THROMBOEMBOLISM	Cristiana Bulato	Received

549-WED-PO	INDIRECT REGULATION OF HEMOSTATIC PROTEINS BY MIR24 AND MIR34A THROUGH HEPATIC NUCLEAR FACTOR 4 ALPHA (HNF4A)	Salloum-Asfar Salam	Received

549-TUE-PO	ARTERIOVENOUS THROMBOSIS IN END STAGE RENAL DISEASE PATIENTS	MUNIRA BORHANY	Received

550-MON-PO	MOLECULAR CHARACTERIZATION OF NEW ANTITHROMBIN MUTATIONS	Zsuzsanna Bereczky	Received

550-WED-PO	INVESTIGATION OF MODE OF ACTION OF SUGAMMADEX EFFECTS ON COAGULATION	Annelieke C. Kruithof	Received

550-TUE-PO	EFFECT OF A CARBOXY-TERMINAL PEPTIDE ON FACTOR VIIA ACTIVITY	Dougald Monroe	Received

551-MON-PO	A REASON TO INCLUDE HOMOCYSTEINE IN THE HYPERCOAGULABLE WORKUP	Mala Varma	Received

552-TUE-PO	TISSUE FACTOR / FVIIa TRANSACTIVATES THE IGF-1R IN PROSTATE CANCER CELLS VIA INHIBITION OF CAVEOLIN-1	Mikael berg	Received

552-MON-PO	PATHOLOGICAL DETERMINANTS OF HUMAN CORONARY THROMBUS FORMATION: DISTINCT PROCOAGULANT ACTIVITY AND LACTATE PRODUCTION OF M1/M2 POLARIZED MACROPHAGES.	Atsushi Yamashita	Received

553-TUE-PO	THE LRP1 RECEPTOR PROMOTES THE IN VIVO CLEARANCE OF ACTIVATED FACTOR VII (FVIIA) IN COMPLEX WITH ANTITHROMBIN	Judicael Fazavana	Received

553-MON-PO	SINGLE PHOSPHORYLATION OF THE CYTOPLASMIC DOMAIN OF TISSUE FACTOR AT SERINE 253 IS SUFFICIENT FOR THE BINDING OF TISSUE FACTOR TO FILAMIN-A	Mary Collier	Received

554-MON-PO	Alternatively spliced Tissue Factor has no function in hemostasis	Betul Unlu	Received

554-TUE-PO	HIGH PLASMA CONCENTRATION OF ACTIVATED FACTOR VII-ANTITHROMBIN COMPLEX IS ASSOCIATED WITH AN ENHANCED THROMBIN GENERATION	Marcello Baroni	Received

555-MON-PO	K63-LINKED POLYUBIQUITINATION OF LYSINE 255 WITHIN TF PROMOTES SELECTIVE TF-DEPHOSPHORYLATION, TRIGGERS TF-ENDOCYTOSIS AND TERMINATES TF ACTIVITY	Camille Ettelaie	Received

556-TUE-PO	THE ROLE OF FACTOR VII MUTATIONS IN ENDOPLASMIC RETICULUM STRESS	Elisabeth Drum	Received

556-MON-PO	CHARACTERISATION OF TF UBIQUITINATION: INVOLVEMENT OF MDM2 AND THE UBE2D FAMILY OF E2 ENZYMES	Camille Ettelaie	Received

557-TUE-PO	FVII DEFICIENCY: UNVEILING THE CELLULAR AND MOLECULAR MECHANISMS UNDERLYING THREE MODEL ALTERATIONS (MISSENSE, DELETION, EXTENSION) OF THE FVII CATALYTIC DOMAIN	Maria Eugenia Chollet Dugarte	Received

557-MON-PO	HIGH LEVEL OF TISSUE FACTOR INDUCES CELL APOPTOSIS IN ENDOTHELIAL CELLS, MEDIATED THROUGH ACTIVATION OF P38 AND P53	Camille Ettelaie	Received

558-TUE-PO	MICRORNAS MODULATE HUMAN TISSUE FACTOR PATHWAY INHIBITOR-a (TFPIa) EXPRESSION IN RESPONSE TO ANDROGENS IN ENDOTHELIAL CELLS	ANA BELÉN ARROYO-RODRÍGUEZ	Received

558-WED-PO	OBSTRUCTIVE SLEEP APNOEA DOES NOT ENHANCE HYPERCOAGULABILITY AS MEASURED BY THROMBIN GENERATION IN THE MORBIDLY OBESE	Paradzai Chitongo	Received

558-MON-PO	THE POTENTIAL OF CANCER CELL LINES TO RELEASE TISSUE FACTOR-CONTAINING MICROVESICLES CORRELATES WITH TISSUE FACTOR AND PAR2 MRNA LEVELS BUT NOT TISSUE FACTOR PROTEIN OR SURFACE ACTIVITY	Camille Ettelaie	Received

559-TUE-PO	SINGLE CENTRE EXPERIENCE OF FACTOR VII DEFICIENCY	Bella Madan	Received

559-WED-PO	VEREMA - AN AFFINITY PROTEOMICS STUDY TO IDENTIFY AND TRANSLATE PLASMA BIOMARKERS FOR VENOUS THROMBOEMBOLISM	Maria Bruzelius	Received

559-MON-PO	TISSUE FACTOR IS INDUCED BY INTERLEUKIN-33 IN HUMAN ENDOTHELIAL CELLS: A NEW LINK BETWEEN COAGULATION AND INFLAMMATION	Stefan Stojkovic	Received

560-TUE-PO	THROMBIN GENERATION IN PATIENTS WITH MILD FACTOR VII DEFICIENCY MEASURED IN THE PRESENCE OF THROMBOPLASTINS OF DIFFERENT ORIGIN	Roza Chaireti	Received

560-MON-PO	SOLUBLE TISSUE FACTOR IMPROVES DETECTION OF THROMBIN GENERATION RESPONSES TO WIDE RANGE OF FACTOR VIIA DOSES	Mikhail Ovanesov	Received

560-WED-PO	ANALYSIS OF PROTHROMBIN MISSENSE MUTANTS AT 596ARG BY SINGLE NUCLEOTIDE SUBSTITUTION FOR ANTICOAGULANT SYSTEM	TAKAGI YUKI	Received

561-WED-PO	RED CELL DISTRIBUTION WIDTH AND FUTURE RISK OF VENOUS THROMBOSIS, MYOCARDIAL INFARCTION, STROKE AND CANCER A CAUSE SPECIFIC ANALYSIS.	Trygve Ellingsen	Received

561-TUE-PO	MUTATIONS IN THE F7 GENE IN SWEDISH PATIENTS WITH DISCREPANT FACTOR VII ACTIVITY IN THE PRESENCE OF THROMBOPLASTINS OF DIFFERENT ORIGIN	Roza Chaireti	Received

562-TUE-PO	FVII DEFICIENCY AND THROMBOSIS, COINCIDENCE OR NEW MECHANISM OFTHROMBOPHILIA Y.LARFI, I.BACHIRI, W.ZAZOUA , N.FENNI, M.GIANCILY-BLAIZOT J.F.SCHVED	Yacine Larfi	Received

563-WED-PO	DEHYDRATION AS A POSSIBLE CAUSE OF SEASONAL VARIATIONS IN THE INCIDENCE OF VENOUS THROMBOEMBOLISM	elias saad	Received

563-MON-PO	TISSUE FACTOR/FACTOR VIIA SIGNALING PROMOTES CYTOKINE-INDUCED BETA CELL DEATH AND IMPAIRS GLUCOSE STIMULATED INSULIN SECRETION FROM HUMAN PANCREATIC ISLETS.	Desirée Edén	Received

564-TUE-PO	ANTI-IDIOTYPIC DARPINS RESTORE ADAMTS13 ACTIVITY IN BABOONS CHALLENGED WITH HUMAN MONOCLONAL ANTIBODIES: FIRST STEP TOWARDS AN ANIMAL MODEL FOR HUMAN ACQUIRED TTP	Monica Schaller	Received

564-WED-PO	AN AFFINITY PROTEOMICS STUDY FOR PLASMA BIOMARKER CANDIDATES OF CARDIOVASCULAR DISEASE IN VENOUS THROMBOEMBOLISM	Maria Jesus Iglesias	Received

564-MON-PO	TISSUE FACTOR ACTIVATION IN PREGNANCY COMPLICATIONS	Martin Prochazka	Received

565-TUE-PO	THE LABORATORY PROFILE THAT PREDICTS FAVORABLE OUTCOME AFTER ECULIZUMAB THERAPY IN PATIENTS WITH CLINICAL FEATURES COMPATIBLE WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME	Hira Mian	Received

565-MON-PO	ACTIVATED PLATELETS REGULATE MONOCYTE TFPI GENE EXPRESSION THROUGH THE NUCLEAR TRANSCRIPTION FACTOR PPARG	Robert Turnbull	Received

566-WED-PO	ASSESSMENT OF RISK FACTORS IN ESTABLISHED CASES OF DEEP VEIN THROMBOSIS (DVT) AND GREAT SAPHENOUS VEIN THROMBOSIS (GSVT) IN INDIAN PATIENTS	CHITHRA BARVADHEESH	Received

566-MON-PO	TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR ASSESSMENT IN EARLY AND LATE SEVERE PREECLAMPSIA	Lara Carvalho Godoi	Received

566-TUE-PO	THE CLINICAL ANALYSIS OF 58 THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS	Cuicui Lyu	Received

567-WED-PO	JOINT EFFECT HOMOZYGOUS CARRIERS OF A RISK ALLELE IN THE FIBRINOGEN GAMMA CHAIN AND OVERWEIGHT ON RISK OF VENOUS THROMBOEMBOLISM.	Tine Lnneberg	Received

568-WED-PO	IMPACT OF THE ABO RS8176719 SINGLE NUCLEOTIDE POLYMORPHISM ON CANCER-RELATED VENOUS THROMBOEMBOLISM	Olga Dziewiecka	Received

568-TUE-PO	CLINICAL AND BIOCHEMICAL STUDIES OF TWO PATIENTS WITH ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA TREATED WITH N-ACETYLCYSTEINE	Junmei Chen	Received

570-MON-PO	QUANTIFICATION OF CELL FREE DNA IN RED BLOOD CELL CONCENTRATES PRODUCED VIA BUFFY COAT (B1) OR WHOLE BLOOD (B2) METHODS	Andrew Shih	Received

570-WED-PO	NEUTROPHILS AND FACTOR XII , UNLIKE PLATELETS, ARE NOT CRUCIAL FOR DEVELOPMENT OF EXPERIMENTAL SPONTANEOUS VENOUS THROMBOSIS	Marco Heestermans	Received

571-MON-PO	RESPONSIVENESS OF PLATELETS DURING STORAGE STUDIED WITH FLOW CYTOMETRY FORMATION OF PLATELET SUBPOPULATIONS AND LAMP-1 AS NEW MARKERS FOR THE PLATELET STORAGE LESION	Anna Sdergren	Received

571-TUE-PO	OBESITY AS A RISK FACTOR FOR THE DEVELOPMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA IN ADAMTS13 DEFICIENT MICE	Elien Roose	Received

572-WED-PO	DIFFERENTIAL EXPRESSION OF MIRNAS IN PLASMA AND PERIPHERAL BLOOD MONONUCLEAR CELLS COLLECTED FROM PATIENTS WITH UNPROVOKED VENOUS THTOMBOEMBOLISM AND HEALTHY CONTROL INDIVIDUALS	Irina Starikova	Received

572-TUE-PO	A MULTICENTER, RANDOMIZED STUDY OF CYCLOSPORINE OR CORTICOSTEROIDS AS AN ADJUNCT TO PLASMA EXCHANGE IN INITIAL THERAPY OF THROMBOTIC THROMBOCYTOPENIC PURPURA	Spero Cataland	Received

572-MON-PO	PRESERVED ULTRASTRUCTURE AND BIOCHEMICAL CHARACTERISTICS OF PLATELET COMPONENTS PREPARED WITH AMOTOSALEN AND UVA FOR PATHOGEN INACTIVATION	Beatrice Hechler	Received

574-MON-PO	RELATIVE EFFECTS OF FRESH FROZEN PLASMA, FIBRINOGEN CONCENTRATE, AND FACTOR XIII IN MASSIVE TRANSFUSION REGIMENS: A LABORATORY STUDY	David Schmidt	Received

576-MON-PO	PROTHROMBIN ACTIVATION IN PACKED RED BLOOD CELL UNITS OVER THEIR STORAGE LIFETIME	Thomas Orfeo	Received

576-TUE-PO	INCORPORATION OF RIGHT VENTRICULAR DYSFUNCTION INTO THE SIMPLIFIED PULMONARY EMBOLISM SEVERITY INDEX AS A PREDICTOR OF COMPLICATED CLINICAL COURSE IN LOW-RISK PATIENTS PRESENTING WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM	David Jimenez	Received

577-TUE-PO	RADIATION AND BREAST CANCER RISK IN WOMEN DIAGNOSED WITH PULMONARY EMBOLISM: CT PULMONARY ANGIOGRAPHY VERSUS VENTILATION-PERFUSION SCANNING	Vicky Tagalakis	Received

578-MON-PO	NEURO-IMAGING DOES NOT CORRELATE WITH DISEASE SEVERITY IN ACUTE THROMBOTIC THROMBOCYTOPENIA PURPURA (TTP), BUT MAY PREDICT LONG TERM SEQUELAE.	Indrani Karpha	Received

578-WED-PO	SECONDARY THROMBOPROPHYLAXIS WITH RIVAROXABAN IN MAJOR INHERITED THROMBOPHILIAS	Karen Schreiber	Received

578-TUE-PO	RISK-ASSESSMENT MODEL OF RECURRENCE WITHIN 3 MONTHS AFTER A FIRST EPISODE OF ACUTE VENOUS THROMBOEMBOLISM: WORCESTER VENOUS THROMBOEMBOLISM STUDY	Wei Huang	Received

579-WED-PO	MONITORING DRUG ACTIVITY OF DABIGATRAN AND RIVAROXABAN BY THROMBIN GENERATION USING THE CALIBRATED AUTOMATED THROMBINOSCOPE.	Andrés Moret	Received

579-MON-PO	PHASE II STUDY OF DANAZOL WITH PLASMA EXCHANGE AND CORTICOSTEROIDS FOR THE TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA	Vamsee Torri	Received

579-TUE-PO	PERFORMANCE OF PULMONARY EMBOLISM RULE-OUT CRITERIA (PERC) COMBINED WITH LOW GESTALT CLINICAL PROBABILITY IN EUROPEAN CHEST PAIN POPULATION	Emilie Friou	Received

580-TUE-PO	AN ELECTRONIC TOOL AND RECORD FOR DEEP VEIN THROMBOSIS (DVT) ASSESSMENT, DIAGNOSIS, TREATMENT AND FOLLOW UP.	jo eggleston	Received

580-WED-PO	DIFFERENT PATTERNS OF THROMBOPHILIA MARKERS IN PREGNANCY COMPLICATIONS	Gabriella Gamba	Received

581-MON-PO	CHARACTERIZATION OF SINGLE SORTED ANTI-ADAMTS13 SPECIFIC B CELLS FROM THE SPLEEN OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) PATIENTS	Magdalena Skowronska	Received

581-TUE-PO	VALIDATION OF THE USE OF AGE ADJUSTED D DIMER CUT OFF VALUES TO REDUCE THE COMPRESSION VENOUS ULTRASOUND RATES IN AN ACUTE AMBULATORY DVT SERVICE	Jane Strong	Received

582-TUE-PO	THE USE OF AN AGE-ADJUSTED CUT-OFF FOR D-DIMER IN SCREENING PATIENTS FOR SUSPECTED DVT IN THE COMMUNITY CAN SAFELY DECREASE THE NEED FOR COMPRESSION ULTRASONOGRAPHY.	Andrew Hughes	Received

582-WED-PO	TOWARDS IDENTIFICATION OF GENETIC RISK FACTORS IN TWO DUTCH FAMILIES WITH UNEXPLAINED HEREDITARY VENOUS THROMBOEMBOLISM	Marisa Cunha	Received

582-MON-PO	THE NATURAL MUTATION ASP173GLY IN THE CATALYTIC SITE OF THE ADAMTS-13 GENE CAUSES A SEVERE UPSHAW-SCHLMAN SYNDROME: CLINICAL COURSE, BIOCHEMISTRY AND MOLECULAR DYNAMICS INVESTIGATION	Stefano Lancellotti	Received

583-WED-PO	RECURRENT VENOUS THROMBOEMBOLISM DURING PREGNANCY IN WOMEN WITH QUANTITATIVE ANTITHROMBIN DEFICIENCY WITH OR WITHOUT ANTITHROMBOTIC PROPHYLAXIS	Serena Maria Passamonti	Received

583-TUE-PO	DIAGNOSTIC PREDICTION MODEL VERSUS GESTALT IN THE DIAGNOSIS OF PULMONARY EMBOLISM IN PRIMARY CARE	Janneke Hendriksen	Received

584-TUE-PO	CLINICAL PREDICTION RULES PLUS D-DIMER TESTING DO NOT ENABLE A SAFE EXCLUSION OF DEEP VEIN THROMBOSIS OR PULMONARY EMBOLISM IN ELDERLY PATIENTS RESIDING IN NURSING HOMES OF HOMES FOR THE ELDERLY.	Geert-Jan Geersing	Received

584-WED-PO	MOLECULAR ANALYSIS OF PROTEIN S DEFICIENCY IN THAILAND	Ponlapat Rojnuckarin	Received

585-WED-PO	INHERITED THROMBOPHILIA AS A HIGH RISK FACTOR OF RECURRENT PREGNANCY LOSS IN GEORGIAN POPULATION	Nino Pirtskhelani	Received

586-WED-PO	DO ENDOTHELIUM-RELATED GENES AND INHERITED THROMBOPHILIA INTERACT IN INCREASING PREGNANCY LOSS RISK?	Ilaria Romagnuolo	Received

588-TUE-PO	REVIEW OF EMERGENCY DEPARTMENT INVESTIGATED DVT	ROSEMARY LAVERY	Received

588-WED-PO	OBSTETRIC HISTORY, COURSE OF PREGNANCY AND LABOUR OF PATIENTS WITH MTHFR MUTATION CASE REPORT AND LITERATURE REVIEW	Justyna Magdalena Teliga-Czajkowska	Received

589-TUE-PO	PREVALENCE OF VENOUS THROMBOEMBOLISM & RELATED MORBIDITY AND MORTALITY AMONG HOSPITALIZED PATIENTS IN SAUDI ARABIA (SAVTE STUDY)	essam aboelnazar	Received

590-TUE-PO	BELOW KNEE DEEP VEIN THROMBOSIS (BKDVT): A BENIGN ENTITY OR NOT?	Prahlad Ho	Received

590-MON-PO	A CASE OF THROMBOTIC MICROANGIOPATHY WITH CFH GENE ALTERATIONS THAT ARE NOT ASSOCIATED WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME	yesim oymak	Received

591-MON-PO	SEVERE FIRST MANIFESTATION OF TTP IN A 96-YEAR-OLD FEMALE	Inge Scharrer	Received

591-TUE-PO	ETIOLOGY OF PORTAL VENOUS THROMBOSIS AND BUDD-CHIARI SYNDROME IN ADULTS	ANIL TOMBAK	Received

591-WED-PO	EXPLOITING THE BIOLOGY OF TISSUE FACTOR PATHWAY INHIBITOR: PROSPECT FOR FUTURE THERAPEUTIC TARGETS.	Samuel Abegunde	Received

592-TUE-PO	INCIDENCE OF CATHETER-RELATED VENOUS THROMBOEMBOLISM EVENTS IN ACUTE LEUKEMIA PATIENTS; A RETROSPECTIVE STUDY OF THE SAFETY OF PERIPHERALLY-INSERTED CENTRAL CATHETER.	Mohammad Refaei	Received

593-TUE-PO	EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM IN THE FRAMINGHAM HEART STUDY	Marja Puurunen	Received

594-WED-PO	COMPREHENSIVE ASSESSMENT OF THE SAFETY AND EFFICACY OF FACTOR VIIA-CTP SUPPORTING PHASE 2A STUDY	Lior Binder	Received

594-TUE-PO	IMPACT OF INCIDENT STROKE ON FUTURE RISK OF VENOUS THROMBOEMBOLISM	Ludvig Balteskard Rinde	Received

594-MON-PO	THE NEW CLINICAL PREDICTION SCORE FOR DIAGNOSIS OF LOWER LIMB DEEP VEIN THROMBOSIS IN UNSELECTED POPULATION OF OUTPATIENTS AND INPATIENTS	Nuttawut Sermsathanasawadi	Received

595-WED-PO	FACTOR VIIA-CTP, A LONG-ACTING COAGULATION FACTOR PROPOSING A NOVEL SUBCUTANEOUS (SC) ROUTE OF ADMINISTRATION FOR PROPHYLACTIC TREATMENT EFFICACY AND SAFETY IN PREPARATION FOR FIRST IN HUMAN STUDY.	Lior Binder	Received

595-MON-PO	OVER-REPRESENTATION OF SEVERE SUBCLAVIAN VEIN OCCLUSION IN THE AFFECTED ARM, COMPARED WITH THE CONTRALATERAL ARM, IN PATIENTS WITH UNPROVOKED UNILATERAL UPPER EXTREMITY DEEP VEIN THROMBOSIS	Shuoyan Ning	Received

595-TUE-PO	EVALUATING THE ACCURACY OF INTERNATIONAL CLASSIFICATION OF DISEASES 10TH REVISION CODES FOR VENOUS THROMBOEMBOLISM (VTE) AND MAJOR BLEEDING (MB) IN EMERGENCY ROOM (ER) DISCHARGES	Fatimah Al-Ani	Received

596-MON-PO	Performance of the Age-Adjusted D-dimer Threshold for Suspected Pulmonary Embolism in Clinically Relevant Subgroups: an Individual Patient Data Meta-Analysis of 7,000 Patients	Nick van Es	Received

597-TUE-PO	CEREBRAL VENOUS THROMBOSIS: A LONGITUDINAL FOLLOW UP	Maria T DeSancho	Received

597-MON-PO	A SIMPLE DECISION RULE INCLUDING THE D-DIMER TEST TO REDUCE THE NEED FOR CT-SCANNING IN PATIENTS WITH SUSPECTED PULMONARY EMBOLISM	Josien van Es	Received

598-MON-PO	ACCURACY OF X-RAY WITH PERFUSION SCAN IN YOUNG PATIENTS WITH SUSPECTED PULMONARY EMBOLISM	Josien van Es	Received

599-MON-PO	DEVELOPMENT OF ELISA SYSTEM FOR DETECTION OF PROTEIN S K196E MUTATION, A GENETIC RISK FACTOR FOR VENOUS THROMBOEMBOLISM	keiko maruyama	Received

600-TUE-PO	LONG-TERM HEALTH-RELATED QUALITY OF LIFE AFTER DEEP VEIN THROMBOSIS IS IMPAIRED COMPARED TO CONTROLS.	Kristin Utne	Received

600-MON-PO	MODIFIED COMPUTER-ASSISTED STRAIN GAUGE PLETHYSMOGRAPHY AS A SIMPLE SCREENING TEST FOR PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS: A COHORT STUDY.	Andrew Hughes	Received

601-MON-PO	MODIFIED STRAIN GAUGE PLETHYSMOGRAPHY CAN DECREASE THE NEED FOR COMPRESSION ULTRASONOGRAPHY IN PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS: A RETROSPECTIVE MULTICENTRE COHORT STUDY.	Andrew Hughes	Received

601-WED-PO	DOSE-RELATED PULMONARY COMPLICATION RATES AFTER FRESH FROZEN PLASMA ADMINISTRATION FOR WARFARIN REVERSAL	Ariela Marshall	Received

602-MON-PO	ULTRASOUD DIAGNOSTIC CRITERIA AND CLOT DIAMETERS OF ISOLATED DISTAL DEEP VENOUS THROMBOSIS	Michelangelo Sartori	Received

602-TUE-PO	RECENT DISCHARGE CONFERS RISK FOR VENOUS THROMBOEMBOLISM	Hiren Shah	Received

603-MON-PO	OUTCOME OF SCREENING FOR OCCULT MALIGNANCY IN PATIENTS PRESENTING WITH UNPROVOKED VENOUS THROMBOEMBOLISM AT A LARGE TERTIARY HOSPITAL IN CENTRAL LONDON	Anne Mwirigi	Received

604-WED-PO	PHOSPHATIDYLINOSITOL-3-KINASE IS IMPAIRED FOLLOWING AMOTOSALEN AND ULTRAVIOLET A LIGHT TREATMENT OF PLATELETS IN CONCENTRATES FOR TRANSFUSION	Hendrik Feys	Received

605-TUE-PO	PREDICTION OF THE BLEEDING RISK DURING ANTICOAGULATION TREATMENT FOR PULMONARY THROMBOEMBOLISM	Zhenguo Zhai	Received

605-MON-PO	VENOUS THROMBOEMBOLISM IN NORTHEAST MELBOURNE, AUSTRALIA: EVALUATION OF EPIDEMIOLOGY, RISK FACTORS AND TREATMENT STRATEGIES IN THE WARFARIN ERA.	Prahlad Ho	Received

606-TUE-PO	RECURRENCES AFTER STOPPING ANTICOAGULANT THERAPY IN THAI PATIENTS WITH NON CANCER-RELATED VENOUS THROMBOEMBOLISM	Pitiphong Kijrattanakul	Received

606-MON-PO	LOW INCIDENCE OF DEEP VEIN THROMBOSIS AFTER TOTAL KNEE ARTHROPLASTY IN AN ASIAN POPULATION	Seok Wei, Stephrene Chan	Received

606-WED-PO	PLATELETS ARE DISPENSABLE DURING THE INITIAL STEPS OF IMMUNOLOGICAL TRANSFUSION RELATED ACUTE LUNG INJURY (TRALI)	Beatrice Hechler	Received

608-WED-PO	RAPID ASSESSMENT OF PLATELET FUNCTION UNDER FLOW FOLLOWING TRAUMA & RECAPITULATION OF TRAUMA-INDUCED COAGULOPATHY IN WHOLE BLOOD MICROFLUIDIC ASSAYS	Ruizhi Li	Received

609-TUE-PO	SHOULD WE USE VENOUS THROMBOEMBOLISM PROPHYLAXIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES RECEIVING CHEMOTHERAPY?	Adam Wiszniewski	Received

609-MON-PO	TIME TRENDS IN INCIDENCE RATES OF VENOUS THROMBOEMBOLISM IN A LARGE COHORT RECRUITED FROM THE GENERAL POPULATION	Nadia Arshad	Received

609-WED-PO	MONITORING PLATELET TRANSFUSION IN THROMBOCYTOPENIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES MEASURED BY THROMBOELASTOMETRY: A PILOT STUDY.	Floor Moenen	Received

610-TUE-PO	LOW-RISK PULMONARY EMBOLISM AND LENGTH OF HOSPITAL-STAY: THE LORPELHS STUDY	marco donadini	Received

610-MON-PO	POOR SELF-RATED HEALTH IS ASSOCIATED WITH FUTURE RISK OF VENOUS THROMBOEMBOLISM IN WOMEN. THE TROMSO STUDY.	Sigrid Braekkan	Received

611-TUE-PO	ANTITHROMBOTIC TREATMENT AND OUTCOMES OF NON-MALIGNANT NON-CIRRHOTIC SPLANCHNIC VEIN THROMBOSIS: A SUB-ANALYSIS FROM THE ISTH REGISTRY	Nicoletta Riva	Received

611-MON-PO	ORAL AND INHALED CORTICOSTEROID USE IS ASSOCIATED WITH RECURRENT PULMONARY EMBOLISM	Marlous Sneeboer	Received

612-WED-PO	ASPHYXIA BY DROWNING INDUCES MASSIVE BLEEDING DUE TO HYPERFIBRINOLYTIC DISSEMINATED INTRAVASCULAR COAGULATION	Michael Schwameis	Received

612-MON-PO	CASE FATALITY AND RECURRENCE RATES AFTER FIRST VENOUS THROMBOEMBOLISM IN A LARGE POPULATION-BASED COHORT	Nadia Arshad	Received

613-WED-PO	THE STABILITY OF FVIII:C, VON WILLEBRAND FACTOR AND FIBRINOGEN IN FFP AND CRYOPRECIPITATE IN THAI BLOOD DONORS	Theera RUCHUTRAKOOL	Received

614-MON-PO	NATURAL HISTORY AND ANTITHROMBOTIC TREATMENT OF INCIDENTALLY DETECTED SPLANCHNIC VEIN THROMBOSIS: FINDINGS FROM THE ISTH REGISTRY	Nicoletta Riva	Received

614-TUE-PO	INFLUENCE OF VKA-POTENTIATING DRUGS ON OVER-ANTICOAGULATION IN ATRIAL FIBRILLATION	Stijn van Vugt	Received

614-WED-PO	INFUSION OF CRYOPRESERVED POOLED PLATELETS IN PATIENTS WITH ACUTE LEUKEMIA: PRELIMINARY RESULTS OF A CLINICAL TRIAL (NCT02032134)	mariasanta Napolitano	Received

615-WED-PO	MASSIVE HAEMORRHAGE MANAGEMENT: FROM CHAOS TO ORDER. LEGNANO HOSPITALS EXPERIENCE.	Chiara Novelli	Received

615-MON-PO	DEEP VEIN THROMBOSIS IN SEPTIC PATIENTS IN THE INTENSIVE CARE UNIT	Vaia Florou	Received

615-TUE-PO	AGREEMENT OF POINT-OF-CARE INR TEST WITH STANDARD VENOUS SAMPLING ASSAY AT HIGHER EXTREME RANGES	Yi Feng Lai	Received

616-WED-PO	INTERVENTIONS TO REDUCE BLOOD LOSS FROM LABORATORY TESTING IN CRITICALLY ILL PATIENTS AND IMPACT ON TRANSFUSION: A SYSTEMATIC REVIEW	Deborah Siegal	Received

616-TUE-PO	IN ANTICOAGULATION TREATMENT WITH VITAMIN K ANTAGONISTS (AVKS): WHICH IS THE BEST MONITORING TEST?	alicia vilaseca	Received

617-WED-PO	COMPARISON OF THE EFFECT OF FRESH FROZEN PLASMA PRE- AND POST-TRANSFUSION IN ITU PATIENTS ON STANDARD AND GLOBAL COAGULATION ASSAYS	Emma Fosbury	Received

617-TUE-PO	COMPARISON OF RISK FACTORS FOR WARFARIN-ASSOCIATED BLEEDING	Muzaffer Demir	Received

618-TUE-PO	EXPANDING TELEMEDICINE TO MEDICAL HOMES FOR COMPREHENSIVE CARE DELIVERY FOR PERSONS WITH HEMOSTATIC DISORDERS: A PILOT STUDY OF THE AMERICAN THROMBOSIS AND HEMOSTASIS NETWORK (ATHN)/NATIONAL HEMOPHILIA PROGRAM COORDINATING CENTER (NHPCC).	Roshni Kulkarni	Received

619-MON-PO	A CANADIAN CONSENSUS ON VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS PREVENTION IN THORACIC SURGERY, A NATIONAL DELPHI CONSENSUS SURVEY	Yaron Shargall	Received

619-WED-PO	DERIVATION OF A NEW SCORE TO PREDICT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AFTER ACUTE PULMONARY EMBOLISM	Erik Klok	Received

620-WED-PO	THE PREVALENCE OF DEEP VEIN THROMBOSIS IN HOSPITALIZED PATIENTS WITH SUSPECTED PULMONARY EMBOLISM RULED OUT BY MULTISLICE CT ANGIOGRAPHY	Fernando Vazquez	Received

620-MON-PO	ADHERENCE TO INTERNATIONAL GUIDELINES IN TREATMENTOF THROMBOEMBOLIC EVENTS IN CANCER PATIENTS: AHOSPITAL-BASED COHORT STUDY IN PARIS, FRANCE	Isabelle MAHE	Received

621-TUE-PO	ASSESSMENT OF THE TIME IN THERAPEUTIC RANGE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN K ANTAGONISTS BY SPECIALISTS IN HAEMOSTASIS IN ARGENTINA. THE TERRA REGISTRY.	JOSE CERESETTO	Received

622-TUE-PO	RESULTS FROM THE PROSPECTIVE FARMAMICO STUDY: INR VARIATIONS IN WARFARIN-TREATED PATIENTS UNDERGOING ANALGESIC AND ANTI-INFLAMMATORY THERAPIES	Laura Russo	Received

624-MON-PO	LONG-TERM USE OF LOW-MOLECULAR-WEIGHT HEPARINS (LMWH) FOR THE TREATMENT OF CANCER-ASSOCIATED THROMBOSIS (CAT): FACTORS ASSOCIATED WITH NON-COMPLIANCE WITH TREATMENT RECOMMENDATIONS (NCTR) IN CLINICAL PRACTICE.	Vidal Benatar	Received

624-TUE-PO	WHAT BLEEDINGS PREDICT HAS-BLED AND HEMORR2HAGES SCALES IN PATIENTS ON LONG-TERM WARFARIN THERAPY?	Olga Moreva	Received

624-WED-PO	Performance of a Diagnostic Strategy Using a Clinical Decision Rule and D-dimer Testing to Exclude Upper Extremity Deep Vein Thrombosis (UEDVT) in Clinically Important Subgroups	Nick van Es	Received

625-TUE-PO	VITAMIN K ANTAGONISTS FAVORABLY MODULATE FIBRIN CLOT PROPERTIES IN PATIENTS WITH ATRIAL FIBRILLATION AS EARLY AS AFTER 3 DAYS OF TREATMENT: RELATION TO COAGULATION FACTORS AND THROMBIN GENERATION	Michal Zabczyk	Received

626-TUE-PO	PREVALENCE OF ANEMIA IN PATIENTS UNDER TREATMENT WITH VITAMIN K ANTAGONISTS	Maria Faria	Received

626-MON-PO	ACUTE PULMONARY EMBOLISM: EXTERNAL VALIDATION OF THE 2014 RISK STRATIFICATION MODEL OF THE EUROPEAN SOCIETY OF CARDIOLOGY	Cecilia Becattini	Received

627-WED-PO	RELATIONSHIP OF PATIENT AFFECT TO CLINICIAN-DERIVED PRETEST PROBABILITY ASSESSMENT FOR PULMONARY EMBOLISM	Jeff Kline	Received

627-MON-PO	RISK FACTORS FOR RECURRENCE AND THROMBOEMBOLIC EVENTS AFTER ISOLATED SUPERFICIAL VEIN THROMBOSIS OF LOWER LIMBS	Michelangelo Sartori	Received

627-TUE-PO	GENETIC VARIATIONS IN EXON 28 OF VON WILLEBRANDS FACTOR GENE IN NIGERIAN POPULATION	Eyiuche Ezigbo	Received

628-MON-PO	EFFICACY AND SAFETY OF TREATMENT WITH ANTICOAGULANTS IN PATIENTS WITH VENOUS THROMBOEMBOLISM IN KOREA	Hun Gyu Hwnag	Received

628-WED-PO	CURRENT PRACTICES IN LUNG SCINTIGRAPHY FOR PULMONARY EMBOLISM (PE) DIAGNOSIS: AN INTERNATIONAL SURVEY IN AUSTRALIA, CANADA AND FRANCE	Pierre-Yves Le Roux	Received

629-MON-PO	PREVALENCE OF VKORC-1 POLYMORPHISMS ACROSS CAUCASIANS AND AMERINDIANS	Maria Paula Vera Morandini	Received

629-WED-PO	COMPARISON OF RISK FACTORS AND OUTCOMES ASSOCIATED WITH COMMUNITY (CAT) VERSUS HOSPITAL ACQUIRED THROMBOSIS (HAT).	Huw Rowswell	Received

630-WED-PO	ASSOCIATION BETWEEN VENOUS THROMBOEMBOLISM (VTE) MINOR RISK FACTORS AND THE RISK OF RECURRENCE AFTER A FIRST UNPROVOKED EPISODE	Luana Farren-Dai	Received

630-TUE-PO	VON WILLEBRAND DISEASE AND MENORRHAGIA: MULTIPLE TREATMENT OPTIONS FOR DIFFERENT PATIENTS	KAAN KAVAKLI	Received

631-WED-PO	DO PATIENTS WHO EXPERIENCED VENOUS THROMBOEMBOLISM DESPITE THROMBOPROPHYLAXIS DURING A MEDICAL IMMOBILIZATION HAVE A WORSE OUTCOME ?	Laurent BERTOLETTI	Received

631-MON-PO	SUSCEPTIBILITY OF VKORC1 AND ITS PARALOG VKORC1L1 TOWARDS DIFFERENT 4-HYDROXYCOUMARINS	Kerstin Liphardt	Received

632-WED-PO	DISCREPANCIES IN SEVERE RI SCREENING IN THE ELDERLY WITH COCKCROFT-GAULT AND MDRD FORMULAS: 20 OF PATIENTS ARE MISEVALUATED.	Nicolas Janus	Received

632-TUE-PO	PERCENTAGE OF PLATELET AGGREGATES AND MACROPLATELETS: A POTENTIAL USEFUL LABORATORY PARAMETER FOR PREDICTING BLEEDING IN VON WILLEBRAND DISEASE TYPE 2B (VWD2B) WITH THE P.VAL1361MET MUTATION	Hugo A. Guglielmone	Received

633-TUE-PO	DEVELOPMENT OF APLASTIC ANEMIA IN A PATIENT WITH ACQUIRED VON WILLEBRANDS SYNDROME AND AUTOIMMUNE PREPONDERANCE	Arief Gunawan	Received

633-WED-PO	ASSOCIATION BETWEEN RED CELL DISTRIBUTION WIDTH AND RISK OF VENOUS THROMBOEMBOLISM	Paolo Bucciarelli	Received

633-MON-PO	CLINICAL AUDIT OF ANTICOAGULATION REVERSAL AND OUTCOME IN WARFARIN-ASSOCIATED INTRACRANIAL HAEMORRHAGE	Danielle Blunt	Received

634-MON-PO	EFFECT OF INR PRECISION AND ACCURACY ON THERAPEUTIC QUALITY CONTROL IN PATIENTS RECEIVING VITAMIN K-ANTAGONISTS	Anton Van den Besselaar	Received

634-TUE-PO	RELATIONSHIP BETWEEN BLEEDING TENDENCY AND THE AFFECTED DOMAIN WITH MUTATIONS RESPONSIBLE OF VWD2M PHENOTYPE	Adriana Woods	Received

635-TUE-PO	CHARACTERIZATION OF VON WILLEBRAND DISEASE SUBTYPES IN 303 PATIENTS - A SINGLE CENTRE STUDY OVER THE PAST 10 YEARS	Anil Pathare	Received

636-WED-PO	IMPACT OF WEIGHT CHANGE ON RISK OF VENOUS THROMBOEMBOLISM: THE TROMSO STUDY	Lars Horvei	Received

636-TUE-PO	VWD2B PHENOTYPE: ITS PREVALENCE WITHIN FAMILIES AND BLEEDING TENDENCY IN AFFECTED MEMBERS	Adriana Woods	Received

637-MON-PO	ANTAGONIZATION OF WARFARIN IN CELLS: WARFARIN BINDING ON HUMAN VKORC1 IS REVERSIBLE	Katrin Czogalla	Received

638-WED-PO	CASE-FATALITY AFTER PULMONARY EMBOLISM AND STROKE IN SUBJECTS WITH ATRIAL FIBRILLATION	Ina Rye-Holmboe	Received

638-TUE-PO	TWO UNUSUAL CASES OF TYPE 2N VON WILLEBRAND DISEASE.	PATRICIA BIGNELL	Received

639-MON-PO	RISK FACTORS FOR GASTRO-INTESTINAL BLEEDING IN ATRIAL FIBRILLATION PATIENTS ON VKA TREATMENT: PROSPECTIVE ANALYSIS OF TWO COHORTS OF PATIENTS	Daniela Poli	Received

640-MON-PO	PREDICTORS OF ICH RECURRENCE ON VKA: SEVERITY OF THE FIRST EPISODE AND HASBLED SCORE FAIL TO IDENTIFY HIGH RISK PATIENTS FROM THE CHIRONE STUDY	Daniela Poli	Received

640-TUE-PO	POOR RESPONSE TO 1-DESAMINO-8-D ARGININE VASOPRESSIN (DDAVP) TEST IN A PATIENT WITH VON WILLEBRAND DISEASE TYPE 2M (VWD2M) WITH P.GLU1549LYS MUTATION	Hugo A. Guglielmone	Received

641-TUE-PO	ALLELE-SPECIFIC SILENCING OF THE VON WILLEBRAND FACTOR GENE TO AMELIORATE THE VON WILLEBRAND DISEASE PHENOTYPE	Annika de Jong	Received

642-WED-PO	INHOSPITAL MORTALITY AMONG CLINICAL AND SURGICAL INPATIENTS RECENTLY DIAGNOSED WITH VENOUS THROMBOEMBOLIC DISEASE	Fernando Vazquez	Received

642-TUE-PO	EVALUATION OF A NEW AUTOMATED RISTOCETIN COFACTOR ASSAY ON THE STA-R EVOLUTION ANALYZER	Jasper Remijn	Received

643-TUE-PO	HOW WELL CAN LABORATORIES DIAGNOSE TYPE 2N VWD? DATA FROM A UK NEQAS (BLOOD COAGULATION) EXERCISE.	Ian Jennings	Received

643-WED-PO	Low Prevalence of Symptomatic Venous Thromboembolism After Hip and Knee Arthroplasty Without Medical Thromboprophylaxis Among Thai Patients at Siriraj Hospital	Chompunut Wongprasert	Received

644-WED-PO	THE PREVALENCE AND DIAGNOSTIC CHARACTERISTICS OF PATIENTS WITH ANTIPHOSHOLIPID ANTIBODIES IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION	William Auger	Received

645-MON-PO	Ruling out von Willebrand Disease in preoperative patients with bleeding symptoms	Minka Vries	Received

646-WED-PO	DABIGATRAN OR WARFARIN IN THE TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM IN ANTIPHOSPHOLIPID SYNDROME	Sam Schulman	Received

646-TUE-PO	CLINICAL AND LABORATORY DETECTION OF TRANSIENT NEUTRALIZING ANTIBODIES IN SEVERE VON WILLEBRAND DISEASE ON LONG TERM PROPHYLAXIS	Analía Sánchez-Luceros	Received

647-WED-PO	MULTICENTER PROSPECTIVE STUDY OF TREATMENT AND RISK FACTORS FOR UNUSUAL SITE THROMBOSIS: TRUST REGISTRY	Kim Ma	Received

647-TUE-PO	VON WILLEBRAND DISEASE: THE PHENOTYPIC CHARACTERIZATION IN THAILAND	Theera RUCHUTRAKOOL	Received

649-WED-PO	RIVAROXABAN VERSUS VITAMIN K ANTAGONIST IN PROVOKED DEEP VENOUS THROMBOSIS - WHICH TREATMENT IS BETTER FOR THE PATIENT ?	Emma Groarke	Received

649-MON-PO	NEW INSIGHTS INTO TYPE 3 VON WILLEBRAND DISEASE: THE TYPE 3 VON WILLEBRAND DISEASE INTERNATIONAL REGISTRIES AND INHIBITOR PROSPECTIVE STUDY (3WINTERS-IPS) PROJECT UPDATE	LUCA MARAVIGNA	Received

649-TUE-PO	IDENTIFICATION OF NOVEL VWF GENE MUTATIONS IN THE TURKISH TYPE 2 VWD PATIENT POPULATION	Ergul berber	Received

650-WED-PO	WARFARIN DOSING AND TIME TO THERAPUTIC INTERNATIONAL NORMALIZED RATIO IN PATIENTS WITH HYPERCOAGULABILITY SYNDROMES	Pushpinderdeep Kahlon	Received

650-TUE-PO	CANCERS IN PATIENTS WITH VON WILLEBRAND DISEASE: A SURVEY FROM THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTRES	Giancarlo Castaman	Received

651-MON-PO	OVERDOSING OF REPLACEMENT THERAPY IN PERIOPERATIVE VON WILLEBRAND PATIENTS: A LOT TO WIN	Hilde Veerman	Received

651-WED-PO	SAFETY OF STOPPING ANTICOAGULANT TREATMENT FOR CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM AFTER REACHING COMPLETE REMISSION FROM CANCER	Tom van der Hulle	Received

651-TUE-PO	MODIFICATIONS OF HEMOSTATIC THERAPY FOR PATIENTS WITH VON WILLEBRAND DISEASE BASED ON COMORBIDITY	Nadezhda Zozulya	Received

652-TUE-PO	ACQUIRED VON WILLEBRAND SYNDROME (AVWS) WITH A TYPE 2B PHENOTYPE SECONDARY TO AN IGA AUTOANTIBODY WITH ANTI-VON WILLEBRAND FACTOR ACTIVITY.	Analía Sánchez-Luceros	Received

652-WED-PO	PROLONGED USE OF LMWH DURING PREGNANCY AND BONE SAFETY	Pivi Galambosi	Received

653-TUE-PO	ACCUIRED VON WILLEBRAND SYNDROME IN PATIENTS TREATED WITH LEFT VENTRICULAR ASSIST DEVICES	Kenki Saito	Received

653-MON-PO	THE USE OF NEXT-GENERATION SEQUENCING TO SCREEN FOR DISORDERS OF COAGULATION USING A 24 GENE PANEL.	PATRICIA BIGNELL	Received

654-TUE-PO	DENTAL INVASIVE PROCEDURES IN VON WILLEBRAND DISEASE (VWD) OUTPATIENTS TREATED WITH HIGH PURITY VWF/FVIII COMPLEX CONCENTRATE: EXPERIENCE OF A SINGLE CENTER.	Valeria De Padua	Received

654-MON-PO	COURSE OF VON WILLEBRAND FACTOR (VWF) DURING PREGNANCY IN WOMEN WITH VON WILLEBRAND DISEASE (VWD)	Carsten Detering	Received

655-MON-PO	IDENTIFICATION OF LARGE VWF GENE DELETIONS AND DUPLICATIONS BY MLPA IN THE SOUTH MORAVIAN (CZECH REPUBLIC) VWD COHORT IN THE BRNO-VWD STUDY	Inge Vangenechten	Received

656-TUE-PO	LONG TERM EXERCISE SIGNIFICANTLY DECREASES VON WILLEBRAND FACTOR ANTIGEN LEVELS IN ABDOMINALLY OBESE ADULTS	Cynthia Pruss	Received

656-MON-PO	BASELINE FACTOR VIII PLASMA LEVELS AND AGE AT FIRST BLEEDING IN PATIENTS WITH SEVERE FORMS OF VON WILLEBRAND DISEASE	Simona Maria Siboni	Received

657-MON-PO	TYPE 1 VWD DOES NOT LEAD TO INCREASED GINGIVAL BLEEDING	Wolfgang Miesbach	Received

657-TUE-PO	DEVELOPMENT OF A VWF PROPEPTIDE ASSAY	Muriel Meiring	Received

658-MON-PO	JOINT SURGERY IN MODERATE AND SEVERE VON WILLEBRAND DISEASE: A CROSS-SECTIONAL STUDY.	Roger Schutgens	Received

658-TUE-PO	CROSS-SPECIES INHIBITION OF HUMAN AND MURINE VON WILLEBRAND FACTOR BY A SINGLE DOMAIN VHH-ANTIBODY	Ibrahim HABIB	Received

658-WED-PO	GLOBAL ADHERENCE TO AMERICAN COLLEGE OF CHEST PHYSICIANS GUIDELINES FOR THROMBOPROPHYLAXIS AFTER MAJOR ORTHOPEDIC SURGERY. HAVE WE IMPROVED? A SYSTEMATIC REVIEW OF THE LITERATURE	MIGUEL ANDRES FARFAN AYALA	Received

659-TUE-PO	HIGH ACTIVITY OF VON WILLEBRAND FACTOR AND LEVELS OF VWF-CLEAVING PROTEASE (ADAMTS-13) IN TERM AND PRETERM NEONATES	Tzipora Strauss	Received

660-TUE-PO	ANGIOGENIC CHARACTERISTICS OF BLOOD OUTGROWTH ENDOTHELIAL CELLS FROM PATIENTS WITH VON WILLEBRAND DISEASE	Dafna Groeneveld	Received

661-MON-PO	TOTAL THROMBUS-FORMATION ANALYSIS SYSTEM (T-TAS) FOR THE MONITORING OF VON WILLEBRAND FACTOR-FVIII CONCENTRATE TREATMENT IN PATIENTS WITH VON WILLEBRAND DISEASE TYPE 3.	Anna gren	Received

662-TUE-PO	VON WILLEBRAND FACTOR TO MONITOR PERCUTANEOUS AORTIC VALVE INTERVENTIONS	Antoine Rauch	Received

662-WED-PO	BIOMARKERS FOR PREDICTION OF REOCCURRENCE OF VENOUS THROMBOEMBOLISM	Abimbola Jarvis	Received

663-TUE-PO	PLATELET AND ENDOTHELIAL FUNCTION EVALUATION IN PEDIATRIC CHRONIC KIDNEY DISEASE (CKD)	Luci Maria SantAna Dusse	Received

663-MON-PO	PREDICTORS OF COMPLETE RESPONSE TO DDAVP IN PATIENTS WITH VON WILLEBRAND DISEASE	eugenia biguzzi	Received

663-WED-PO	MEDICATION ADHERENCE OF NOVEL ORAL ANTICOAGULANT VERSUS WARFARIN	Yi Feng Lai	Received

664-TUE-PO	FUNCTIONAL STUDY OF TWO NEW MUTATIONS IN THE C4 DOMAIN OF VON WILLEBRAND FACTOR	Cecile Denis	Received

665-TUE-PO	POSTOPERATIVE CHANGES IN VON WILLEBRAND FACTOR (VWF) AFTER ORTHOPAEDIC SURGERY IN HAEMOSTATICALLY HEALTHY PATIENTS	Carsten Detering	Received

666-TUE-PO	GENERATION OF REFERENCE INTERVALS FOR TWO AUTOMATED, NEW-GENERATION VON WILLEBRAND FACTOR ACTIVITY ASSAYS ON A LARGE DONOR POPULATION.	Katarzyna Mayger	Received

667-TUE-PO	EXPOSURE OF VON WILLEBRAND FACTOR (VWF) TO VORTEX SHEAR SIGNIFICANTLY ENHANCES ITS PROTEOLYSIS BY PLASMIN	Teresa Brophy	Received

668-TUE-PO	BELGIAN MULTICENTER STUDY INTO VON WILLEBRAND DISEASE (B-WILL STUDY): FIRST RESULTS	Inge Vangenechten	Received

669-TUE-PO	THE VON WILLEBRAND FACTOR A2 DOMAIN DISULFIDE BOND EXISTS IN OXIDIZED AND REDUCED STATES IN THE CIRCULATION AND REGULATES FUNCTION	Philip Hogg	Received

669-MON-PO	CO-OCCURRENCE OF V.WILLEBRAND DISEASE AND BERNARD SOULIER-SYNDROME	Carl-Erik Dempfle	Received

669-WED-PO	ACCURACY OF A WARFARIN MAINTENANCE DOSE PREDICTOR AFTER COMPLETION OF THE 10 MG INITIATION NOMOGRAM	Parvaneh Fallah	Received

670-MON-PO	IDENTIFICATION AND CHARACTERIZATION OF ABERRANT SPLICING FROM A NOVEL BRANCH SITE MUTATION IN VON WILLEBRAND FACTOR	Lindsey Hawke	Received

670-WED-PO	A NATIONAL ANTICOAGULANT MANAGEMENT SERVICE PROVIDED BY COMMUNITY PHARMACIES IN NEW ZEALAND ACHIEVES A HIGH LEVEL OF ANTICOAGULANT CONTROL	Paul Harper	Received

671-TUE-PO	REFERENCE VALUE OF VON WILLEBRAND FACTOR ACTIVITY BY IMMUNO-TURBIDIMETRY METHOD	DHARMA RAHAJUNINGSIH	Received

671-WED-PO	RECURRENT THROMBOTIC EVENTS AFTER DISCONTINUATION OF VITAMIN K ANTAGONIST TREATMENT FOR SPLANCHNIC VEIN THROMBOSIS: A MULTICENTER RETROSPECTIVE COHORT STUDY	Nicoletta Riva	Received

671-MON-PO	FUNCTIONAL LINK BETWEEN VON WILLEBRAND FACTOR (VWF) AND TISSUE FACTOR (TF) IN FLOW-DEPENDENT THROMBUS FORMATION: AUGMENTATION OF INTRA-THROMBUS FIBRIN GENERATION BY CATHEPSIN G ON VWF-TF COMPLEX	Mitsuhiko Sugimoto	Received

672-TUE-PO	ANALYSIS OF PLASMA VON WILLEBRAND FACTOR AND COMPLEMENT FACTOR H POLYMORPHISMS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION	Mariko Yamashita	Received

673-WED-PO	SIMILAR PERFORMANCE OF HASBLED, CHADS2 AND CHA2DS2VASC SCORES IN BLEEDING RISK PREDICTION: DO WE NEED A BLEEDING SCORE?	Daniela Poli	Received

673-MON-PO	MIR-24 REGULATES VON WILLEBRAND FACTOR IN DIABETES	YAOZU XIANG	Received

674-MON-PO	THE FIRST CASE OF AN INTRON RETENTION RESULTING FROM A SILENT MUTATION IN THE VWF WHICH EXERTS A STRUCTURAL IMPACT ON THE 5 SPLICE SITE	Hamideh Yadegari	Received

674-TUE-PO	ANALYSIS OF OXALIPLATIN-BASED CHEMOTHERAPY INDUCED LIVER INJURY IN PATIENTS WITH ADVANCED COLORECTAL CANCER WITH SPECIAL REFERENCES TO VON WILLEBRAND FACTOR	Naoto Nishigori	Received

674-WED-PO	LOW INCIDENCE OF BLEEDING EVENTS IN A REAL WORLD, VITAMIN K ANTAGONIST-TREATED PATIENT POPULATION: RESULTS FROM THE START-REGISTER	Emilia Antonucci	Received

675-WED-PO	THE START-REGISTER (SURVEY ON ANTICOAGULATED PATIENTS REGISTER): FOCUS ON PATIENTS TREATED FOR NON-VALVULAR ATRIAL FIBRILLATION	Emilia Antonucci	Received

675-MON-PO	ASSESSMENT OF VON WILLEBRAND FACTOR PANEL AND PLATELET FUNCTION IN PATIENTS WITH MODERATE TO SEVERE RENAL INSUFFICIENCY UNDERGOING RENAL BIOPSY	Bundarika Suwanawiboon	Received

675-TUE-PO	DESMOPRESSIN TREATMENT IMPROVES PLATELET FUNCTION UNDER FLOW IN PATIENTS WITH POSTOPERATIVE BLEEDING	Paola Van der Meijden	Received

677-WED-PO	POLYHEDROCYTES IN WHOLE BLOOD CLOTS OF PATIENTS WITH VENOUS THROMBOEMBOLISM TAKING VITAMIN K ANTAGONISTS: A ROLE OF THE QUALITY OF ANTICOAGULATION	Michal Zabczyk	Received

677-MON-PO	MINIMUM LEVELS OF VON WILLEBRAND FACTOR AND PLATELETS TO CREATE OCCLUSIVE HIGH SHEAR THROMBOSIS	Lauren Casa	Received

678-MON-PO	AGING AND ABO BLOOD TYPE REGULATE VON WILLEBRAND FACTOR AND FACTOR VIII LEVELS THROUGH DISTINCT PATTERNS OF BOTH SECRETION AND CLEARANCE	Silvia Albanez	Received

679-TUE-PO	EVALUATION OF AGE AND GLYCAN-RELATED CHANGES ON VON WILLEBRAND FACTOR (VWF) CLEARANCE IN A VWF DEFICIENT MOUSE MODEL	Silvia Albanez	Received

680-TUE-PO	ANNEXIN A2 SNP REGULATES PLASMA VON WILLEBRAND FACTOR LEVELS AND IS ENRICHED IN PATIENTS WITH VON WILLEBRAND DISEASE	Waander L. van Heerde	Received

ISTH 2015 Congress

20-25 June 2015 Toronto

About us

THE SUBMISSION DEADLINE HAS BEEN EXTENDED UNTIL WEDNESDAY 15TH JULY AT 23:00 GMT+1.

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 20/06/2015 TO 25/06/2016

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.ISTH2015.2015



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access